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S u m m a r y
The p resen t s tudy was conducted  to evaluate  a lte rn a tive  
methods to prolong the persistence of ampicillin in the horse. 
Artificial alkalinisation (pH > 7.91 ± 0.13) and acidification (pH < 
4.24 ± 0.13) of equine urinary pH achieved by in tragastric  
administration of sodium bicarbonate (100, 200, 300, and 400 
[x3] mg/kg) over a six day period, and ammonium chloride (200, 
300, and 400 [x3] mg/kg) over a five day period respectively, did 
not produce any significant changes in the plasma disposition of 
ampicillin when administered as an IV bolus (10 mg/kg) of the 
sodium salt to horses. These results were attributed to the lack of 
changes in the extent of reabsorption of ampicillin from the urine 
into plasma caused by the zwitterion characteristics  of the 
antibiotic. However, the alkalinisation of urine appeared to affect 
the fraction of the dose of ampicillin recovered in the urine since 
only a small fraction could be measured, (<15 %) presumably 
resulting from a degradation of the antibiotic in the basic media. 
T he p lasm a d isp os it ion  of am pic illin  was a lte red  when 
probenecid , a com petitor of the active tubular secretion of 
penicillins, was administered intragastrically to horses at a 75 
m g/kg dose rate one hour prior to the adm in istra tion  of 
am picillin  IV. The p resence  of p robenecid  p ro longed  the 
elimination of ampicillin significantly (P< 0.05), as reflected in an 
almost twofold increase in the elimination half-life (tl/2(3 = 0.701 
h vs t l/2  (3 = 1.198 h) and mean residence time values (MRT = 
48 .32  min vs M RT = 95.37 min) of am pic illin  when
coadministered with probenecid. It was therefore concluded that 
adm in is tra tion  of p robenec id  was a su itab le  m ethod for 
prolonging the persistence of ampicillin in the horse. In addition, 
the presence of probenecid appeared to restrict the distribution 
of ampicillin as reflected in a significant reduction (P< 0.05) in the 
volume of distribution of the antibiotic at steady-state (Vdss0bs = 
207.17 ± 20.89 ml/kg vs Vdss0bs = 166.70 ± 11.21 ml/kg).
The short persistence of ampicillin  in the horse was also 
overcome by the adm inistration of the antib iotic  as an IV 
infusion over a p ro longed  period. This novel m ethod of 
administration of ampicillin in the horse, enabled accurate control
XXII
on the amount of ampicillin delivered per unit of time and was 
show n to be su itab le  for those c ircu m stan ces  when a 
compromised vascular supply would impair the absorption of the 
antibiotic from the injection site when administered IM. Changes 
in the infusion rate delivered (Ro= 13.78, 19.34, and 23.48 
jig/min/kg) correlated well (R=0.994) with the concentration of 
the antibiotic at steady-state (Cpss = 4.98, 6.37 and 8.25 j ig /m l)  
and the AUC obtained (AUC = 27.83, 33.89 and 42.10 p g .h /m l)  
indicating the reliability of this method of administration.
The slower absorption and elimination achieved following oral 
administration of drugs was investigated by the administration of 
bacam picillin , an am picillin  prodrug, in horses and ponies. 
Following intragastric administration of bacampicillin to horses 
and ponies , more than 40 % was abso rbed  from  the
gastrointestinal tract (F = 41.01 %), and the concentrations 
achieved suggested that oral adm inistration of bacam picillin  
hydrochloride at dose equim olar to 10 mg/kg of ampicillin 
sodium every 8 to 12 hours, would be suitable to treat infections 
caused by sensitive bacteria. In an attempt to slow the hydrolysis 
of bacampicillin into ampicillin and thus prolong the persistence 
of the antibiotic within the body, the esterase activity present in 
plasma and in red blood cells was artificially reduced. The oral 
administration of dichlorvos, an organophosphate anthelmintic, 
produced a depression of p lasm a and ery th rocy te  esterase 
activity  greater than 95 %, at the tim e of bacam picillin
administration. However, the reduction of esterase activity did 
not have any influence on the absorption and pharmacokinetics 
of bacampicillin as no significant differences were found between 
the pharmacokinetic results obtained following administration of 
bacam pic il lin  and those  fo llow ing  the a d m in is tra t io n  of 
bacampicillin and dichlorvos. It appeared therefore that the small 
residual esterase activity present in plasma and red blood cells 
was sufficient to convert bacampicillin into ampicillin, or that 
other factors such as the plasma pH and the esterase activity 
present in other body tissues may have played a role in the 
results obtainned.
The absorption of bacampicillin from the gastrointestinal tract 
was im paired  when the an tib io tic  was ad m in is te red  in
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conjunction with probenecid, as reflected by significantly (P < 0 .0 5 ) 
lower am picillin  peak plasma concentrations. In addition, the 
reduced absorption  of bacam picillin  and consequently  higher 
intestinal concentration of antibiotic, was characterised by the 
presence of gastointestinal disturbances presumably caused by 
an alteration of the microbial ecosystem. The transformation of 
the inactive bacampicillin into ampicillin in the gastrointestinal 
tract was probably caused by a more alkaline pH in the large 
intestine and by the production of esterases by enteric bacteria. 
The presence of probenecid did prolong the fraction of ampicillin 
present in plasma as reflected in a significantly longer (P <0.05) 
mean residence time (MRT = 255.5 min vs MRT = 95.82 min) 
when b acam pic il l in  was adm inistered  in con junc tion  with 
p ro b en ec id .
A three-year survey was conducted to establish the sensitivity 
patterns of commonly encountered equine bacterial pathogens to 
a range of antibiotics. Ampicillin appeared to be effective against 
a number of bacteria including all Actinobacil lus  equuli  a n d  
Strep tococcus  zooepidemicus  tested, however, a large proportion 
of Escherichia  coli  and Sa lm one l la  typh im ur ium  isolates were 
resistant (47.8 % and 81.8 % respectively). In addition all 
P s e u d o m o n a s  spp. isolates were resistant to ampicillin. This 
suggests that antimicrobial therapy should be evaluated in every 
c ircum stance  and ind ica tes  the need for rou tine  in vitro  
sensitivity testing particularly on those bacterial strains where 
resistance is likely to be present. In addition, the survey revealed 
that other an tib io tics , such as the f luoroqu ino lones , were 
particularly effective against the bacteria tested and that they 
might play a role in the future of equine antimicrobial therapy, 
although pharm acokinetic  and toxicological studies should be 
carried out in order to evaluate their therapeutic potential in the 
equine species.
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C h a p te r  1 
G e n e r a l  i n t r o d u c t i o n
1
1.1 Antim icrobia l  therapy in the horse
1 .1 .1  G en era l  co n s id er a t io n s
Antibiotics are probably the most commonly administered drugs 
in veterinary  m edicine. They are substances that have the 
capac ity  to k ill  (b ac te r ic id a l)  or to in h ib it  the growth 
(bacteriostatic) of bacteria , and are used therapeutically  and 
prophylactically in many conditions.
M any criteria  de te rm ine  which an tib io tic  and what dosage 
regimen should be chosen including the organ or tissue infected, 
the m icroorganism  responsible of the disease, the age of the 
animal, and others factors which are common to antibacterial 
treatment in all species. However, there are other considerations 
which are of particular importance in the horse.
For instance, the enormous variation in size from one animal to 
a n o th e r  w h i th in  the eq u in e  sp e c ie s ,  re q u ire s  c a re fu l  
consideration of the dosage to be administered, especially when 
antib io tics with a narrow  therapeutic  w indow such as the 
am inoglycosides are to be adm inistered . Furtherm ore, great 
differences in the value of horses make the costs of treatment 
another important consideration to be taken into account during 
equine antibacterial therapy.
Local reactions frequently  occur following intramuscular (IM) 
injection in the neck region of the horse. Thus alternative routes 
o f ad m in is tra t io n  shou ld  be c o n s id e red  when p ro longed  
treatments are required or large doses have to be given (Ricketts 
& Hopes, 1983). The horse's large jugular veins make the IV 
route  suitable for occasions where aggressive  an tibacterial 
therapy is needed during acute infections. Nevertheless, this 
route should be used with care when some antibiotics are 
adm in is te red  because  of the p o ss ib i l i ty  of ph leb itis  and 
subsequent thrombosis (Gabel, 1977). Phlebitis is a very common 
if not unavoidable sequel to the use of IV route of administration 
in the neonatal foal.
Other general adverse reactions to antibiotic therapy in the horse 
include  hypersens it iv ity  reactions induced  by some drugs, 
pa rticu la rly  the p e n ic il l in s  (Ingham  & Large, 1969) and
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en te roco li t is  frequen tly  a ttributed  to the adm in is tra tion  of 
o x y te t ra c y c l in e  (A n d e rsso n  et al.y 1971; Cook, 1973) and 
lincomycin (Raisbeck et al ., 1981).
It is also im portant to rem ember that many horses require 
an tim icrob ia l trea tm ent during training and an tib io tics  may 
produce lethargy (Ricketts & Hopes, 1984). In addition, treatment 
must be withdrawn an adequate time before racing to comply 
with the Rules of Racing dictated in the U.K by the Jockey Club. A
know ledge of the elim ination half-life and c learance of the
antibiotic being used is therefore necessary, although for most 
antibiotics the standard period of eight days recommended for
the withdrawal of most drugs will be adequate.
Another important consideration to be taken into account during 
the treatment of equine infections is the emergence of bacterial 
resistance. This is particularly relevant and has to be taken into 
account during the local application of antibiotics into the mare’s 
uterus to prevent endometritis and also during the topical use of 
antibiotics in penile washings in the stallion to prevent the
transmission of pathogens to the mare during the coitus. Both 
procedures can affect the normal com m ensal bacterial flora 
leading to superinfection with more resistan t m icroorganism s 
such as Pseudomonas aeruginosa and Klebsiella pneumoniae  or 
overgrowth by yeast and fungi (Asbury, 1986).
In general terms, three main factors are essential to achieve 
successful antibiotic treatment. The microorganism  responsible 
for the infection has to be susceptible to the antibiotic being used, 
the drug must be present in sufficient concentrations at the site 
of infection and the m icroorganism must be exposed to the 
antibiotic for a sufficient period of time to be killed or removed 
(Aronson & Brownie, 1982).
In an ideal situation, before the start of the antibacterial therapy 
the clinician should identify the microorganism responsible for 
the infection. Having identified the pathogen, qualitative (disk- 
diffusion) or if  possible quantitative antimicrobial susceptibility 
testing, m inim um  inhib itory  concentra tion  (MIC), should be 
performed. Normally the aim of the treatm ent is to provide 
plasma concentrations that will exceed the MIC several times 
(Baggot & Prescott, 1987). Nevertheless for most antibiotics the
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extent of such excess has not been well defined. The fact that the 
MIC va lues allow ta ilo ring  of drug dosage to ind iv idual 
microorganisms, make this data more useful than the qualitative 
data (Baggot & Prescott, 1987). Having determined which is the 
most suitable antim icrobial in vitro , the treatment should be 
started. However, in most practical situations the clinician has to 
initiate  the treatm ent em pirically , basing his choice on the 
probability of the presence of a particular bacteria with likely 
sensitivity in that specific infection. The successful therapy, will 
depend on his own clinical experience and on the information 
available about susceptib ility  pa tterns. Several authors have 
collected such information (Knight & Hietala, 1978; Adamson et  
a l . , 1985; Hirsh et al ., 1985; Hirsh & Jang, 1987; Snyder et a i y 
1987; Ensink et al.y 1993) which is of considerable value for the 
equine practitioner. Nevertheless, sensitivity tests and MIC for 
different antibiotics should be perform ed in cases were the 
animal does not seem to respond to the established antibiotic 
th e ra p y .
In order to succeed during treatm ent it is also necessary to 
achieve sufficiently high concentrations of the antibiotic at the 
site of infection for an adequate period. The achievement of these 
antibiotic concentrations will depend on several factors including 
the dose and route of administration and the pharmacokinetic 
behaviour of the antibiotic in the animals treated.
The route of administration determines the extent and rate of 
absorption and consequently the achievable plasma and tissue 
concentrations. The IV route provides rapid and total absorption 
with the an tib iotic  reaching  high peak p lasm a and tissue 
concentrations but also being eliminated rapidly from the body. 
The d irec t  adm in is tra t ion  of the drug in to  the cen tra l  
compartment provides a bioavailability (extent of absorption) of 
one hundred per cent, and therefore  perm its very accurate  
dosage. N evertheless very high concentrations are attained in 
p lasm a and tissues im m ed ia te ly  a fte r  a d m in is tra t io n , and 
consequently this route should be used carefully when antibiotics 
with low therapeutic  indices are adm inistered . In addition, 
hypersensitivity reactions which sometimes appear following the 
administration of some antibiotics tend to be much more severe
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when the drug has been adm in istered  IV (B ogan, 1983). 
Distribution throughout the body and elimination are very rapid 
following IV administration, generally making the dose interval 
shorter compared to a lternative routes of adm inistration. For 
these reasons the IV route  of adm in istra tion  is generally  
restricted to the treatment of acute infections where high plasma 
and tissue concentrations are required rapidly.
The IM route on the other hand provides lower plasma and tissue 
concentrations but the antibiotic persists for a longer period in 
the body. In the horse, the gluteal muscles and the neck muscles 
(serratus muscle) are the two usual sites for IM administration. 
It would appear that some antibiotics are better absorbed from 
the neck region in the horse, probably because there is a greater 
blood supply and more movement in this area than in the 
gluteals (Firth et al ., 1986). However the local reactions after 
intramuscular injection seem to be more common in the neck 
than gluteal region (Keen & Livingston, 1983). The bioavailability 
following IM injection depends on the formulation of the drug, 
vascularisation at the site of injection and to a lesser extent on 
the lipid solubility of the substance (Prescott & Baggot, 1988a). 
Despite the fact that the oral route is probably the easiest method 
of administration, few antibiotics can be administered in this way 
to the adult horse. This is the result of poor gastrointestinal 
absorp tion  from  the in te s t in a l  lum en in to  the system ic  
circulation, high intraluminal concentration of the antibiotic and 
consequently disruption of the intestinal flora commonly leading 
to colitis (Clark & Becht, 1987). However, some of the antibiotics 
that do not seem to be absorbed after oral administration in the 
adult, reach reasonable plasma concentrations when administered 
orally to foals and do not adversely affect the gut (Brown et al ., 
1984).
The most common antibiotics administered orally to horses are 
trimethoprim / sulphonamide combinations although cephalexin, 
cephadroxil, and chloramphenicol have been administered (Clark 
& Becht, 1987). Other antibiotics that are effective in the horse 
when administered orally include metronidazole (Sweeney et al ., 
1986; Baggot et al ., 1988 b) and rifampin (Baggot, 1992) with the 
former having proven a successful for the treatment of anaerobic
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p le u ro p n e u m o n ia  (M air  & Yeo,  1987) and r i fam pin  being the 
t rea tm ent  of choice  when com bined  with e ry th rom ycin  for the 
t rea tm ent  of  pneum onia  in foals caused by R h o d o c o c c u s  eq u i  
(Hil l idge, 1987; Sweeney et a l ., 1987). Finally, pivampici l l in ,  an 
am pic i l l in  p rod rug  for  oral ad m in is t ra t io n ,  has recen t ly  been 
shown to be absorbed to a larger extent  than any other penicill in 
when ad m in is te red  in tragas t r ic a l ly  to horses  and conseq uen t ly  
cou ld  be a va luab le  a l te rna t ive  for the  t rea tm en t  of equ ine  
infections by the oral route (Ensink et a l ., 1992).
Intravenous infusion of antibiotics has not  been well described in 
the  h o rse .  T h e  a im  is to m a in t a in  k n o w n  s te ad y  s ta te  
concentra t ions  of the drug in p lasma for a pro longed period of 
time. Its practical  application would be when antibiotics with a 
n a r r o w  t h e r a p e u t i c  w i n d o w  h a v e  to be a d m i n i s t e r e d  
c o n t i n u o u s l y  ( i n t e n s i v e  ca re  p a t i e n t s )  or  w h e n  d e f i n e d  
concen tra t ions  of the antib iotic  have to be main ta ined  over  a 
specif ic  period of time (prophylaxis during surgery).
The  a c h ie v e m e n t  of  su f f ic ien t  c o n ce n t ra t io n s  at the si te  of 
in f e c t i o n ,  no t  on ly  d e p e n d s  on the d o se  and ro u te  of 
a d m i n i s t r a t i o n  of  the  a n t i m i c r o b i a l  b u t  a l so  on i ts  
p ha rm acok ine t ic  charac ter is t ics .  Pha rm acok ine t ic  s tudies provide  
in fo rm at ion  about  the behav iour  of a drug in the body ,  by 
sho w in g  pa t te rns  of p la sm a  and t issue  con cen t ra t io n s  versus  
t im e.  C o n s e q u e n t ly ,  the p h a r m a c o k in e t i c  b e h a v io u r  o f  the 
antibiotic  indicates whether  the antibiotic  will achieve sufficient  
concentra t ion to kill or inhibit  the bacteria  and also the period 
d u r in g  w h ich  this  c o n c e n t r a t i o n  wil l  be m a in ta in e d .  The 
pharmacokinet ic  behaviour  of any drug is determined by various 
factors which include the phys icochem ica l  character is t ics  o f  the 
drug,  the ex ten t  of  t issue and pro tein  b inding,  the rou te  of 
adminis t ra t ion  and the species to be treated. All these factors , 
affect  the rate of absorption,  distr ibution and e l imination of  the 
d ru g  to be a d m i n i s t e r e d ,  and  t h e r e f o r e  k n o w l e d g e  of  
p h a rm a c o k in e t ic s  is r eq u i red  to se lec t  the m os t  ap p ro p r ia te  
antimicrobial  and dose to be adminis tered.  Finally, other factors 
which will de termine  the effective concentra t ion  of the drug at 
the site of infection include the location of  the infection and the 
pathology of the tissue where the infection is occuring.
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1.1 .2  T r e a tm e n t  fai lure
When the concentration of the antibiotic achieved is not high 
enough or when it has not persisted at the site of infection for a 
sufficient length of time the treatment is likely to fail. Inadequate 
concen tra tions  may be the result of an incorrec t dosage 
administered and may be accounted for by a number of reasons. 
Variations between individual animals can be enormous when 
pharm acokinetic  studies are carried out. The recom m ended  
dosage rates are based on results from the mean of a group, and 
variations between individuals, can sometimes explain why some 
animals treated with the recommended dosage will not respond 
in the expected way. It is also important to take into account the 
variation of tissue blood supply within the body, and to consider 
sites to which antibiotics do not gain access because of physical 
barriers. Antibiotic concentrations are generally lower in poorly 
perfused tissues and in sites such as the eye, the brain and the 
jo in ts  where specific barriers such as the blood-brain barrier 
make the diffusion of drugs more difficult or even impossible 
depending on the drug. If there is a large amount of tissue debris 
(pus, fibrin etc) in the infection site the vascular supply will be 
compromised and the pH altered. These particular conditions at 
the infection site, will not allow poorly penetrating antibiotics to 
reach the foci of infection, and may result in treatment failure. 
Many antibiotics and especially the bacteriostatic ones, rely on a 
competent host imm unological system, therefore impaired host 
defence m echanisms will be a possible contributory cause of 
treatment failure. This fact should be considered when antibiotics 
are ad m in is te red  co n cu rren tly  with c o r t ico s te ro id s  for a 
prolonged period of time (Jenkins, 1984) or in the event of any 
other type of underlying im m unodeficency (m alignant viral
infections, chronic diseases). Conditions where fever, uraemia, 
d e h y d ra t io n  or h y p o a lb u m in ae m ia  ex is t  a lso  a l te r  the 
pharmacokinetics of drugs and an adjustment of the dose will be 
necessary when they exist (Baggot, 1989).
The use of antimicrobial combinations is a common practice in 
veterinary medicine (Brumbaugh, 1986) and can also cause the 
treatment to fail. Antibacterial combinations are widely used and
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can  have a synerg is tic  e ffec t when less than ha lf  the 
concen tra tion  of each antib iotic  is required to inh ib it the 
organism to the same extent as either individual agent alone. If 
the amount of each antibiotic given in combination is half of the 
in h ib i to ry  co n cen tra t io n  requ ired  when g iven  alone , the 
combination is defined as additive and when more than half of 
the individual concentrations are required when given together 
then the combination is antagonistic (Rahal, 1978). In general, a 
sy n e rg is t ic  e f fe c t  is a ch iev ed  w hen  tw o b a c te r ic id a l  
antim icrobials such as the penicillins and aminoglycosides are 
combined (W atanakunakorn, 1971). However this is not always 
the case since it depends on the particular antibiotic used and the 
bacteria responsible for the infection. W henever an antagonistic 
combination is used, the treatment is likely to fail. In general, 
bac te r io s ta t ic  agents ( te tracyc lines ,  ch lo ram p hen ico l)  when 
com bined with bactericidal ones (penicillins , cephalosporins, 
aminoglycosides) tend to have an antagonistic effect especially 
when the bacteriostatic antibiotic is administered first. This has 
been a ttributed  to the conversion of a growing bacterial 
population into a static one by the bacteriostatic agent, on which 
bactericidal antibiotics such as the penicillins cannot exert their 
effect (Rahal, 1978; Paul, 1987). Also some workers have shown 
th a t  the p re sen c e  o f  a b a c te r io s ta t ic  agen t such as 
chloramphenicol can inhibit the enzymes responsible for bacterial 
lysis in the presence of penicillins (Rahal, 1978).
Finally, the presence of resistance among bacterial isolates has to 
be considered as a common cause of treatment failure during 
antibiotic therapy. Resistance to some antibiotics and variations 
in the MIC values have appeared more and more frequently in
the equine litera ture. The antib iotics com m only used with
prophylactic or therapeutic intention, especially in the field of 
reproduction, tend to eliminate the susceptible strains of bacteria 
leaving resistant ones which become the dominant population. 
The genetic information responsible for the resistance in some
strains can also be transm itted , mainly by plasm ids, into
susceptible bacteria  (L inton, 1982). The clinician should be 
suspicious of the presence of resistant strains in therapeutic 
failure especially when the dosage being used is based on
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relatively old sensitivity and MIC values. In order to limit the 
potential for development of resistance, antibiotics should not be 
used indiscrim inately .
1.2 The penic il l ins
1.2.1 C h em istry  and m etabol ism
The penicillins constitute a group of antibiotics characterised by a 
common basic chemical structure consisting of a thiazolidine ring 
and a beta-lactam  ring together with a side chain (Fig 1-1). 
Penicillin was discovered in 1928 by Alexander Fleming, and 
subsequently a large number of semisynthetic penicillins were 
deve lop ed .
Variations of the side chain have led to the development of new 
penicillins which differ in their spectrum of activity, acid stability 
and pharm acokinetic  behaviour. Following adm inistration, the 
penicillins undergo little metabolism and are excreted mainly as 
the parent compound .in the urine (Mandell & Sande, 1980).
1.2.2 M echanism  of action
The penicillins owe their activity to their effect on the bacterial 
cell wall. The cytoplasmic membrane of bacteria is surrounded by 
a robust wall which confers shape on the cell and prevents its 
osmotic rupture. The cell walls of gram -positive and gram- 
negative bacteria  differ. Both contain peptidoglycan which is 
formed by two alternating amino sugars (N-acetylglucosamine 
and N-acetylmuramic acid) with peptide side chains cross-linked 
by peptide bonds. The peptidoglycan of gram positive bacteria is 
relatively thick (50 to 100 molecules) and is interspersed and 
covalently linked to other polymers such as teichoic acid and 
p o ly s a c c h a r id e s .  G ra m -n e g a t iv e  b a c te r ia  have  a thin  
peptidoglycan layer (1 to 2 molecules) surrounded by an outer 
m em b ran e  c o n s i s t in g  o f  p h o s p h o l ip id s ,  p ro te in s  and 
lipopoly saccharide .
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Figure 1-1. Basic molecular structure of penicillin and ampicillin 
m olecules.
The lack of peptidoglycan in m ammalian cells makes this 
structure an excellent target for antibacterial action since its 
presence is necessary for bacterial integrity (Brumbaugh, 1987). 
P ep tid o g ly can  p recu rso rs  are syn thesized  in the bacteria l 
cytoplasm and transported across the cytoplasmic membrane on 
a lipid carrier molecule. The peptidoglycan cross-linking is the 
f ina l s tage  in the b io sy n th es is ,  and is ach ieved  by a 
transpeptidation reaction. It is at this final stage of peptidoglycan 
synthesis that the beta lactam antibiotics work. N-acetyl muramic 
acid, contains a peptide side chain which cross links to its 
neighbours. The transpeptidase enzyme interacts with the D- 
alanyl-D-alanine end of the peptide side chain during the cross 
linking transpep tida tion  reaction (Park, 1987). Beta  lactam  
antib io tics are steriochem ically  sim ilar to D -alanyl-D -alanine 
(W axm am  et al ., 1980) and the transpeptidase enzyme may use 
the penicillin as a false substrate interaction which inactivates it 
to a covalently  bound penicilloyl-enzym e complex (Fig. 1-2) 
(Tipper & Strominger, 1965).
Transpeptidase is the main target protein for the beta lactam 
antibiotics, however many bacteria have been shown to contain 
other penicillin binding proteins (PBPs) which are enzymes whose 
interaction may also be detrimental to the organisms (Spratt, 
1975). The bactericidal activity of penicillins is the result of lysis 
of bacterial cells. The lytic action is thought to be associated with 
cell wall "autolysins" which are normally released in a genetically 
controlled manner during the separation of daughter cells during 
bacterial reproduction. It appears that the presence of penicillins 
with their detrimental effect on the peptidoglycan biosynthesis, 
cause bacterial death during the phase of autolysin activity. 
However some workers have suggested that the autolysins are 
in h ib ited  n a tu ra lly  by am ph ipa th ic  m em brane  assoc ia ted  
substances within the bacteria and beta lactams may dissociate 
autolysin inhibitor complexes (Tomasz, 1979; Russell & Chopra, 
1990 a).
The penicillins have greater activity against actively growing 
bacteria than non-growing bacteria. The reason for this is not 
fully understood although it has been suggested that when PBPs 
which are not synthesising peptidoglycan are bound by beta
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Figure 1-2. Analogous structure of penicillins and D-alanyl-D- 
alanine (Tipper & Strominger, 1965).
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lactam s the interaction does not activate autolysins whereas 
interaction with active PBPs does activate the autolysins (Russell 
& Chopra, 1990 a).
Finally, the spectrum of activity of the various penicillins is not 
related to the affinity of penicillin binding proteins for the
an tib io tic  but rather to the ability  of the broad spectrum  
penic illins to penetrate the outer bacterial m em brane of the
gram -negative bacteria and thus reach the loci of the target 
proteins. This penetration of the outer membrane occurs through
aqueous channels created by proteins called porins which are
present within the lipopolysaccharide and phospholipid of the
outer m em brane.
1.2.3 Tox ic i ty  and adverse reactions
Hypersensitivity, which may present as mild urticaria, fever or 
angioneurotic oedema or as acute anaphylaxis and collapse, is the 
most common side effect following the administration of any
penicillin and there is cross-sensitization in animals for different 
members of the group. Penicillins or their break-down products, 
in particu lar the penicilloyl moiety (with opened beta lactam 
ring), become antigenic as haptens upon binding with plasma 
proteins. Hypersensitivity reactions to penicillins in horses are
rare, affecting less than five per cent of treated horses (Ingham & 
Large, 1969) and where they have been reported it is as a 
consequen ce  of adm in istra tion  of benzy lpen ic il lin  and the 
associated sodium and potassium salts may have contributed to
the reactions observed (English & Roberts, 1983)
The administration of the penicillins by the oral route to adult 
horses is likely to result in severe gastrointestinal disturbances. 
This has been reported by Baggot and others (1990) following the 
administration of penicillin G and penicillin V to adult horses. 
These d istu rbances are likely to be the result of a large 
proportion of the administered penicillin not being absorbed into 
the sys tem ic  c ircu la tio n  and consequen tly  d is rup ting  the 
microbial ecosystem of the equine large intestine.
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Ampicillin achieves high concentrations in the caecum of horses 
following oral administration and may also be detected in the 
caecum after intravenous administration although at much lower 
concentra tions. Furtherm ore  the bacterial popu la tions in the 
caecum change after oral administration of ampicillin  with an 
increase  in v iab le  co lifo rm s, s trep tococci, lac to b a c i l l i  and 
clostridia (Horspool, 1992). These changes are sim ilar to those 
described following administration of oxytetracycline which also 
caused the development of enterocolitis (Andersson et al ., 1971; 
White & Prior, 1982).
The aetiology of antim icrobial associated enterocolitis  is not
understood, however it seems likely that a num ber of factors 
affect its development. These include the amount of antimicrobial 
de livered  to the caecum  and colon and its spectrum  of
an tim ic ro b ia l  ac tiv ity , the com m ensal bac teria l  popu la tion  
present in the gut, the presence of potential bacterial pathogens
in the environment, and other factors which could affect the 
commensal bacteria such as dietary changes and "stress".
Other forms of toxicity and adverse reactions are extremely rare 
with penicillin antibiotics although where oil-based preparations 
are given by the intramuscular route they may cause pain and 
swelling at the injection site. Penicillin has been associated with 
haem olytic  anaem ia and acute hepatic failure although the
incidence of this is likely to be very low (Step et al ., 1991).
1.3 Penicil l ins in the horse
1.3.1 Penicill in G and penicillin V
Penicillin G is the basic penicillin molecule and the most active on 
a molar basis against susceptible gram-positive aerobic bacteria 
(Sandholm  et a l ., 1990). This antibiotic is widely used in the 
equine for the treatment of meningitis and polyarthritis caused 
by Streptococcus  zooepidemicus  in the foal, wound infection, and 
genitourinary infections (Prescott & Baggot, 1988b). It is also the 
antibiotic of choice for the treatment of S t r e p to c o c c u s  equi  
infections ( ie ,  strangles) and is a very useful antibiotic for the
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treatment of suppurative respiratory disease in the horse where 
S. zooep idem icus  is the most commonly found pathogen (Reif, 
1979; Love et al., 1983). It can be administered as the sodium or 
potassium salt (also called 'soluble' or 'crystalline' penicillin), as 
the procaine or benzathine salt of penicillin and as the acid 
res is tan t  phenoxym ethyl form for oral adm inistration. These 
different forms vary in their absorption rates from the site of 
a d m in is t r a t io n
In the horse there are no phenoxymethyl penicillin (penicillin V) 
preparations licensed and penicillin G is generally administered 
IV, IM and as a uterine infusion. W hen penicillin  G was 
administered orally to horses, only 2.87 % was absorbed from the 
gastro in tes tina l tract and severe gastro in tes tina l disturbances 
followed (Baggot et al ., 1990).
The highly soluble salts (sodium and potassium) are mainly used 
when rapid high concentrations are required such as the initial 
stages of acute infections, and they should also be considered the 
drugs of choice for the treatment of infections caused by beta- 
haemolytic streptococci which are common in the equine patient 
(Traver & Riviere, 1981). Nevertheless the high solubility and 
rapid absorption of these aqueous forms after IM administration 
and their very short half-life means that, when therapeutic levels 
are to be maintained, repeated doses (every four to six hours) 
should be given (Spurlock & Wilcke, 1986). In addition, Durr 
(1976) found that 52 to 54 % of penicillin G was bound to plasma 
proteins and this might limit the tissue concentrations achievable. 
It should also be borne in mind that the sodium and potassium 
salts of penicillin G should be used with care in the compromised 
patient with electrolyte imbalance since the formulations contain
2.3 mEq of sodium and 1.7 mEq of potassium respectively per 
million iu of penicillin (Brumbaugh, 1987).
To overcome the very short half-life of the sodium and potassium 
penicillin G salts, a longer acting compound such as procaine 
penicillin G can be used in later stages of infections caused by 
g ra m -p o s i t iv e  b a c te r ia .  Even w ith  the p ro c a in e  sa lt,  
concentrations greater than MIC values will be achieved very 
quickly. W hen used at twenty-four hour dosage intervals the 
procaine salt is the commonest preparation of penicillin used in
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equine medicine (Prescott & Baggot, 1988b). Love and others 
(1983) recommended that treatment should begin with an IM 
administration of penicillin G at a 10,000 iu/kg follow ed by 
procaine penicillin administered IM at 15,000 iu/kg every 12 h 
or 30,000 iu/kg every 24 h. However, some w orkers have 
suggested that the single administration of procaine penicillin  
may not be as effective against gram-positive bacteria as the 
soluble penicillin G salts because lower peak concentrations of the 
drug are achieved regardless of the amount administered, and for 
this group of antibiotics peak concentrations may be more 
important than maintenance concentrations (Sullins et a l ., 1984). 
In addition, the possibility of detection of procaine residues two 
weeks post-treatment and the fact that some adverse reactions to 
procaine have been recorded in the horse should also be 
considered before initiating any treatment with this penicillin 
preparation in the horse (Tobin et al ., 1977).
W here very sensitive  m icroorgan ism s are re sp o n s ib le  for 
infection, benzathine penicillin G, a very long acting form of 
penicillin G may be used. The very slow absorption of benzathine 
penicillin G from the site of intramuscular injection allows an 
interdosing interval of seventy two hours (Prescott & Baggot, 
1988b). However, benzathine penicillin is seldom used due to the 
very low maximum concentrations achievable (Love et a l ., 1983; 
Ricketts & Hopes, 1984).
The acid resistant form of penicillin G, phenoxymethyl penicillin 
(Penicillin V) used for oral administration, has been shown to 
have a very low bioavailability  when administered orally to 
horses and foals (1.65 % and 16.04 % respectively). In addition, 
signs of colic and watery diarrhoea were a common feature in the 
adult horses given this antibiotic (Baggot et al ., 1990). Therefore 
the administration of oral penicillin V is unlikely to prove 
appropriate for the treatment of penicillin G sensitive pathogens 
in the horse.
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1.3 .2  P en ic i l l in a se  res is tan t  pen ic i l l in s
Some bacteria such as S ta p h y lo c o c c u s  aureus  are capable of 
destroying the penicillins by breaking down the beta-lactam ring. 
For successfu l treatm ent against infections caused by these 
m icroorganism s, penicillinase-resistant penicillins, the isoxazolyl 
penicillins, have been developed. Oxacillin is the most commonly 
used in the horse and following IM administration good and rapid 
absorption is achieved (Stover et al., 1981).
An alternative to the use of a penicillinase resistant penicillin is 
the use of a combination of a penicillin with an inhibitor of the 
beta-lactamase enzyme such as clavulanic acid and although this 
type of treatment is commonly used in other species (dog, cattle) 
it does not seem to be effective in the horse.
1.3 .3  A n t ip s e u d o m o n a l  p e n ic i l l in s
The carboxypen ic illins  (carbenicillin  and ticarcillin) and the 
ureidopenicillins (mezlocillin, azlocillin and piperacillin) are in 
general active against microorganisms resistant to the common 
broad spectrum penicillins. The carboxypenicillins (carbenicillin 
and tica rc ill in )  are very effective  against P s e u d o m o n a s  
a e r u g i n o s a  infections, some P r o t e u s  and en te rob ac te r iac iae  
although Klebs ie l la  spp are resistant (Wright & Wilkowske, 1983). 
In equine antibiotic therapy they are used for the treatment of 
bacterial endometritis administered as uterine infusions and also 
as part of semen extenders (Asbury, 1986). K lebs ie l la  spp can be 
treated with the ureidopenicillins as can infections caused by the 
anaerobe Bacteroides fragilis .
How ever in general, these new antibiotics are seldom used 
systemically in equine practice because of their prohibitive price 
and lack of kinetic data in the horse and their administration 
should only be recommended in the event of an intransigent 
penicillin resistant bacterium.
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1.3.4 Broad spectrum  penic i l l ins
The pen ic illins described so far, except the antipseudom onal 
penicillins, have activity mainly against gram-positive bacteria. 
This makes their use unreliable when the pathogen responsible 
for the in fec tion  is not known or when more than one 
m icroorganism  is present in the infection. To overcom e this 
p rob lem  p e n ic il l in s  with a w ider spectrum  can be used. 
Am picillin and amoxycillin are two broad spectrum penicillins 
used in equine antibiotic therapy which are characterised by a 
broader spectrum than penicillin G. They are also destroyed in 
the presence of beta-lactamase producing bacteria.
It should be emphasised that in the event of an infection caused 
by susceptible  gram -positive bacteria, it is preferable to use 
penicillin G rather than ampicillin or amoxycillin, since plasma 
concentrations are likely to exceed MIC values by a greater 
margin for equivalent doses.
Amoxycillin is widely used in small animals and man. In these 
species and in calves it has been shown to be absorbed to a large 
e x te n t  f ro m  the  g a s t ro in te s t in a l  t ra c t  fo l lo w in g  o ral 
adm inistration (Zarowny, et al ., 1974; Pugh, 1977; Palmer et al .,
1983). It has been shown that the systemic bioavailability of 
am oxycillin  trihydrate  after oral adm inistration is reasonably 
high (42.7 %) when administered to neonatal foals and therefore 
it could be used in systemic infections (Baggot et al ., 1988 a). Oral 
amoxycillin trihydrate achieved concentrations sufficient to treat 
streptococcal and staphylococcal (non beta-lactamase producing) 
in fec tion s  and su scep tib le  S a l m o n e l l a  t y p h i m u r i u m  and 
Actinobacil lus  equuli  when administered to foals (Love et al.,  
1981). H o w e v e r ,  the p o o r  a b so rp t io n  fo l lo w in g  oral 
adm in is tra t io n  of am oxycillin  in the adu lt horse with a 
bioavailability of 5.3 -10.4 % (Wilson et al., 1988; Ensink et al., 
1992), restricts its use to the IM and IV routes of administration 
in the adult animal.
When sodium amoxycillin was administered IV to mares, the 
antibiotic was rapidly eliminated from the body as reflected in an 
elimination half-life of less than forty minutes, and therefore 
f req u e n t  d o sa g e s  are req u ire d  to m ain ta in  th e ra p eu tic
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concentrations (Wilson et al ., 1988). Another study carried out by 
Montesissa and others (1988) found that amoxycillin sodium was 
rap id ly  d is tr ibu ted  and elim inated  from the body, the IM
bioavailability following administration was 67 % and that 37 % 
of amoxycillin was bound to plasma proteins. On the other hand, 
the administration of amoxycillin trihydrate by the IM route was 
characterised by concentrations greater than 0.5 jig /m l for a 
period of 24 hours although precipitation at the injection site 
occurred when the antibiotic  was adm inistered as a 25 %
formulation (Wilson et al ., 1988).
Ampicillin, the other broad spectrum penicillin used in equine 
prac tice , was the an tib io tic  used during  our studies and 
consequently a full description follows.
1.4 Ampicill in in the horse
Ampicillin (Fig. 1-1) is a widely administered broad spectrum 
antibiotic in equine practice, available as ampicillin sodium for IV 
and IM ad m in is tra t io n  and am pic illin  tr ihydra te  for IM
adm in is tra tion . In add ition , am pic illin  p rodrugs, inc lud ing  
pivampicillin and bacampicillin, have been developed for oral 
administration in human medicine. Recently pivampicillin was 
investigated in the horse as an alternative for the treatment of 
infectious diseases by the oral route (Ensink et al ., 1992). 
Ampicillin sodium seems to produce fewer reactions at the site of 
injection than the trihydrate  form ula tion  and better blood 
concentrations are achieved (Tobin, 1979). However, the soluble 
sodium salts are unstable and lose their activity a few hours after 
being reconstituted, the insoluble trihydrate form is much more 
stable and has a storage lifespan of a few months. The differences 
in solubility make the sodium preparation more suitable for those 
situations where higher plasma and tissue concentrations are 
required. Ampicillin trihydrate on the other hand, produces lower 
plasm a concen tra tions  over longer periods making it very
suitable for the treatment of highly sensitive microorganisms. In 
addition, both formulations can be administered either on their
own or in combination with other bactericidal antibiotics such as
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the aminoglycosides in order to achieve a synergistic effect or in 
combination with beta-lactamase inhibitors. The combination of a 
penicillin with an aminoglycoside has been shown to have a 
syne rg is t ic  e f fe c t  in m any in fec tio n s ,  p a r t icu la r ly  when 
gentamicin is the aminoglycoside used. However, the widely used 
combination of penicillin with streptomycin did not demonstrate 
a synergistic effect against many enterococci isolated from urine 
and wounds (Rahal, 1978).
Ampicillin is used for the treatment of many bacterial infections 
caused by gram-positive and gram-negative bacteria. Its activity 
against common equine pathogens, its wide safety margin and
relatively low price make this penicillin a popular choice for the 
treatment of equine infections (Baggot & Prescott, 1987). 
Ampicillin has been shown to be effective in the treatment of 
many equine conditions including resp ira tory  infections, skin 
infections, skeletal and synovial infections or septicaemia when 
administered alone or in combination (Keefe et al., 1980; Ricketts 
& Hopes, 1984; Baggot & Prescott, 1987; Furr, 1989). There are 
wide variations in the recommended dosage and it may be
appropriate to adjust the dose for specific cases depending on the 
severity of the infection, susceptibility of the pathogens that are 
likely to be involved and the site of infection. However, a dosage 
regime of 10 to 20 mg/kg every 6 to 8 hours with ampicillin 
sodium and every 8 to 12 hours with ampicillin trihydrate has 
been recommended by different authors as the most suitable for
the treatment of sensitive pathogens in the horse (Beech et al ., 
1979; Prescott & Baggot, 1988b; van Miert, 1988; Horspool et al ., 
1992).
1.4.1 Chem istry  and metabol ism
Ampicillin and its ester congeners, bacam picillin  (1-ethoxy-
carbonyloxyethy l ester) and p ivam picill in  (p ivaloyloxym ethyl 
ester), are semi-synthetic penicillins. The side chain on the beta 
lactam ring confers greater acid stability, on ampicillin compared 
to benzylpenicillin, and increases its bioavailability in the host 
after oral administration and entry into gram-negative bacteria. 
Both ester congeners are inactive as parent molecules since they
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have a side chain on the th iazolidine ring. Follow ing oral 
administration they are hydrolysed, both in the mucosal cells of 
the gastrointestinal wall and in plasma, to the active ampicillin 
molecule. In the horse the ester side chain markedly improves 
the oral b ioava ilab ili ty  o f the am picillin  h y d ro ly sa te  of 
pivampicillin (30.9 % in fasting horses and 35.9% in fed horses) 
(Ensink et al ., 1992) compared to ampicillin (3.5%) (Horspool, 
1992). A small proportion of ampicillin is metabolised, and three 
m etabolites, (5R, 6R )-pen ic illoate , the (5S, 6R )-ep im er and 
p iperaz ine-2 ,5 -d ione , were de tec ted  in the urine fo llow ing  
administration of ampicillin to human beings (Haginaka & Wakai, 
1986). However, like the rest of the penicillins, ampicillin is 
rapidly elim inated by glom erular filtration and renal tubular 
secretion mainly in the unchanged form. Experim ental studies 
have shown that ampicillin is partially eliminated in the bile of 
human beings (Mortimer et al ., 1969). Also, a small amount of 
am picillin  (<4%) may be elim inated via the bile into the 
gastrointestinal tract following intravenous administration to pigs 
(Galtier & Alvinerie, 1979) and ponies (Horspool, 1992).
The use of prodrugs could po ten tia lly  overcom e the risk 
associated with orally administered ampicillin. These drugs are 
administered in an inactive form which should not affect the 
enteric microflora, and this rationale has been utilised for the oral 
administration of pivampicillin (Ensink et al., 1992).
1.4 .2  P h a r m a c o k in e t i c s
The efficacy of ampicillin and other antibiotics in the treatment of 
equine infectious diseases is directly related to the concentration 
and the duration achieved at the site of infection (Prescott & 
Baggot, 1988a). These two factors, depend on the physicochemical 
properties of the antibiotic, the route of administration and the 
dosage administered.
The pharm acokinetic  charac teris tics  of am picillin  have been 
studied in the horse after intravenous administration at different 
dosage rates (Durr, 1976; Bowman et al ., 1986; Ensink et al ., 
1992; Horspool et a l , 1992). These studies showed that ampicillin 
was distributed and eliminated rapidly and had short distribution
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and elimination half-lives and high body clearance rates in the 
horse. For instance, the elim ination half-life ranged from a 
minimum of 0.75 h (Horspool et al ., 1992) to a maximum value of 
1.72 h (Ensink et al ., 1992). These results indicate that frequent 
dosage is required to maintain therapeutic plasma and tissue 
concen tra tions  of am picillin  unless the pe rs is tence  of the 
antib iotic  is prolonged, by form ulation charac teristics  or by 
competitors of elimination.
The rapid elimination of ampicillin from the body is the result of 
a very efficient excretory mechanism located in the proximal 
tubule o f the nephron. An active transport m echanism , is 
responsible for the transfer of ampicillin from the blood stream 
into the urinary filtrate. In addition, a proportion of the non 
protein bound fraction of ampicillin is also eliminated into the 
urine by glomerular filtration. From the urinary filtrate, the 
transferred substances can passively diffuse back into the plasma 
from the tubules. This diffusion occurs when the substances 
present in the urinary filtrate are in their nonionized form which 
depends on the pH of the filtrate and the pKa of the antibiotic. 
Alteration of urinary pH has been shown to affect the excretion 
rate of several drugs and is used therapeutically  in human 
medicine to prolong the effects of some drugs or to increase the 
elimination rate during intoxication. However, no studies have 
been carried out to date to evaluate whether changes in urinary 
pH would affect the pharmacokinetic behaviour of ampicillin in 
the horse. Potential changes in the plasma disposition of the 
antibiotic may require the establishment of different therapeutic 
regimes according to whether the horse had an acidic urine 
(horses in training) or an alkaline urine (horses grazing).
The concurrent administration of penicillins with probenecid, a 
competitive inhibitor of the renal tubular secretion of organic
anions, decreases significantly the rate of excretion of penicillins 
and cephalosporins (Juzwiak et al ., 1989; Donecker et al ., 1986; 
Levy, 1965; Gibaldi et al., 1968). This could be a practical method
of prolonging the excretion of ampicillin in the horse and will be
discussed later.
In addition to the characteristic  rapid elim ination and high 
c le a ra n c e  ra te  o f  a m p ic i l l in ,  d e te rm in a t io n  o f  o th e r
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pharm acok inetic  variab les in various studies in d ica te s  that 
ampicillin has a relatively poor distribution in the body following 
administration. This is reflected in the values obtained for the 
volume of distribution at steady-state ranging from 170.0 ml/kg 
(Bowm an et al ., 1986) to 210.8 ml/kg (Horspool et al., 1992). 
Antibiotic levels in tissue fluids are in equilibrium with the non 
protein bound fraction of the drug in plasma (Keen, 1989) and 
ampicillin is bound to equine serum proteins only <10 per cent 
(Durr, 1976). It is likely therefore that am picillin  distributes 
alm ost exclusively  in the ex tracellu lar fluid and does not 
penetrate into the intracellular fluid in significant amounts.
In practice, IM injection is probably the most comm only used 
route for the administration of ampicillin in the treatm ent of 
equine bacterial infections. Several equine studies, have shown 
that peak plasm a concentra tions after IM adm in istra tion  of 
ampicillin sodium are achieved within the first half hour and that 
the concentrations obtained are sufficient to kill susceptib le  
organisms for several (up to eight) hours (Evans et al., 1971; 
Knight, 1975; Beech et al., 1979; Keefe et al., 1980; Traver & 
Riviere, 1982; Firth et al., 1988). On the other hand, when 
am pic il lin  tr ihy d ra te  was adm in is te red  IM, peak  p lasm a 
concentrations occurred later (tmax 4-6 hours) and lower plasma 
concentrations were achieved compared to the ampicillin sodium 
formulation given at the same dose rate (Cmax 1.48 pg/ml vs 6.0 
pg/ml) (Beech et al., 1979; Brown et al., 1982). The differences in 
absorption could be due to a slower rate of d issolution or 
precipitation at the injection site. The less soluble trihydrate salts 
give lower concentrations but can be administered at 12 h 
intervals (Beech et al., 1979; Prescott & Baggot, 1988b). Both the 
sodium  and trihydra te  salts produce  plasm a concen tra tions  
directly related to the dose administered and the absorption of 
the antibiotic from the site of injection. However, when rapid and 
high tissue concentrations are required, the intravenous route 
should be used as tissue levels are directly related to peak 
plasma concentrations.
The oral administration of most penicillins in the horse is 
a s so c ia ted  w ith  p oor ab so rp t io n  and the p re se n c e  of 
gastro intestinal disturbances (Baggot et al., 1990). Among the
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am inopenicillins, am oxycillin  has been adm inistered orally to 
horses in different experimental studies. In 5-to-10-day-old foals 
the absorption achieved was 36.2 % (20 mg/kg) and 42.7% (30 
mg/kg) (Baggot et al ., 1988 a), but only 10.4 per cent (Wilson e t  
a l ., 1988) and 5.3 per cent (Ensink et a l ., 1992) of the dose 
administered was absorbed in studies carried out in adult horses. 
A m p ic i l l in  a d m in is te re d  o ra l ly  a c h ie v e d  peak  p la s m a  
concentrations of 5 p g /m l in two-day-old foals but only 2.7 
p g /m l  in 1 6 -to -21 -day -o ld  foals . U n fo r tu n a te ly  the oral 
bioavailability was not determined in this study (Brown et al .,
1984). In adult animals, the administration of ampicillin orally 
was characterised by lack of absorption with a bioavailability of 
3.5 per cent (Horspool, 1992).
Recently, the experimental oral administration to horses of an 
ampicillin prodrug, pivampicillin, has shown that high absorption 
from the gastrointestinal tract can be achieved (Ensink et a l ., 
1992). The rapid transformation of this ester of ampicillin into 
the active compound is carried out by the intestinal and plasma 
non-specific esterases. Furthermore, the enhanced absorption of 
this prodrug reduces the chances of dysbacteriosis that may be 
caused by the oral administration of the active compound. Once in 
the plasma the transformation into ampicillin has been shown to 
be completed in less than ten minutes in man (Neu, 1981). In the 
horse, the bioavailability of pivampicillin ranged from 30.9 per 
cent in fasted horses to 35.9 per cent in fed horses (Ensink et a l ., 
1992). The peak plasma concentrations after administration of 
pivampicillin to fed horses was reached within the first hour and 
ampicillin was subsequently eliminated in the usual way. The 
high oral bioavailability obtained with this ampicillin prodrug 
may allow oral therapy in the horse whereas very few 
an tib io tic s ,  in c lu d in g  o ther p e n ic il l in s ,  are su i tab le  for 
administration by this route.
To evaluate the penetration of ampicillin into equine body 
cavities, various studies have measured ampicillin in different 
body f lu ids . W hen am p ic il l in  sodium  was a d m in is te re d  
intramuscularly at a 10 mg/kg dosage rate, maximum synovial 
f lu id  c o n c e n tra t io n s  w ere  a c h iev e d  50 m in u te s  a f te r  
administration and synovial fluid concentrations greater than 1
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jig/ml were maintained for more than eight hours (Firth et a l .y 
1988). Once ampicillin attained equilibrium between the synovial 
fluid and the plasma, the elimination of the antibiotic from the 
synovia paralelled the antibiotic decline in plasma (Bowman e t  
a l . y 1986). In addition, higher concentrations of ampicillin were 
obtained in the synovial fluid of joints with induced synovial 
inflammation (Firth et al ., 1988). When ampicillin trihydrate was 
administered to horses by the IM route in two separate studies, 
mean peak synovial fluid concentrations of 1.65 jig/ml and 2.3 
jig/ml were reached at four and six hours respectively, and the 
antibiotic could still be detected in synovial fluid 48 hours after 
its administration (Beech et al ., 1979; Brown et al ., 1982). A mean 
peak peritoneal fluid concentration of 1.81 Jig/ml was also 
measured 4 hours after the IM adm inistration of ampicillin  
trihydrate at a dosage of 20 mg/kg bodyweight to adult mares 
(Brown et al., 1982).
1.4.3 Am pic i l l in  spectrum of  activity
Pharmacokinetic data for antimicrobial agents cannot be used to 
predict dosage regimens without knowledge of the susceptibility 
of the target organisms. Sensitivities of the bacteria can be
obtained in vitro by the Kirby-Bauer disc method which gives 
qualitative inform ation (Bauer et al ., 1966) or by the broth 
dilution method which gives quantitative data (Prescott & Baggot,
1985). Quantitative sensitivity patterns are defined in terms of 
minimum inhibitory concentrations (MIC), which represent the 
minimum antibiotic  concentration necessary to inhibit visible 
bacterial growth. Although this in vitro measurement of bacterial 
susceptibility does not take into account many of the effects that
occur in vivo such as the bactericidal activity of the serum, the
enhanced activ ity  of macrophages against antibiotic damaged 
bacteria and the post-antibiotic effect, MIC data are still the most 
reliable laboratory method for the determination of bacterial 
susceptibility . A ppropriate  dosages based on pharm acokinetics 
and bacterial sensitiv ity  should ultim ately  be confirm ed in
clinical trials (Prescott & Baggot, 1985). In the horse, different 
workers have investigated  the sensitivity  of common equine
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pathogens to ampicillin and other antibiotics (Knight & Hietala, 
1978; Keefe et a l ,  1980; Adamson et al., 1985; Hirsh & Jang, 
1987; Snyder et al., 1987; Moore et al., 1992; Ensink et al., 1993). 
It has been suggested that an organism is susceptible when the 
mean plasm a concentration obtained during the usual dosing 
interval is at least twice the MIC value. On this basis, it was 
suggested that bacteria with MIC values for ampicillin of less 
than 1 j ig /m l should be considered as suscep tib le  to this 
an tib io tic  (A dam son et al., 1985). In addition, the National 
Com mittee for C lin ical and Laboratory Standards (NCCLS), 
considers bacteria with MIC values for ampicillin of 2 to 16 
pg/m l as moderately susceptible and bacteria with MIC greater 
than 16 Jig/ml as resistant (Prescott & Baggot, 1988c). In the 
United Kingdom , the Veterinary Products Com m ittee (VPC) 
guidelines recommend that peak plasma concentrations of at least 
double the MIC value should be achieved and that plasma 
concentrations greater or equal to the MIC should be maintained 
for at least half the dosing interval.
Various studies carried out on equine isolates reported that non 
beta lactamase producing Staphylococcus aureus, Streptococcus  
zooepidemicus,  Streptococcus equi, Streptococcus pneumoniae,  
Pasteurella, Corynebacterium pseudotuberculosis , Fusobacterium  
n e c r o p h o r u m ,  B a c t e r o i d e s  species, and most isolates of 
A ct inobac i l lu s  equuli  are sensitive to ampicillin (Keefe et al., 
1980; Prescott, 1981; Adamson et al., 1985; Hirsh & Jang, 1987). 
In addition, many Escher ich ia  coli,  R h o do co ccu s  equi  and 
S a l m o n e l l a e  fall into the moderately susceptible category with 
Klebs ie l la  p n e u m o n ia e , P seu d om o n as  aeru g in o sa  and P r o t e u s  
species being resistant to ampicillin. The presence of resistance 
among the different bacteria such as Staphylococcus aureus, E. 
coli, Bacteroides fragilis ,  and  E. coli strains, can be related in 
general to the production of beta-lactam ase enzymes. It is 
important to point out that the number of bacterial isolates 
becoming resistant to ampicillin is increasing, particularly among 
the isolates belonging to the moderately susceptible category E . 
coli  and S a lm o n e l la  species (Donahue, 1986; Snyder et al., 1987; 
Sato et a l ,  1988).
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1.4 .4  R e s i s ta n ce
Resistance of bacteria to antim icrobials can be classified  as 
intrinsic such as resistance of some gram-negative organisms to 
penicillin G or acquired resistance, which is a result of the 
widespread and often irrational use of antibiotics (Linton, 1982; 
Ndikuwera and Winstanley, 1987).
Acquired resistance to beta-lactam antibiotics occurs when the 
permeability of the outer membrane of gram-negative bacteria to 
the beta-lactam decreases, when beta-lactamases are synthesized 
or when the penicillin binding proteins are modified (Russell & 
Chopra, 1990 b).
Reduction in the permeability of the outer membrane may be the 
result of mutations which lead to the loss of porin proteins. These 
normally allow the diffusion of the broad spectrum beta lactams 
th ro u g h  the  o u te r  m em b ran e  o f  the  g r a m -n e g a t iv e  
m icroorganism s. However, the production of beta-lactm ase, an 
enzyme responsible for the degradation of penicillins into the 
inactive penicilloic acid is probably the most common mechanism 
of resistance to beta-lactam antibiotics. The enzyme synthesis can 
be plasmid or transposon encoded or alternatively some bacteria 
have the innate genetic ability to generate beta-lacatamase. In 
these bacteria, beta-lactamase is normally produced at low levels 
until the bacteria are exposed to a beta lactam antibiotic or a 
m utation occurs. W henever this happens, bacteria  may be 
induced to produce beta lactamase in large quantities leading to 
the appearance of resistance. Finally, mutations can also affect 
the penicillin binding proteins which become insensitive to the 
beta lactam antibiotic. This form of resistance has been shown to 
occur in the treatment of S tre p to c o c c u s  p n e u m o n ia e  w i t h  
penicillin G in humans (Russell & Chopra, 1990 b).
In veterinary medicine, ampicillin resistant strains of P r o t e u s  
spp., E. coli  and S a l m o n e l l a  spp. (Prescott & Baggot, 1988b; 
Donahue, 1986; Moore et a l ., 1992) are a common finding. In 
addition, a large proportion of S. aureus  (up to 80% in human 
infections) produce beta lactamase which diffuses extracellularly 
due to the absence of the outer cell membrane in gram-positive 
bacteria (Sande & Mandell, 1985). To overcome the problem
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created by the production of beta-lactamases, the penicillins can 
be com bined with beta-lactam ase  inhibitors. A m oxycillin  is 
currently  com bined with clavulanic acid and often used in 
veterinary medicine although not in the horse. Ampicillin has 
been combined with sulbactam, another beta lactamase inhibitor 
although this combination has been restricted almost exclusively 
to human therapy. Both clavulanic acid and sulbactam  are 
i r r e v e r s ib le  b e ta - la c ta m a s e  in h ib i to r s  w ith  v e ry  l i t t le  
antibacterial activity of their own. Little information is available 
on their effects in horses, a lthough the adm in istra tion  of 
c lavulanic  acid has been shown to produce gastro in testina l
d isturbances in 10% of treated human patients (Prescott & 
Baggot, 1988b). Com bining the am inopenic illins with beta- 
lactam ase inhibitors would be a useful and rational way of 
overcom ing this type of resistance. U nfortunately  the beta
lactamase inhibitors are not currently marketed on their own 
and anim al therapy depends on fixed dosage com binations 
licensed for specific animal species.
The incidence of bacterial resistance is increasing in veterinary 
medicine and this may be due to the irrational use of antibiotic 
therapy. For instance errors in the dosage administered such as 
the administration of small dosages or inadequate frequency of 
treatment can yield sub-MIC plasma and tissue concentrations 
which increase the incidence of resistance (Powers et a l ., 1984). 
In addition, the choice of the wrong antibiotic can cause the
elimination of sensitive organisms, leading to the establishment 
of a resistant bacterial population while the original aetiological 
agents are present. In equine therapy, little inform ation  is 
available on the extent of bacterial resistance to antibiotics. 
However, nosocomial infections are the most common cause of 
infections with resistant bacteria. These infections are defined as
the infections acquired and produced by microorganisms present 
during hospitalisation. One report on the incidence of nosocomial 
infections in an equine hospital showed that 3.5% of the horses 
hospitalised acquired nosocomial infections and of these, 96% 
were multiresistant to antibiotics. The incidence of ampicillin 
resistant strains among the nosocomial infections was 100% for
E.co l i  and 83% for E n te ro b a c te r  spp compared to an incidence of
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57% and 50% for the same bacteria isolated from patients 
infected oustside the hospital (Koterba et al ., 1986). In addition, 
the incidence of resistant E. coli and K l e b s i e l l a  was studied 
showing that the number of resistant strains isolated from faecal 
samples increased significantly seven days after hospitalisation 
(Koterba et al ., 1986)
These results show that the use of antimicrobial therapy should 
be evaluated in every circumstance, taking into acount all the 
factors that can lead to the appearance of res is tance  and 
therefore trying to minimize its incidence especially in those 
situations where the appearance of resistance is most likely to 
occur (ie, in hospitals).
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C h a p te r  2 
G e n e ra l  m a te r i a l s  a n d  m e th o d s
3 0
2.1 A nim als
Five Thorougbred geldings (numbers 1 - 5 )  with ages ranging 
from 7 to 22 years (13.4 ± 2.97, mean ± SEM), two riding mares 
(numbers 6 and 7) aged 8 and 12 respectively, two Shetland 
pony mares (numbers 8 and 9) 6 and 18 years of age and two 
Shetland pony geldings (numbers 10 and 11) aged 13 and 14 
years, were used during the experiments.
The w eigh ts  of each  ind iv idua l  an im al va ried  be tw een  
experiments and the dosage rates were adjusted for each animal 
according to its weight prior to the experimental procedure.
2.2  H u sb a n d r y
All the animals were stabled in boxes during the experimental 
procedures with free access to water and were fed hay twice a 
day. A minimum acclimatisation period of four days was allowed 
for animals that had been kept outdoors before commencing any 
experiment and a washout period of at least two weeks was 
allowed between experiments.
2.3 Drug adm inis trat ion  and sampling
2 .3 .1  I n t r a v e n o u s  b o lu s  d o s e  a d m i n i s t r a t i o n  and  
s a m p l i n g
Ampicillin sodium (Penbritin, Beecham Pharmaceuticals) as a 100 
mg/ml solution (20 ml sterile, pyrogen free water (Animalcare 
Ltd, York, UK) per 2 g vial of ampicillin) was administered 
in travenously, via a Microlance (0.9 mm x 25 mm) needle 
(Becton, Dickinson and Company, Ireland), at a dose rate of 10 
mg/kg bodyweight into the right jugular vein. Heparinised blood 
samples were collected in lithium heparin syringes ( 1 0  ml 
M onovette, Sarstedt Lim ited, Leicester, England) by jugu la r  
v e n e p u n c tu re  from  the c o n tra la te ra l  ve in  b e fo re  drug
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administration and at 2, 5, 10, 15, 30 and 45 minutes and 1, 1.5,
2, 4, 8 , 12 and 24 hours afterwards. Blood samples were 
centrifuged at 1700 g for 10 minutes, the plasma was removed 
and stored at 0 - 4 Q C together with prepared am picillin
standards in p lasm a. P lasm a sam ples and s tandards were 
subsequently analysed on the following day.
2.3 .2  In travenou s  infus ion  ad m in is tra t ion  and sam p lin g
Ampicillin sodium was administered as an intravenous infusion 
to horses over a four-hour period at various dosage rates.
In order to achieve steady-state levels rapidly, an intravenous 
bolus dose of 2  mg/kg of ampicillin sodium was administered
immediately prior to each infusion. For the administration of 
ampicillin sodium as an intravenous infusion, 5 ml of local 
anaesthetic was injected subcutaneously over both jugular veins 
in the mid-neck region and a 14 gauge, 80 mm IV catheter
(Intraflon 2, Trocart catheter IV Teflon, Vygon, France) was 
placed in each jugular vein connected to a three-way tap (Rocket, 
England) and sutured to the skin. The catheter was flushed with 
heparinised saline.
Vials containing 2 g of ampicillin sodium powder (Penbritin, 
Beecham Pharmaceuticals) were made up with 20 ml of pyrogen 
free water to give sterile solutions with a concentration of 1 0 0  
mg/ml. The volume required for infusion was calculated and an 
equivalent volume removed from a 500 ml sodium chloride fluid 
replacement bag (Aqupharm, Animalcare Limited, York). This 
was replaced with the required volume of the 1 0 0  mg/ml
ampicillin sodium solution, and was connected to an intravenous 
solution adm inistration set with filter (Travenol Laboratories 
LDT, Thetford, Norfolk, England). The infusion apparatus was fed 
through a peristaltic pump (Fig. 2-1) (IVAC 531 Infusion Pump, 
IVAC House, Bessborough Rd, Harrow) calibrated so that at the 
established speed a volume of 500 ml was administered over a 
four hour period (Fig. 2-2).
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Fig. 2-1. Peristaltic infusion pump (IVAC 531) used to administer 
ampicillin IV at a constant rate.
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Fig. 2-2. Infusion system during the administration of ampicillin 
to horse number 4.
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Sam ples were taken in lith ium  heparin  tubes from  the 
contralateral jugular vein at 2 , 5 , 10, 15 , 30 and 45 minutes and 
at 1 , 1.25 ,1.5 , 1.75 , 2 , 2.25 , 2.5 , 2.75 , 3 , 3.25 , 3.5 , 3.75 and 
4 h during the infusion period. Immediately after the 4 h 
sample, the infusion pump was disconnected and further samples 
were taken at 2, 5, 10,15, 30 minutes and 1, 2, 4, 8 , 12, and 24
hours thereafter. The samples were centrifuged at 1700 g for ten 
minutes and stored as described previously.
2.3 .3  In tragastr ic  drug adm in is tra t ion  and sam p lin g
Drugs adm inistered in tragastrically  were suspended in w ater 
(500 ml for horses and 250 ml for ponies) and administered via 
stomach tube (18 mm x 3.5 m for horses; 15 mm x 3 m for 
ponies, Vet Drug Company pic, Falkirk, U.K). A volume of water 
equivalent to the volume of the suspension was used to flush the 
stomach tube im m edia te ly  after drug adm in istra tion . W hen 
probenecid was the drug administered in tragastrically , blood 
samples were collected in lithium heparin syringes from the left 
jugular vein before the administration and at 15, 30 and 45 
minutes and 1, 1.5, 2, 4, 6 , 8 , 12 and 24 hours afterwards. The 
samples were subsequently centrifuged as described previously 
and stored at - 20 Q C until analysis during the following two 
w eeks.
2.4 Am pic i l l in  analys is
2.4 .1 M icro b io lo g ica l  analys is
Ampicillin sodium concentrations in plasma were assayed using 
the agar diffusion microbiological assay described by Bennett and 
o th e r s  (1966). A ntib io tic  concentra tions were ca lcu la ted  by 
comparing the zones of inhibition of bacterial growth produced 
by the samples on an agar plate seeded with bacteria, to the 
zones of inhib ition  produced by known standard an tib io tic  
concentrations made up in blank equine plasma.
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2.4 .2  Preparat ion  o f  am pic i l l in  s tandards
The range of ampicillin standard concentrations for each assay 
was prepared according to the concentrations expected in the 
animals after administration of each dosage regimen.
W hen ampicillin was administered as a 10 mg/kg intravenous 
bolus, ampicillin standards were prepared in plasma at 0, 0.25, 1, 
5, 10, 20 and 50 |ig /m l. Ampicillin (Sigma Chemical Co Ltd., 
Dorset, UK) was used to fortify blank equine plasma. To carry out 
the preparation of standards in plasma, an initial stock standard 
solution of 500 jag/ml of ampicillin was prepared in 0.05 M
sterile phosphate buffer at pH=7.0. From the initial stock, serial
dilutions were carried out in buffer and were subsequently used 
to prepare the plasma standards. A maximum volume of buffer 
stock solution equivalent to one tenth of the total volume of the 
plasma standard was used.
When the experiments carried out were expected to produce
lower levels of ampicillin, such as the intravenous infusion and 
the oral administration of bacampicillin hydrochloride studies,
ampicillin plasma standards of 0, 0.25, 0.5, 2, 5, 10, and 20 Jig/ml 
were used to inoculate the plates.
2.4.3 P lat ing
Glass plates (30 x 30 cm) were attached to an aluminium frame 
by eight clips. The plate, was levelled on a triangular levelling 
stand, cleaned with alcohol and flamed with a Bunsen flame to 
eliminate contamination. Aluminium covers were available for 
the plates (Fig. 2-3).
2.4.4 Agar and spore preparation
Antibiotic medium 2 (Difco Laboratories, Detroit, USA) was used 
to prepare the agar. Fifty one grams of the medium were added 
to two litres of warm tap water and then placed in a steamer 
until the powder was completely dissolved (approximately 1 h).
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Fig. 2-3. Glass plate, metal frame and aluminium cover used for 
the determination of ampicillin by microbiological assay.
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The two litres were then divided into 310 ml volumes, which 
were autoclaved and then stored at 0 - 4 Q C until the day of 
assay. On the day of assay, the autoclaved bottles containing the 
agar were liquefied in the steamer and placed in a 54 Q C bath for 
a minimum period of one hour. Each bottle was then inoculated 
with one millilitre of a 1 in 2 0  sterile distilled water dilution of 
Bacillus subtilis spore suspension (Subtilis Spore Suspension, Difco 
Laboratories, Detroit, USA). The agar inoculation was gently 
swirled to prevent bubble formation while mixing the spore 
suspension. Immediately after inoculation and thorough mixing, 
the agar was poured in a circular motion onto the plate covering 
equally all the parts of the plate. The plated agar was then left to 
cool for half an hour on the levelling stand and subsequently 
placed over a template. Sixty-four holes were punched in an even 
matrix pattern  with a hand-held  agar-cutting tool o f nine 
millimetres external diameter and the contents of the wells were 
removed by suction.
The 64 wells were then inoculated with seven plasma standards 
and ten samples. Each sample and five of the plasma standards 
were inoculated in four different wells with the remaining two 
standards inoculated in two wells each. All the samples and 
standards were distributed throughout the plate in a Quasi-Latin 
square design  (S u therland  & R olinson , 1978). F o llow ing  
inoculation the plates were incubated for 18 hours at 31Q C.
2.4.5 Reading the plates
The zones of inhibited bacterial growth (Fig. 2-4) were measured 
using an electronic digital calliper (Electronic digital calliper Max- 
Cal 0-6", CP Instruments, Bishop Stortford, England) and recorded 
on a p rin te r/ca lcu la to r (Q C-Printer, CP Instrum ents, Bishop 
Stortford, England) connected to the calliper (Fig. 2-5). This 
recorder calculated the mean of the measurement of the four 
wells corresponding to each standard or sample.
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Fig. 2-4. Antibiotic agar number 2 after 24 hour incubation 
p e r iod  s h o w in g  zones  of b ac te r ia l  g row th  in h ib i t io n  
corresponding to different antibiotic concentrations inoculated.
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Fig. 2-5. Digital calliper and recorder for the measurement of 
zones of bacterial growth inhibition.
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W hen all the measurements were taken, the diameters of the 
in h ib it io n  zones around  the am p ic i l l in  s tandards  a llow ed 
preparation of a standard curve from which unknown sample 
concentrations could be measured and allowed the calculation of 
a correlation coefficient for the accuracy of each assay.
2.4 .6  Sensitiv ity  and reproducib il i ty  o f  the assay
To evaluate the sensitivity of the assay the bacterial growth 
inhibition zone diameters from 12 replicates (4 measurements 
per sample in each replicate) of a range of ampicillin standards 
were plotted against the logio of the concentrations. The best fit 
line for ampicillin was described by the equation y= 10.448 
log io(x) +28.334 where y is the zone of inhibition diameter in mm 
and x is the concentration (jig/ml). In addition, a good linear 
correlation coefficient (r) of 0.996 was obtained for ampicillin in 
p lasm a standards. C onsidering  that the m inim um  zone of 
inhibition that could be measured accurately in this assay was 12  
mm, a limit of detection of 0.03 jig/ml was found after replacing 
y= 1 2  in the equation.
To assess the accuracy and reproducibility of the microbiological 
assay a range of standards was inoculated on four different plates
on the same day and on eight different plates on separate days.
The readings allowed the calculation of the coefficient of variation 
by dividing the standard deviation by the mean of the zone 
diameter for a particular concentration of ampicillin. The results 
from the samples analysed the same day and on separate days 
showed little variation and good reproducibility as shown by the 
coefficients of variation of less than 5% (Table 2-1).
2.5 Probenec id  ana lys is
2.5 .1 Standard prepa ra t io n  and ex tract ion
P ro b e n e c id  was a n a ly se d  by h igh  p e r fo rm a n c e  l iq u id  
chromatography (HPLC).
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Cone.
( j ig /m l)
Zone diameter 
(m m ) 
(mean ± SD)
Coefficient of Variation 
(%>
W ith in -d a y  B e tw e e n -d a v
0 0 . 0 0  ±0 . 0 0 (n= 1 2 ) 0.00 (n=4) 0 . 0 0 (n=8 )
0 .25 21.18 ±0.77 (n= 1 2 ) 4.36 (n=4) 3.27 (n=8 )
0.5 25.41 ±0.77 (n= 1 2 ) IIc
(N1—H(N 3.43 (n=8 )
2 32.48 ±1.51 (n= 1 2 ) 4.00 (n=4) 3.40 (n=8 )
5 36.17 ±1.26 (n= 1 2 ) 1.55 (n=4) 3.45 (n=8)
1 0 38.68 ±1.39 (n= 1 2 ) 1.36 (n=4) 3.79 (n=8)
2 0 41.14 ±1.52 (n= 1 2 ) II
qr*H 3.83 (n=8 )
Table 2-1. Zone diameters (mean ± SD) and coefficients of 
variation of ampicillin in equine plasma.
An initial probenecid (Sigma Chemical Co Ltd., Dorset, UK) stock 
so lution was prepared  in m ethanol (M ethanol HPLC grade, 
Rathburn Chem icals L im ited, W alkerburn, Scotland) at a 20
mg/ml concentration. Subsequently, serial dilutions of the initial
stock solution were prepared at 2 mg/ml, 500 jig/ml, 100 jig /m l  
and 20 jig/ml. A range of standards in blank equine plasma was 
then prepared at 500 jig/ml, 100 jig/ml, 50 jig/ml, 25 |ig /m l, 10 
jig/ml, 2  |ig/ml, and 0  j ig /m l.
The extraction method was carried out by adding 1 ml of 0.1 N 
HC1 (Convol ®, The British House Chemicals Limited) and 5 ml of 
dichloromethane (DCM, Rathburn Chemicals Limited, W alkerburn, 
Scotland) to 1 ml of standard in plasma. The mixture was gently
mixed in a rotor for ten minutes at 30 rpm and then centrifuged
for ten minutes at 1700 g. After centrifugation, the aqueous layer 
was removed by aspiration and 3 ml of the remaining organic 
phase were transferred into clean glass tubes and evaporated 
under air at 50 Q C. The residues were then reconstituted in 
methanol and injected into the HPLC system.
2.5 .2  In jec t ion
A Gilson pump (Model 302, Scotlab, Coatbridge, UK) equipped 
with a Gilson manometric module (Model 802, Scotlab, Coatbridge, 
UK) was used to pump the mobile phase through an ODS hypersil 
column (5 ji, 100 x 5 mm) (Shandon Scientific Ltd, Cheshire, 
England, UK). A variable X uv/vis de tector (M odel SP8450, 
Spectra Physics, Burke Electronics, Glasgow, UK) was connected to 
the column and the results were recorded on a variable chart 
recorder set at lOmV with a 5 mm/min speed (Vitatron, M. S. E. 
Scientific, Crawley, UK). The mobile phase was a mixed solution of 
methanol (Methanol HPLC Grade, Rathburn Chemicals Limited, 
W alkerburn, Scotland, UK), potassium  perm anganate  d istilled  
water (60:40) and perchloric acid (1.2 ml per 500ml of mobile 
phase). The perchloric acid used was a one in fifty-five water 
dilution of a 70% perchloric acid solution with specific gravity of
1.7 (Analar, BDH Chemicals Limited, Poole, England, UK).
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Before pumping the mobile phase through the HPLC system, it 
was degassed for fifteen to thirty minutes using a sonic bath and 
a vacuum pump. When the mixture was free of air bubbles, it 
was pumped at 1 ml/min with the detector set at a wavelength of 
254 nm and the absorbance at 0.02 absorbance unit full scale 
(AUFS). Once the baseline became stable, normally 30 minutes 
after the start of pumping, the plasma drug standards and the 
samples were injected into the system. After every two samples, 
a probenecid standard made up in methanol at a 2 0  parts per 
million concentration, was injected. The values obtained from the 
probenecid standards were used to evaluate the recoveries of the 
plasm a standards and work out the standard curve for the 
calculation of plasma probenecid concentrations. A retention time 
(time from injection of the sample until appearance of its 
corresponding peak on the chromatogram) of 2.5 minutes was 
observed for probenecid (Fig. 2-6).
2.5.3 Sensit iv i ty  and reproducib il i ty  o f  the assay
To evaluate the reproducibility  of the analysis, results  from 
probenecid plasma standards ranging from 2 to 500 jig/m l were 
compared by means of a coefficient of variation test. The 
coefficient of variation was calculated by dividing the standard 
deviation of the recovery by the mean recovery for a particular 
p robenecid  concen tra tion . Three sets of standards analysed 
during the same day showed little variation as shown by a 
maximum coefficient of variation of 5.65 %. When the standards 
were analysed on separate days, the reproducibility was also 
good as reflected in a maximum coefficient of variation of 6 . 01  % 
(Table 2-2). The mean recovery of probenecid plasma standards 
(range 2 - 500 jig/ml) was 100.23 %.
To evaluate  the sensitiv ity  and linearity  of the assay the 
probenecid plasma peak concentrations were plotted versus the 
peak heights obtained. A good linearity (r=1.00) was obtained 
between the p lasm a probenecid  concentra tion  and the peak 
heights.
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AFig. 2-6. Typical chromatographic trace of probenecid.
A : Probenecid in buffer. B: Probenecid in equine plasma
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Cone.
(jug/m l)
Recovery (%) 
(m ea n )
Coefficient of Variation (%) 
W ith in -d a y  B e tw e e n -d a y
2 99.57 (n=6 ) NS 5.34 (n=6 )
1 0 96.70 (n=9) 3.63 (n=3) 4.63 (n=6 )
25 99.71 (n=9) 1.07 (n=3) 6.01 (n=6 )
5 0 98.67 (n=9) 5.65 (n=3) 3.85 (n=6 )
1 0 0 104.32 (n=9) 2.50 (n=3) 2.47 (n=6 )
5 0 0 102.43 (n=9) 1.57 (n=3) 4.58 (n=6 )
M ean 100.23 (n=5 1) 2 . 8 8 (n=15) 4.48 (n=36)
Table 2-2. Mean recoveries and coefficients of variation of 
probenecid in plasma samples.
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The best fitting line equation obtained (y= 2.22x + 0.662) was 
used to calculate the lim it of detection of 0.15 j ig /m l for 
probenecid in plasma taking one unit as the minimum height 
peak that could be read accurately.
2.5.4 Effects o f  probenecid on the microbiological  assay
To ensure that the presence of probenecid in the plasma samples 
did not affect the bioassay results, three sets of plasma standards 
containing ampicillin, ampicillin in combination with probenecid 
and probenecid on its own, were measured by microbiological 
assay .
The results showed that the presence of probenecid did not 
enhance nor reduce the activity of ampicillin as shown by the 
coefficients of variation of less than 1 % when the zone diameter 
of plasma containing ampicillin was compared to the zones 
obtained for the ampicillin and probenecid combination (Table 2- 
3). In addition, no bacterial growth inhibition was observed when 
the plasma standards inoculated contained only probenecid.
2.6 P h a r m a co k in e t ic  ana lys is
Plasm a concen tra tion  versus time data  were analysed  by 
com partm ental m odel analysis and noncom partm enta l model 
analysis described in the literature (Baggot, 1977a; Gibaldi & 
Perrier, 1975; Kinabo & McKellar, 1989; Riegelman & Collier, 
1980; Sams, 1987).
2.6.1 C om p artm enta l  model  analys is
Plasm a concentra tions versus time from  each animal were 
analysed using a curve stripping computer programme CSTRIP 
(Sedman & Wagner, 1976).
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C o n c e n t r a t io n
( p g / m l )
1- Ampicillin 
( m m )
(mean ± S D )
2- Ampicillin 
& Probenecid 
( m m )  
(mean ± S D )
C o e f f i c ie n t  
of  Variation
(%)
0 0  ± 0 . 0 0 0  ± 0 . 0 0 (n=8 ) 0 . 0 0
2 31.13 ± 0.11 31.26 ± 0.21 (n= 8 ) 0.64
5 34.48 ± 0 .0 9 34.75 ± 0 .1 9 (n= 8 ) 0.63
1 0 37.48 ± 0 .21 37.67 ± 0 .1 8 (n=8 ) 0.64
2 0 39.59 ± 0 .33 39.64 ± 0 .1 8 (n= 8 ) 0.64
Table 2-3. Zone diameters (mean ± SD) and coefficients of 
variation of plasma standards containing ampicillin and ampicillin 
with probenecid.
The c o n c e n tra t io n s  ( j i g / m l )  are both for am pic illin  and 
p ro b en ec id .
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The observed plasma concentrations were fitted with mono-, bi- 
and triexponential equations in the form of Cp= Be'P1, C p = A e _at + 
B e 'P 1 and Cp= Pe_7Ct + Ae_at + Be'P1 respectively. Cp represents the 
p lasm a concentra tion , P and A are the in te rcep ts  o f  the 
distribution slopes and B is the intercept of the elimination slope 
on the y-axis while n and  a  the distribution constants and P the 
overall elimination rate constant. The number of coefficients and 
exponents  of the equations best describ ing  the da ta  were 
confirmed using Akaike's information criterion (Yamaoka et al ., 
1 9 7 8 ) .  P lasm a d istribu tion  half- lives  (tl/2rc and t l / 2 a )  were 
estim ated as 0 .693 In and 0 .693/a  and the elim ination half-life 
( t l / 2 P )  was calculated as 0 .693/p . The e lim ination  half-life  
represents the time taken for the plasma drug concentration to 
decrease by half its value.; where p is the hybrid rate constant for 
the terminal phase of drug concentration decline in plasma. The 
initial plasma concentration at time 0  for an intravenous bolus 
administration, CpO (jig/ml) was calculated by adding the y-axis 
intercepts P, A and B or A and B for a biexponential curve. The 
area under the zero moment curve (AUC), in j ig .h /m l,  was 
calculated by adding the y- axis intercepts and exponents ratios 
i.e. A /a  + B/p for a biexponential curve. The apparent volume of 
the central compartment Vc (ml/kg) was calculated as the dose, D 
in the appropriate units, divided by CpO. W henever the drug 
fitted a two-compartmental model, the apparent volume of the 
d istr ibu tion , Vd(area) in ml/kg was calculated by the area 
m ethod, where V d(area)=  D/AUC p. The apparent volume of 
distribution at steady-state, Vdss in ml/kg, was calculated with 
the equation Vdss= [(ki2 + k2 i ) / k 2 i]-Vc in a two-com partm ent 
system and Vdss= [(k2 1 k 31 + k i 2 k 3 i + k 2 i k i 3 ) /k2 i k 3 i]-Vc in a 
three-com partm ent system were k i 2 , k2 i , k i 3 , and  k 3 i r e p r e s e n t  
the first-order transfer rate constants between the central and 
the peripheral compartments. Finally, the total body clearance Clb 
( m l / h  kg) was calculated as Clb = D/AUC and the rate  of 
e l im in a tio n  from  the cen tra l  com partm en t,  k ei ( / h ) , was 
calculated as kei= Clb/Vc.
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2.6 .2  N o n -c o m p a r tm e n ta l  m odel  ana lys is
V arious  p aram eters  w ere ca lcu la ted  by n o n -com partm en ta l  
analysis based on the statistical moments theory. The area under 
the plasma concentration versus time curve for observed values 
( A U C o b s )  from 0 to ©o in pg.h/m l was calculated with the linear 
trapezoidal equation where A U C 0 bs = [(Cn + Cn- i ) / 2 ].Af with C 
representing the plasma concentrations, and A t - t n -tn. \  where 
Ti-1 and n are adjacent data point times. When the drug was 
administered IV, the A U C 0bs for the first trapezoid, AUCfirst -obs  
was ca lcu la ted  by substitu ting  Cn - i  by the in itial plasma 
concentration at time 0, ie. CpO. The area under the last triangle, 
A  U  C la s t -ob s  was calculated by dividing the last detectable 
concentra tion  Ciast by the elimination rate constant p, when the 
drug was administered IV. When the drug was administered 
orally, Ciast was divided by the slope of the best fitting line, Xz ,
obtained after plotting three or more points in a semilogarithmic
graph to a monoexponential equation (Riegelman & Collier, 1980). 
The area under the first moment curve A U M C 0bs from 0  to »  in  
| i g . h 2/ml was calculated with the linear trapezoidal equation
A U M C o b s  = [(^ /z Cn + t n. i C n - 1 ) / 2 ] . At.  The AUMCfirst-obs w a s  
calculated as [(tn. \ C n.\) /2]-At  since tn was 0. For the last triangle, 
A U M C l a s t - o b s  was calculated with the extrapolation equation
where A U M C i ast-obs = (Mast* C iast) /P + Q as t / ( P ) 2 when the drug 
was administered IV. When the drug was administered orally, 
the p value was substituted by Xz .
The mean residence time, M R T ,  was calculated  as M R T  = 
A U M C o b s / A U C o b s  and expressed in hours. The M R T  is defined as 
the average time that a molecule spends in the body between the 
time it is administered and the moment when it is eliminated or 
as the time for 63.2% of the administered dose to be eliminated 
by all processes. In addition, the total body clearance observed 
C l  bobs (ml/h kg) was calculated as the dose administered IV, D 
(mg/kg), divided by the A U C 0bs (j ig .h /m l). The volum e of 
d is tr ibu tion  at s teady-sta te  was subsequently  ca lcu la ted  as 
VdsSobs = Clbobs'MRT.
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Whenever the drug was administered orally, the mean absorption 
time MAT in hours, was calculated as the difference between 
MRT following oral administration and MRT following intravenous 
administration. In addition, the maximum plasma concentration 
after oral ad m in is tra tion  Cm a x and the time at which this 
concentration was achieved, tmax, were noted.
Finally, the oral bioavailability, F (%), which represents the extent 
of drug absorption into the systemic circulation following oral 
administration, was calculated by dividing the A U C 0 bs following 
oral administration by the A U C 0bs following IV administration.
C h a p te r  3
S tud ies on the  effects of u r in a r y  pH  on 
p h a rm a c o k in e t ic s  o f  a m p ic i l l in  in the
p lasm a
h o rse
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3.1  I n t r o d u c t io n
Renal excretion is probably the most common route for the 
elimination of polar, water-soluble drugs from the body and an 
alteration in the rate of renal excretion should affect the plasma 
disposition of drugs excreted by this pathway. However, this is 
not a feature common to all drugs and changes in the renal 
excretion of phenylbutazone, amphetamine and procaine did not 
affect their overall plasma disposition in the horse (Piperno et al ., 
1968; Houston et al ., 1985; Baggot et al., 1972; Evans & Lambert, 
1974). It has been claimed that urinary pH is an important 
d e te rm in a n t  for p lasm a  c o n cen tra tio n s  o f  p e n ic il l in  and 
cephalothin (Whelton et al., 1967), although most of the studies 
undertaken when the urinary pH was altered have measured 
exclusively the urine concentrations of the drugs and not the 
p lasm a concen tra tions . P lasm a pha rm acok ine tic  s tud ies  on 
penicillins where the urinary pH was artificially altered have not 
been described in the horse.
In the present study, a two-part experiment was undertaken to 
evaluate the effects of artifitial alteration of urinary pH on the 
plasma disposition of ampicillin sodium in the horse. In the first 
part, sodium bicarbonate a urine alkalinizer, was administered 
orally to horses until the urine became alkaline, ampicillin
sodium was then adm inistered in travenously  and the plasma 
disposition of the drug determined. The same model was used
when the urine was acid ified  by oral adm in is tra tion  of
ammonium chloride. In addition, urinary concentrations of the 
antib iotic , volume of urine excreted and urinary  pH were
m easu red  d u r in g  the  fo r ty -e ig h t  hou rs  fo l lo w in g  the 
administration of ampicillin sodium.
3.2 Materials  and methods
3.2.1  Anim als
Three Thoroughbred geldings and a riding mare (numbers 1, 2, 3 
and 6 ) and weighing 621, 587, 510, and 494 kg, respectively, 
were used.
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3.2 .2  A lkal in isat ion  of  urine
Urinary pH was monitored for two days before administration of 
the alkaliniser (days 0 and 1). Sodium bicarbonate (Analar, BDH 
Chemicals, Merck Ltd, Dorset, England) was suspended in 500 ml 
of water and then administered via stomach tube during six 
consecutive days (days 2, 3, 4, 5, 6 , and 7) at the dose rates of 
100, 200, 300, 400, 400 and 400 mg/kg respectively until the 
urine became consistently alkaline (pH > 7.91 ± 0.13). Ampicillin 
sodium was administered IV on day 6 at a 10 mg/kg dosage rate. 
A washout period of sixty days was allowed before starting the 
second part of the study.
3.2 .3 Acidif icat ion of  urine
A cid if ica t io n  of urine was carried  out by adm in is te r ing  
ammonium chloride (Analar, BDH Chemicals, Merck Ltd, Dorset, 
England) via stomach tube. The urinary pH values during the two 
days prior to the start of ammonium chloride adm inistration 
(days 0 and 1) were used as baseline values. To achieve urinary 
acidification, ammonium chloride was diluted in 500 ml of water 
and administered during five consecutive days (days 2, 3, 4, 5 
and 6 ) at the doses rates of 200, 300, 400, 400 and 400 mg/kg 
respectively until the urine became consistently acidic (pH < 4.24 
± 0.13). Ampicillin sodium was administered IV on day 5 at a 10 
mg/kg dosage rate.
Blood sampling, storage and m easurement of am picillin  were 
carried out as described previously (See General Materials and 
M ethods).
3.2.4 Urine collection
The urine was collected in plastic urine bags positioned under the 
geldings' penis (Fig. 3-1). These were emptied and their position 
checked regularly to ensure that all the urine was collected. A 
fresh urinary catheter was used once daily to collect the urine 
from the mare (animal number 6 ).
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Fig. 3-1. Urine collection bag in animal number 2.
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Following administration of ampicillin sodium in both parts of the 
study, all the urine was collected for 48 hours. During this period 
an indwelling Foley catheter (Argyle, Sherwood Medical) was 
placed in the mare's urethra and connected to a urine bag (Fig. 3-
2). The volume and pH of each sample collected during the 48 h
period were measured. From each sample 10 ml of the urine was
stored at 0 - 4 QC for retrospective measurement of ampicillin
co n cen tra tio ns .
3.2.5 Urine pH m easurem ent
The pH values were determ ined with a portable pH m eter 
(W h a tm a n ® , pH ji-S enso r)  which was calibrated  before the 
measurement of each urine sample collected, using standard pH 
buffers (Buffer solutions, BDH Chemicals, Merck Ltd, Dorset, 
England). The time of collection and the pH measured were 
system atically  recorded.
3.2 .6  Urine a m p ic i l l in  m easurem ent
A sim ilar b ioassay was utilised for urine m easurem ent of 
ampicillin concentrations as the one used for plasma ampicillin
measurement. However the samples were diluted in blank urine 
in order to bring them within the range of the standard curve. 
Standards of 0, 2, 5, 10, 20, 40 and 80 pg /m l were used when 
urine concentrations were measured.
3.2.7 S tat is t ica l  ana lys is
Statistical evaluation was carried out using a paired Student's t-
test to compare plasma ampicillin concentrations and urine pH 
values. A Mann Whitney-U test for nonparametric data was used 
to com pare  ph a rm aco k in e tic  pa ram eters  fo llow ing  urinary  
acidification and alkalinisation (Powers, 1990). A value of P < 0.05 
was considered to be statistically significant, and P < 0.01 was 
considered to be highly significant.
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Fig. 3-2. Foley catheter in position in the mare's 
urethra and connected to a urine collection bag.
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3.2.8 In vitro degradation  of  am pic i l l in
To evaluate  the effects of a lka lin isa tion  on urine samples 
containing ampicillin an in vitro study was carried out. Blank 
urine (pH = 7.2) was collected and ampicillin urine standards of 5, 
10, 20, 40 and 80 pg/m l were prepared as described previously. 
In addition, part of the blank urine was alkalinized by adding 
sodium bicarbonate until the pH became consistently alkaline (pH 
= 8.5). The same ampicillin urine standards were then prepared 
in the basic urine. Both sets of urine standards, were kept at 0 - 4
2 C and measured 1, 4, 7 and 10 days thereafter. Each day new
freshly made urine standards, were measured together with the 
original sets. This perm itted  observation  of the degree of 
degradation of ampicillin in normal and alkaline urine.
3.3 Results
3.3.1 Alkal in isat ion o f  urine
3.3.1.1 Urinary pH values
The administration of sodium bicarbonate orally resulted in a rise 
in the urinary pH from the 4th day of administration (day 5)
onwards. The pH became gradually more alkaline as the dose of 
sodium bicarbonate was increased. A dose of 300 mg/kg was 
needed to increase the pH substantially and with a dose of 400
mg/kg the pH stabilised at around a value of pH = 8 (Fig. 3-3). On
day 4 of adm inistration of sodium bicarbonate (day 5) the 
urinary pH was significantly different (P< 0.05) from the normal 
values and on days 6 , 7 and 8 the urinary pH values became
highly significantly different (P < 0.01) from the normal values 
(Table 3-1).
3.3 .1.2 Urine volume.
The urine volumes collected during the 48 hours following the 
administration of ampicillin sodium are shown in Table 3-2.
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Fig. 3-3. Urine pH values in 4 horses during administration of 
sodium bicarbonate. Arrows, indicate daily administ rat ion of 
sodium bicarbonate (100, 200, 300, 400 [x 3] mg/kg). Ampicillin 
sodium was administered at a dose rate of 10 mg/kg on day 6.
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Animal num ber
Day Dose 1 2 3 6
0 0 7 .1 0 7 .2 0 7 .1 0 7 .5 0
1 0 6 .7 0 7 .3 0 7 .0 0 7 .3 0
2 1 0 0 6.80 ± 0 . 2 0 7.05 ± 0 .1 5 7.03 ± 0.09 7 .9 0
3 2 0 0 6.80 ± 0 . 1 0 6.97 ± 0 .12 6.90 ± 0.21 7 .8 0
4 3 0 0 7.15 ± 0 .15 7 .1 0 7.27± 0 .26 7 .9 0
5* 4 0 0 7.25 ± 0 .25 7.43 ± 0 .09 7.90 ± 0 .0 4 8 . 2 0
4 0 0 7.82 ± 0 .08 8.10 ± 0 .13 8.10 ± 0 .05 8.40 ± 0.03
7 ** 4 0 0 7.60 ± 0 .05 8 . 1 0  ± 0 .26 7.80 ± 0 .0 9 8.16 ± 0 .16
g** 0 7.90 ± 0 .25 7 .9 0 8.30 ± 0 .07 8.43 ± 0.03
Table 3-1. Mean ± S.E.M. urinary pH values in four horses after 
administration of sodium bicarbonate. Dose in mg/kg.
* Significantly different (P < 0 .0 5 )
** Highly significantly different (P < 0 .01 )
Animal number
1 2 3 6 Mean ± SEM
U rine  
volume (1)
14.48 8 .89 12.38 9 .12 11.22 ± 1.34
A nim al 
weight (kg)
621 5 8 7 5 1 0 4 9 4 553 ± 30.42
Daily
u r in a r y
excre tion
(m l/k g )
1 1 . 6 6 7 .58 12 .14 9.23 10.15 ± 1.06
Table 3-2. Urine volume and excretion during 48 hours after 
administration of ampicillin sodium to horses with alkaline urine.
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A mean ± S.E.M value of 11.22 ± 1.34 litres was collected from the 
anim als. The mean daily excretion of urine per animal was 
calculated to be 10.15 ± 1.06 ml/kg of bodyweight.
3 .3 .1 .3  P lasm a a m pic i l l in  c o n c en tra t io n
Ampicillin sodium was administered when the urinary pH was
8.1 ± 0 . 1 2 .  The p lasm a am picillin  concentra tion  (Table 3-3; 
Appendix A Tables A -l and A-2) versus time data fitted a b i­
exponential decay curve (Fig. 3-4). None of the pharmacokinetics 
values obtained (Tables 3-4 and 3-5; Appendix A Tables A - 6  and 
A-7) were statistically different from the values obtained for 
horses with normal urinary pH (Appendix A Tables A-4 and A-5) 
or from the results obtained during the acidification of urine 
(Appendix A Tables A -8 and A-9).
3.3.1.4  Urine ampicil l in  amount (fraction of  dose)
The results from the urine concentrations of ampicillin sodium 
show that only a small percentage of the ampicillin  sodium 
administered intravenously  was recovered in the urine. Only 
14.20 ± 1.92 % of the total dose administered was recovered in 
the alkaline urine. Of the total ampicillin recovered in urine, more 
than 90% was excreted during the first six hours. However after 
30 hours some ampicillin sodium could still be detected in urine 
from all four animals and some ampicillin could be measured in 
one of the animals after 36 hours (Table 3-6; Fig. 3-5).
3.3.2 Acidif icat ion  of  urine
3.3.2.1 Urinary pH values
A highly significant reduction (P < 0.01) of the urinary pH (pH of 
4.24 ± 0 .1 3 )  was achieved in all anim als when am m onium  
chloride was administered at a 400 mg/kg dosage on the fourth 
day of administration (day 5). Urinary pH levels ranging between 
3 and 5 were maintained during day 6 and 7 of the study. (Fig. 3- 
6 ; Table 3-7).
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T im e
(h)
Normal (n=4) * 
Mean ± SEM
Alkaline (n=4) 
Mean ± SEM
Acidic (n=4) 
Mean ± SEM
0 .0 3 3 3 57.22 ± 2.13 60.33 ± 4.18 66.45 ± 2.37
0 .0 8 3 3 47.38 ± 2.95 50.24 ± 2.43 61.02 ± 4.14
0 .25 35.28 ± 1.74 36.34 ± 3.76 38.44 ± 1.22
0 .50 24.59 ± 3.07 23.24 ± 1.65 24.59 ± 1.16
0.75 16.44 ± 2.38 14.15 ± 0.27 16.28 ± 0.56
1 10.85 ± 1.97 11.61 ± 0.55 11.13 ± 0.59
1.5 6.11 ± 0.98 7.88 ± 0 .9 4 5.76 ± 0.45
2 3.27 ± 0.37 4.03 ± 0 .38 3.52 ± 0.33
4 0.63 ± 0.21 0.92 ± 0 .25 0.61 ± 0 . 1 0
8 0.04 ± 0.03 0 .0 2  ± 0 . 0 1 0.05 ± 0.02
1 2 0 .0 0  ± 0 .0 0 0 .0 0  ± 0 . 0 0 0 .0 0  ± 0 .0 0
2 4 0 .0 0  ± 0 .0 0 0 .0 0  ± 0 .0 0 0 .0 0  ± 0 .0 0
Table 3-3. Plasma concentrations of ampicillin in horses with 
normal, alkaline and acidic urine.
* Three of the animals from Horspool et al ., 1992.
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Fig. 3-4. Mean ± SEM (p g /m l)  concentra t ion  of 
ampicillin in plasma of horses with normal, alkaline 
and acidic urine after IV administration of ampicillin 
sodium at a dose rate of 10 mg/kg.
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V a ria b le Normal urine * Alkaline urine Acidic urine
(n=4) (n=4) (n=4)
a  ( /h ) 3.72 ± 1.14 6.64 ± 2 .85 3.93 ± 0.46
P ( / h ) 0.88 ± 0.13 0.90± 0 .07 0.85 ± 0.12
tl /2  a  (h ) 0 .1 8 6 0 .10 5 0 .1 7 6
t l /2  p (h ) 0 .7 8 7 0 .7 7 2 0 .8 2 0
CpO (p g /m l) 60.16 ± 3.01 71.31 ± 8 .72 73.91 ± 4.24
AUC (pg.h/m l) 39.01 ± 3.98 40.53 ± 1.57 41.61 ± 1.62
Vc (ml/kg) 167.47 ± 8.35 145.92 ± 15.67 136.65 ± 7.87
V d area (m l/kg ) 316.40 ± 40.30 281.37 ± 23.55 300.22 ± 37.80
Vdss (ml/kg) 230.55 ± 18.16 235.47 ± 20.79 220.35 ± 15.95
Clb (ml/h.kg) 265.30 ± 29.63 248.30 ± 9.84 241.35 ± 9.28
k 2l ( /h ) 2.22 ± 0.93 3.14 ± 1.08 1.90 ± 0.38
k ci ( / h) 1.59 ± 0.18 1.78 ± 0.24 1.78 ± 0.08
ki2  ( / h) 0.78 ± 0.29 2.62 ± 1.59 1.104 ± 0.16
Table 3-4. Pharmacokinetic values obtained after compartmental 
analysis in horses with normal, alkaline and acidic urine.
* Three of the animals from Horspool et al., 1992.
V ar ia b le Normal urine * Alkaline urine Acidic urine
(n=4) (n=4) (n=4)
AUCobs 39.17 ± 4.10 41.75 ± 1.31 41.89 ± 1.66
(p g .h /m l)
AUMCobs 33.57 ± 6.44 38.61 ± 5 .0 7 34.73 ± 3.24
( p g .h 2 /m l)
MRT 50.32 ± 4.65 55.09 ± 6.13 49.57 ± 3.63
(m in)
V dssobs 217.17 ± 16.27 220.17 ± 21.17 197.47 ± 13.92
(m l/k g )
Clbobs 264.32 ± 29.04 240.26 ± 7.79 239.81 ± 13.92
(m l/h .k g )
T ab le  3-5 P h a rm a c o k in e t ic  v a lu es  o b ta in ed  a f te r  non- 
compartmental analysis in horses with normal, alkaline and acidic 
urine. * Three of the animals from Horspool et al., 1992.
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Animal number
Time (h) 1 2 3 6 Mean ± SEM
6 17.17 15 .82 8 . 8 8 11 .67 13.39 ± 1.90
1 2 1.16 0 .18 0 .78 0 .45 0.64 ± 0.21
1 8 0 .08 0 .06 0 .05 0 . 2 1 0.10 ± 0 .03
2 4 0 .0 4 0 .0 4 0 .06 0 . 0 0 0.03 ± 0.01
3 0 0 . 0 2 0 .03 0 . 0 1 0 .03 0 .0 2  ± 0 . 0 0
3 6 0 . 0 0 0 . 0 0 0 .05 0 . 0 0 0 .0 1  ± 0 . 0 1
48 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 .0 0  ± 0 . 0 0
Total 18.47 16.13 9.83 12 .36 14.20 ± 1.92
Table 3-6. Percentages of ampicillin sodium recovered in alkaline 
urine after IV administration of ampicillin sodium at a 10 mg/kg 
dosage rate.
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Fig. 3-5. Urinary recoveries of ampicillin following 
administration of ampicillin sodium at a 10 mg/kg 
dose rate to horses with alkaline and acidic urine.
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Fig. 3-6. Urine pH values in 4 horses during administration of 
ammonium chloride. Arrows, indicate daily administra t ion of 
ammonium chloride (200, 300, 400 [x 3] mg/kg). Ampicillin 
sodium was administered at a dose rate of 10 mg/kg on day 5.
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Animal num ber
Day Dose 1 2 3 6
0 0 6 .90 5 .6 0 6 .5 0 7 .70
1 0 6 .80 5 .60 7 .1 0 7 .60
2 2 0 0 6.85 ± 0 .05 5 .7 0 7.00 ± 0 .1 0 7 .60
3 3 0 0 6.95 ± 0 .15 5 .70 7.20 ± 0 .10 7 .50
4 4 0 0 6.93 ± 0 .38 4.70 ± 0 .1 0 4 .76±  0 .09 6 . 0 0
5** 4 0 0 4.25 ± 0.21 3.97 ± 0.17 4.13 ± 0 .14 4.60 ± 0.31
4 0 0 4.13 ± 0 .1 0 3.86 ± 0 .06 3.91 ± 0 .10 4.26 ± 0.21
7 ** 0 3 .90 3.52 ± 0 .06 3.88 ± 0 .06 4.14 ± 0 .03
Table 3-7. Mean ± S.E.M. urinary pH values in four horses after 
administration of ammonium chloride. Dose in mg/kg.
Single values are given when only one urine sample was 
collected.
** Statistically highly significant (P < 0 .01 )
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3.3 .2 .2  Urine volume
A mean urine volume of 31.14 ± 5.64 litres was excreted by three 
of the animals during the 48 hours after the administration of 
ampicillin sodium. This is equivalent to a mean daily urinary 
excretion of 27.4 ± 4.84 ml/kg bodyweight by the horses (Table 
3-8). Not all the urine could be collected from the mare (animal 
number 6 ) and therefore it was excluded from the calculations.
3 .3 .2 .3  P lasm a a m pic i l l in  c o n c en tra t io n s
Mean ± S.E.M plasma ampicillin concentrations are shown in 
F igure  3-4 , Table 3-3 and A ppendix A table A-3, and
pharm acokinetic  values are given in Tables 3-4 and 3-5 and 
Appendix A Tables A -8 and A-9. There were no statistically 
s ig n if ic an t  d if fe ren ces  in the p h a rm aco k in e t ic  p a ram ete rs  
obtained in normal horses com pared with horses fo llow ing 
urinary acidification. There were also no significant differences in 
pharm acokinetic  values of ampicillin when com paring horses 
with acidic or alkaline urine. The concentration of ampicillin at 45 
minutes was significantly (P < 0 . 0 5 ) lower after alkalinisation than 
after acidification, but was significantly (P < 0 . 0 5 ) higher at 90 
minutes. Significant differences were not observed on any other 
occasion.
A Mann Whitney-U test did not reveal any significant differences 
between pharm acokinetic  data from an experim ent in which 
three of the horses were administered an IV bolus of ampicillin 
sodium  at the same dose rate  w ithout urinary  a ltera tions 
( H o r s p o o l  et al. ,  1992) c o m p ared  to the  a m p ic i l l in  
p h a rm a co k in e t ic  va lues ob ta ined  a fte r  a lk a l in isa t io n  and 
acidification of the urine.
3.3.2.4 Urine ampicil l in  amount (fraction of  dose)
The mean recovery of ampicillin in acidic urine was 86.64 ± 8 . 6 8  
% of the total dose administered. Animal number 6  was excluded 
in this calculation as the total urine volume could not be 
collected.
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Animal number
1 2 3 Mean ± SEM
U rine  
volume (1)
24 .8 6 42 .41 26 .17 31.14 ± 5 .64
A nim al 
weight (kg)
621 5 8 7 5 1 0 572.7 ± 32.8
Daily
u r in a r y
ex cre tion
(m l/k g )
2 0 . 0 2 3 6 .5 2 25 .66 27.4 ± 4.84
Table 3-8. Urine volume and excretion during 48 hours after 
administration of ampicillin sodium to horses with acidic urine.
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More than 90% of the ampicillin recovered was excreted in the
first 6 hours after administration of the antibiotic. Ampicillin 
could still be detected in the acidic urine 30 hours after the
ampicillin sodium administration in one animal and 36 hours in 
the two other horses (Table 3-9; Fig. 3-5).
3.3.3 In vitro degradation  of  ampici l l in
High concentrations of the antibiotic suffered less degradation (%) 
than the smaller concentrations (Table 3-10). However, this might 
be due to the logarithm ic relationship  between the zone of 
bacterial inhibition and the concentration of the standard. This 
was observed in normal and basic urine standards during each 
measurement. When comparing the degradation of ampicillin in 
normal and alkaline urine, it appears that the drug disappeared 
more quickly in the basic urine with only a maximum of 27.5 %
left on day 4 and 7.5 % on day 10 compared to 77.7 % on day four
in normal urine and 63 % on day 10.
3.4 D isc u ss io n
M ost pharm acokinetic  studies carried out in the horse are 
undertaken in resting animals. This could be misleading as it has 
been observed  that horses under hard tra in ing  cond itions 
produce more acidic urine (Evans & Lambert, 1974). This is 
probably the result of an increase in lactic acid production (Wood 
et al ., 1990) or an increase in protein in the diet of those animals 
(Baggot, 1977b). Care must therefore be taken when predicting 
the excretion of drugs in animals where their urinary pH could be 
altered by natural physiological mechanisms (Moss, 1976). 
Following absorption most antimicrobials are metabolised by the 
liver and then excreted by different routes including the kidneys 
(English & Roberts, 1979). Penicillins however, are excreted in the 
urine mainly unchanged (Baggot, 1977b).
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Animal number
Time (h) 1 2 3 Mean ± SEM
6 7 5 .2 4 100 .53 7 3 .5 4 83.10 ± 8.73
1 2 3 .8 4 1.59 1 . 8 6 2.43 ± 0 .70
1 8 1.24 1.07 0 .18 0.83 ± 0 .32
2 4 0 .0 6 0 .57 0 .1 4 0.26 ± 0 .1 5
3 0 0 . 0 2 0 .03 0 . 0 0 0 .0 2  ± 0 . 0 0
3 6 0 . 0 1 0 . 0 1 0 . 0 0 0 .0 1  ± 0 . 0 0
4 8 0 . 0 0 0 . 0 0 0 . 0 0 0 .0 0  ± 0 . 0 0
Total 80.41 103 .8 0 7 5 .8 0 86.64 ± 8 . 6 8
Table 3-9. Percentages of ampicillin sodium recovered in acidic 
urine after IV administration of ampicillin sodium at a 10 mg/kg 
dosage rate.
Cone. Day 1 Day 4 Day 7 Day 10
( | ig /m l) A N A N A N A
5 28 .0 4 2 .0 7.6 24 .0 3 .2 13.9 1 . 6
1 0 40 .9 4 6 .4 1 0 . 6 24.5 4 .0 16.7 2 . 2
2 0 60 .2 65 .0 17.6 41.5 5.9 28 .5 3.7
4 0 73 .2 67.5 21 .4 62 .6 9.4 4 9 .9 5.4
80 79 .6 77 .7 27.5 75.1 13.1 63 .0 7.5
Mean % 56 .3 8 5 9 .7 2 16 .94 4 5 .5 4 7 .1 2 3 4 .4 0 4 .08
Table 3-10. In vitro degradation of ampicillin in alkaline urine 
expressed as percentages. A: alkaline urine. N: normal urine.
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Although detectable amounts of penicillin are found in faeces 
after biliary excretion (Mandell & Sande, 1980), it is considered 
that the kidney is the main pathway of excretion  for the 
penicillins. More precisely, it has been shown in human patients 
that between 75 and 100% of ampicillin is excreted unchanged in 
urine (Rang & Dale, 1987a).
Renal excretion of drugs may occur by glomerular filtration and 
tubular secretion. Glomerular filtration itself accounts for a small 
proportion of the excreted drug in the urine because only 1 0 % of 
the blood reaching the kidney is filtered at this level and in 
addition, only the unbound fraction of the drug is capable of 
crossing this physiological barrier.
The drug fraction which is not excreted at the glomerulus passes 
into the peritubular capillaries, and may get into the renal tubule 
by non specific carrier mechanisms which principally exert their 
effect in the proximal tubule. There are thought to be two major 
types of carrier mechanisms; one for acidic substances and the 
other for basic ones. The first is responsible for the transfer of 
ionized am picillin  from  the peritubular cap illa ries  into the 
proximal tubule lumen and has been shown to account for the 
excretion of 80% of penicillin in the equine urine (Knudsen, 
1960). In human beings it has been shown that approximately 10 
% of penicillin is excreted in the urine by glomerular filtration, 
the rest being excreted by the carrier system (Rang & Dale, 
1987b).
Once the drug is inside the renal tubule, it may diffuse back into 
the blood across the epithelium of the distal tubule. The extent to 
which the drug will diffuse back through the tubular epithelium 
into the peritubular capillaries depends on different factors such 
as the concentration gradient across the membrane, the thickness 
of the membrane, the surface over which transfer occurs and the 
diffusion constant of the drug. This last factor is determined by 
the m olecular weight of the compound, its solubility  in the 
membrane and its steric configuration. In addition, the diffusion 
of weak organic compounds ( ie most drugs) across biological 
membranes is largely determined by their degree of ionisation, 
since only the nonionised fraction of the drug is capable of 
crossing physiological barriers. The degree of ionisation of a
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particu lar  compound is dependent on its dissociation constant 
(pKa), which is the pH of the aqueous solution in which the 
compound is 50 % ionised, and the pH of the media, and it can be 
calculated when pH and pKa are known by use of the Henderson- 
Hasselbalch equation (Curry, 1980). This phenomenon is of major 
importance when considering the excretion of drugs, since the 
ionised form of the drug is not capable of diffusing across the 
phospholipid membranes of the distal tubule back into the blood 
stream and will therefore be excreted rapidly in the urine. On the 
o ther hand when the drug present in the urinary filtrate  is 
largely in the nonionised form, the overall renal elimination will 
be reduced since the drug will diffuse back into the blood.
When the pH of the urine increases (alkalinisation) the fraction 
of a weakly acidic drug in the nonionised form is also increased 
(Equation 3-1).
pH - pKa = log [concentration of ionised acid 1 = log \ A~1
[concentration of nonionised acid] [ AH ]
Eq. 3-1. Henderson-Hasselbalch equation for weak acids.
Weakly acidic compounds like the penicillins, will therefore tend 
to be ionised in an alkaline urinary filtrate and consequently 
eliminated rapidly, a phenomenon described as the ion-trapping 
effect. On the contrary, when the urine is acidic the weakly 
organic acids will be mainly unionised and thus will be 
reabsorbed  into the b loodstream  and therefore  less rapidly  
eliminated. The property of ion-trapping can be used to alter the 
excretion pattern of many drugs by artificially  changing the 
urinary pH and therefore the diffusion of the drug across 
physiologic membranes. From  a practical point of view the 
urinary pH can be changed with the intention of prolonging the 
effects of some drugs by retaining them in the plasma and tissues 
or to obtain a more rapid elimination in the event of drug 
intoxication. In addition, artificial changes in the urinary pH can 
be induced when doping tests are to be carried out (Wood et a l .,
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1990) or when high concentrations are required for therapeutic 
effect within the urinary tract.
The urine pH values obtained during this tw o-phase study 
permitted the calculation of theoretical changes in the extent of 
ionisation both in plasma and urine for ampicillin. These changes 
calculated on the basis of ampicillin with a pKa of 2.8, reflect a
8.5 decrease in the number of molecules on the plasma side of 
the tubule when the urine is alkalinised to pH = 8.10, compared 
with normal urinary pH values of pH = 7.15, suggesting that the 
p lasm a concentration of the antibiotic should decrease  more 
rapidly when the urine is alkaline (Fig. 3-7). On the other hand 
the number of molecules in plasma should theoretically increase 
2300 fold when the urine is acidified to pH = 4.24, leading to a 
prolonged elimination half-life and a lower body clearance of the 
antibiotic (Fig. 3-8).
It is important to point out that only a qualitative prediction of 
the effects of changes in urine pH on the plasma disposition of 
ampicillin can be made since a quantitative estimation of changes 
on plasma disposition would require knowledge of additional 
factors such as renal blood flow.
Theoretical calculations indicate that urinary pH changes should 
have a direct effect on ampicillin plasma disposition. However, 
the results obtained showed that no substantial change occurred 
in either part of the study. None of the pharmacokinetic variables 
calculated were significantly  different or were different from 
pharm acokinetic  values obtained in c lin ically  norm al horses 
(Horspool et al ., 1992). Thus changes in urine pH did not affect 
the behaviour of ampicillin in the horse.
Several studies carried out in the horse have demonstrated the 
effects of urinary pH on the pharm acokinetics and rate of 
excretion of certain drugs. For instance, phenylbutazone a widely 
used nonsteroidal antiinflammatory drug in the horse was shown 
to persist longer in the body when administered to animals with 
acid urine (Moss & Haywood, 1973). Although the elimination in 
the urine of phenylbutazone, which is a weak organic acid (pKa = 
4.7) was slower when the urine was acidic, o ther workers 
demonstrated that this did not affect the plasma kinetic values.
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Before alkalinisation of urine
PLASMA pH= 7.38
38019 A” + H'
V
a h ;
URINE pH= 7.15
A“ + H + 22387
AH
Total = 38020 Total = 22388
For each molecule in urine there are 1.7 molecules 
in plasma.
A fter  a lk a l in i sa t io n  of the ur ine .
PLASMA pH= 7.41 URINE pH= 8.10
40738 A + H' 
/I
A” + H 199526
AH 1
Total 40739 Total 199527
For each molecule in urine there are 0.2 molecules 
in plasma.
Fig. 3-7. Theoretical effect of urinary alkalinisation on ampicillin 
molecules ratio across the tubular epithelium.
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Before acidification of urine
PLASMA pH= 7.39
38904 A + H 
A
/
AH
URINE pH= 6.72
A” + H 
A
V
AH
8318
Total 38905 Total 8319
Therefore for each molecule in urine there are 4.8 
molecules in plasma.
A f te r  ac id if ica t ion  of u r i n e
PLASMA pH= 7.29
30903 A"+ H 
/I
A H \ -
URINE
A"+ H" 
A
V
AH
pH= 4.24
27
Total 30904 Total 28
For each molecule in urine there are 11034 
molecules in plasma.
Fig. 3-8. Theoretical effect of urinary acidification on ampicillin 
molecules ratio across the tubular epithelium.
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In fac t,  p lasm a  c o n ce n tra t io n s  of p h e n y lb u ta z o n e  w ere 
independent of the urinary pH values (Piperno et al., 1968; 
H ouston et al., 1985). Similarly urinary pH has been shown to 
affect the rate of excretion of amphetamine in the horse. This 
weak organic base (pKa = 9.9) was excreted much faster in acidic 
u rine, although the p lasm a disposition of the drug was not 
apparen tly  altered (Baggot et al., 1972). F inally , Evans and 
L am bert (1974) observed  that after adm in istering  procaine, 
another weak organic base (pKa = 8.95), to horses with acidic 
urine, the concentrations in urine increased. However this change 
did not alter significantly the plasma pharm acokinetics of the 
d ru g .
The reason that changes in the excretion of phenylbutazone, 
amphetamine and procaine in the horse's urine did not affect 
their plasma disposition, may be attributable to the fact that 
these drugs are excreted unchanged in the urine to a very limited 
degree. Only 3.7% of the administered phenylbutazone, 2% of the 
am phetam ine and less than 1 % of procaine were recovered 
u n chang ed  in the u rine . T here fo re  a lth o u g h  the u rine  
concentrations can vary widely when the pH is altered, the 
amount of unchanged drug lost by this route is not sufficiently 
large to have a major influence on the plasma half-life of these 
drugs. It seems more likely that the plasma disposition of these 
drugs is determined by their metabolism rather than by their 
renal excretion (Tobin & Woods, 1979).
From a clinical point of view, the alteration of the urinary pH may 
only affect the plasma disposition of drugs that are mainly 
excreted unchanged in urine (Baggot, 1977b) and for these drugs 
a significant difference in urinary excretion will produce a major 
difference in the overall removal of the compound from the body 
(Curry, 1980).
It was anticipated that a change in urinary pH would affect the 
plasma kinetics of ampicillin sodium since the drug is thought to 
be principally excreted by the kidney unchanged. According to 
theoretical calculations the changes of pH obtained should have 
had an effect on the excretion and plasma pharmacokinetics of 
ampicillin. However all plasma concentration values obtained 
after alkalinisation or acidification of urine were not significantly
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different from the normal values (except the 45 minute sample in 
horses with alkaline urine). The 45 and 90 minute values during 
urinary alkalinisation were statistically different when compared 
to horses with acidified urine. Thus the changes in plasma 
concentration were insignificant when the pH was altered and the 
alteration of the PH does not seem to play a major role in the 
o v e ra l l  p la sm a  d isp o s i t io n  o f  a m p ic i l l in  sod ium  when 
administered intravenously to horses.
It has been reported that following increased diuresis some drugs 
have altered plasma disposition. It was observed that following 
adm in is tra tion  of fu rosem ide  the p lasm a concen tra tions of 
codeine declined more rapidly than in normal animals. Morphine, 
a metabolite of codeine biotransformation, reached higher levels 
rapidly in urine when diuresis was established (Stevenson et al.y 
1990). The normal urinary excretion of the horse is 3 to 18
ml/kg per day (Gans & Mercer, 1984) therefore the excretion of 
urine following sodium bicarbonate in the present study can be 
considered normal as the average urine excreted following the 
administration of ampicillin sodium was 10.15 ± 1.06 ml/kg of
bodyweight (Table 3-2). However, a marked diuresis with a mean 
urinary output of 27.4 ± 4.84 ml/kg of bodyweight was observed 
following acidification of urine with ammonium chloride (Table 3- 
8 ). This d iuresis during the acid ification  experim ent, could 
explain why ampicillin plasma disposition was not altered when 
the urine was acidified. Theoretically, at a lower urine pH, higher 
ampicillin plasma concentrations of the drug should have been 
observed. However, excessive diuresis would have resulted in 
dilution of the ampicillin in the tubules and thus reduction in the 
concentra tion  grad ien t w ith a consequen t increase  in the 
excretion of ampicillin in urine. However when the urine was 
alkali n i s e d , no d iu res is  was obse rved , yet the p lasm a
pharmacokinetics did not change. On this occasion, lower plasma 
concentrations would have been expected, and it seems likely 
that there may be another explanation for the results observed. 
These results correlate with those of Stevenson et al. (1990) since 
they found that codeine plasma concentrations were reduced
when a diuresis was established, however plasma disposition was
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u n a lte re d  fo r th e o p h y l l in e ,  p h e n y lb u ta z o n e ,  p e n ta z o c in e ,  
guaifenesin and flunixin.
Penicillins have been claimed to persist in individuals with acidic 
urine, however the fact that they are very water-soluble may 
explain why they were not dramatically affected by the pH of the 
urine in the present study. The solubility of a drug in a biological 
membrane will affect its diffusion, in the present case this 
rep resen ts  a l ip id - to -w a te r  parti tion  co e ff ic ien t  ( ie . ,  lipid 
solubility) since the renal tubular epithelium is a phospholipid 
bilayer. It may be that because penicillins are very water-soluble 
in both the ionised form and the unionised form they will be 
excreted rapidly even in acidic urine and therefore the pH should 
not play a major role (Katzung, 1984). Ampicillin sodium is very 
water-soluble and poorly lipid-soluble, and may be excreted in 
the urine regardless of the urinary pH especially  after IV 
administration where the bioavailability is total and the drug 
reaches the kidney immediately.
However, the presence of an amino (NH2 ) group in addition to the 
carboxyl (COOH) group within the ampicillin molecule has been 
shown to confer zwitterion characteristics to ampicillin. This 
would appear to be the most likely reason of the results obtained 
in this study since the presence of a carboxyl group with a pKa of 
2.8 and of an amino group with pKa of 7.24, means that ampicillin 
will have one of its groups or even both in the ionised form at 
any pH (Hou & Poole, 1969). Consequently, it seems logical to 
think that the artificial changes of urinary pH carried out during 
this study, would not affect the extent of reabsorption of the 
antibiotic from the urinary filtrate across the distal tubule, since 
no ampicillin free of ionised groups was likely to be found.
In the present study very small amounts (14.20 ± 1 .9 2  % of the 
dose) of ampicillin were detected in the alkaline urine. It is most 
likely that because the samples were stored at 0 - 4 Q C for nine 
days prior to analysis, the drug was degraded or inactivated in 
the basic media. It has been reported that in alkaline urine, two 
penicillanic acid sodium salts, mezlocillin and azlocillin, suffered a 
degradation of 70% after 8 hours of incubation at pH = 9 
(Gundert-Remy & Weber, 1981).
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The in vitro experim ent showed that ampicillin was degraded 
faster in alkaline urine as reflected in a maximum of 7.5 % of the 
original ampicillin remaining on day 10  when tested in alkaline 
urine compared to 63 % on day 10 in normal urine. It seems 
therefore that the length of time that the urine samples were 
kept before being analysed and their high pH ranging from 8 to 9 
could explain the poor recoveries obtained when the urine 
concentra tions were m easured. How ever, it is im possible  to 
ex trapola te  the results  obtained in vitro  and calculate  what 
concentrations should have been attained in urine during the in  
v ivo  experiment.
Artificial acidification of urine after administration of ammonium 
chloride has been reported to enhance the activity of some 
antibiotics such as the tetracyclines and penicillins in humans 
(Rang & Dale, 1987c). Many studies have shown the relationship 
between the alteration of the pH of the growth medium and the 
antibacterial activity of penicillin  (Foster & W oodruff, 1943; 
Abraham & Duthie, 1946; Eagle et al., 1952; Mou, 1962). All these 
studies found that penicillin was more active when the medium 
was acidified possibly because penicillins are less ionised when 
the pH is lowered and they are thus more lipid-soluble, and can 
penetrate more readily into the bacterial cell. As most antibiotics 
have to penetrate the bacterial cells to act, a change in the 
penetrating ability (changes in ionisation) affects directly their 
activity. It is unlikely that changes in the degree of ionisation 
would increase the activity of penicillin in acidic medium since 
penicillins act on the cell wall and therefore do not have to 
penetrate the bacteria to exert their activity. It is more likely 
that the penicillins suffer some type of degradation in basic 
media and that is the reason for the greater activity in an acidic 
environm ent. G albraith , (1984) dem onstra ted  by fluorim etry , 
that ampicillin suffered a degradation of greater than 2 0 % in 
plasma after 14 days storage at 2QC but was not degraded after 
the same period of time when the samples were kept in an acidic 
environment. It seems likely that the penicillins are less effective 
in the basic media m ainly because of an increased rate of 
degradation. The urine samples collected during the acidification 
experiment were analysed after two days and the recoveries
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obtained (86.64 ± 8.68 %) were similar to the normal values that 
would be expected (75 to 100%) in humans (Rang & Dale, 1987a). 
Following both acidification and alkalinisation of urine, more than 
90% of the total am picillin  sodium excreted in urine was 
recovered in the first 6 hours, however low concentrations of
antibiotic could still be detected in the urine after 30 hours.
3.5 C onclus ion
In the horse the excretion of many drugs may be affected by the 
urinary pH, however, possibly because of its high water solubility 
and the presence of two ionisable groups within its molecule, 
am picillin  sodium excretion  does not appear to be greatly 
a ffec ted  by the u rina ry  pH when ad m in is te red  by the 
intravenous route. Although great variations in pH have been 
observed in the horse population, ranging from 4.5 to 9.0 
(Houston et al.y 1985), it appears that the plasma disposition of
ampicillin sodium will not be affected by the urinary pH. It is
unlikely that special considerations, such as the status of training 
or type of diet require to be taken into account when treating 
horses with ampicillin sodium.
It appeared that ampicillin was rapidly degraded in alkaline 
urine, something that should be considered when animals with 
alkaline urines (e.g. grazing) are to be treated for cystitis. In this 
event, the normal dosage interval should be shortened as the 
ampicillin is degraded and therefore loses its activity, however
further studies in the horse's urine should determine the extent 
of such degradation.
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C h a p te r  4
S tud ies  on the  e ffec ts  of p ro b en e c id  on am p ic il l in  
p h a r m a c o k in e t i c s  in  th e  h o rse
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4.1  I n t r o d u c t io n
One of the major drawbacks in the clinical use of penicillins is 
their rapid elimination from the body and consequently, frequent 
dosage regimes have to be used to maintain adequate plasma and 
tissue levels of the antibiotic over prolonged periods of time. 
A ctive secretion  in the proxim al convolu ted  tubule of the 
nephron is the main m echanism responsible  for the effective 
excretion of penicillins into the urinary filtrate (Knudsen, 1960) 
and this is reflected in an elimination half-life of less than two 
hours for ampicillin sodium in the horse (Durr, 1976; Bowman e t  
al., 1986; Baggot & Prescott, 1987; Horspool et al ., 1992; Ensink et  
al., 1992).
As already discussed (Chapter 3), ampicillin has an acidic and a 
basic group within its m olecule, and these physicochem ical 
properties restrict its ability to diffuse from the urinary filtrate 
into the peritubular capillaries at any pH. It appears then, that 
the e lim ination of ampicillin from the body and its plasma 
disposition, cannot be altered by changing the pH of the urinary 
filtrate. On the other hand, the presence of a nonspecific carrier 
mechanism responsible for the transfer of penicillins from plasma 
into the urine, has led to the use of substances that can compete 
for this carrier and therefore delay the rapid excretion of 
penicillins and cephalosporins.
Probenecid (Fig. 4-1) is a com petitive inhibitor of the renal 
tubular secretion of organic anions and has been shown to 
prolong the elimination of beta-lactam antibiotics (Levy, 1965; 
Gibaldi & Schwartz, 1968; Gibaldi et al., 1970; Kampmann et al., 
1972 ; Galtier & Alvinerie, 1979; Ziv et al., 1979; Ziv & Horsey, 
1979; Juzwiak et al., 1989). In addition, studies carried out in the 
horse have shown that the bioavailability of probenecid after oral 
adm in istra tion  was grea ter than n inety  per cent and that 
m aximum plasm a concentra tions were achieved approxim ately  
one hour after administration (Donecker et al ., 1986). The present 
study, comprised a two phase experiment, was carried out to 
compare the effects of an oral dose of probenecid on the plasma 
disposition of ampicillin sodium in the horse with the disposition 
of ampicillin when administered alone.
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c h 3c h 2c h 2 „V  II / /  \\N—  S—P  COOH
c h 3c h 2c h 2 II “o
Figure 4-1. Structural formula of probenecid.
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4.2 M ater ia ls  and m ethods
4 .2 .1  A n im als
T hree  Thoroughbred geldings (animals 1, 2, 5) and a mare
(animal 7) weighing 582, 568, 603 and 507 kg respectively were
used during both phases of the experiment.
4 .2 .2  A m p ic i l l in  sod ium  and probenec id  adm in is tra t ion
Ampicillin sodium was administered at a dose rate of 10 mg/kg 
into the right jugular vein in both phases of the study. Sample 
co llection , storage and analysis was carried out as described 
p rev io u s ly .  D uring the second phase  of the experim ent, 
p robenecid  (Benem id, M erck Sharp & Dohme L im ited) was
suspended in 500 ml of water and administered via a nasogastric 
tube  at a dose rate  o f 75 mg/kg one hour before  the 
administration of ampicillin sodium. Collection of samples, storage 
and probenecid analysis were carried out as described previously
4 .2 .3  P h a r m a c o k in e t i c  A nalys is
A m p ic i l l in  p la s m a  c o n c e n t r a t io n s  w ere  a n a ly s e d  by 
com partm ental and noncom partm ental pharm acokinetic  analysis 
as described previously. Probenecid plasma concentrations were 
analysed by noncom partm ental analysis and Cmax and tmax 
were also determined.
4.2 .4  S ta t is t ica l  ana lys is
A Mann Whitney-U test for nonparametric statistical analysis was 
used to com pare the pharm acokinetic  values for am picillin  
obtained after administration of ampicillin and probenecid with
values obtained from animals where ampicillin was given on its 
own. A paired Student's t-test was carried out to compare plasma 
ampicillin concentrations obtained on both occasions.
A value of P < 0.05 was considered to be statistically significant 
and P < 0.01 was considered to be highly significant.
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4.3 Results
W hen probenecid  was adm inistered  in tragas tr ica lly , a peak 
p lasm a concentra tion  (Cmax) of 188.60 ± 19.27 j ig /m l was 
achieved at 120.00 ± 21.21 min (Table 4-1; Appendix B Table B- 
1). T hereafter , the p lasm a concentra tion  declined; how ever 
relatively high values (17.69 ± 7.38 jig/ml) were still found after 
25 hours (Table 4-2; Appendix B Table B-2; Fig. 4-2). The non­
compartm ental analysis of the probenecid plasma concentrations 
indicated an area under the plasma concentration versus time 
curve for observed values (A U C 0bs) of 2028.00 ± 346.00 p g .h /m l,  
an area under the first moment curve (A U M C 0bs) of 21339.00 ± 
6505 p g .h 2/ml and a mean residence time (M R T ) of 9.70 ± 1.62 
hours (Table 4-1; Appendix B Table B -l). No adverse effects were 
observed in any of the animals following adm inistration of 
p ro b en ec id .
W hen analysed by compartmental analysis, plasma disposition of 
ampicillin sodium was best described by a biexponential decline 
curve on both occasions. When ampicillin was administered on its 
own, it was detected up to four hours after its administration 
(T ab le  4-3; A ppend ix  B Table  B-3; Fig. 4-3). P lasm a 
concentrations were still detected in all four animals at 12 hours 
when antibiotic was administered after probenecid (Fig. 4-3; 
Table 4-3, Appendix B Table B-4). When plasma concentrations of 
am picillin  in horses coadm in iste red  with p robenecid  were 
analysed sta tis tica lly , all were highly significantly  d ifferen t 
(P < 0 . 0 1 ) from the control values except at the 2 min and the 90 
min samples which were significantly different (P < 0 .0 5 ) (Table 4- 
3). The com partm ental pharm acokinetic  variables obtained in 
both phases of the study for ampicillin were calculated (Table 4- 
4, Appendix B Tables B-5 and B-6). The statistical analysis 
showed a significant increase (P <0.05) in the elimination half-life 
of ampicillin when probenecid was administered (tl/26  = 1.198 h 
versus 0.701 h; harm onic  mean). The prolonged an tib io tic  
elimination was reflected in a significantly (P <0.05) greater AUC 
(AUC = 92.33 ± 5.10 pg.h/m l versus 36.55 ± 3.42 jig .h/m l), and 
reduced {P <0.05) body clearance Clb (Clb = 109.40 ± 6.71 ml/h.kg 
versus 280.87 ± 26.19 ml/h.kg).
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V ariab le Mean ± SEM 
(n=4)
Cmax (H g /m l) 188.6 ± 19.27
tm a x (m in ) 120.00 ± 21.21
AUCobs (p g .h /m l) 2028.00 ± 3 4 6 .0 0
AUM Cobs ( j ig .h 2/m l) 21339.00 ± 6 5 0 5 .0 0
MRT (h) 9.70 ± 1.62
Table 4-1. Probenecid pharmacokinetic variables (mean ± SEM) 
following intragastric administration of probenecid at a 75 mg/kg 
dosage rate.
T im e
(h)
P ro b e n e c id  
(n=4) 
Mean ± SEM
0.25 63.08 ± 5.55
0.5 109.78 ± 8.16
1 146.73 ± 21.57
1.50 175.7 ± 26.36
2 167.54 ± 19.02
3 161.93 ± 9.36
5 135.60 ± 17 .49
9 81.55 ± 18.66
13 50.47 ± 9.61
25 17.69 ± 7.38
Table 4-2. Probenecid plasm a concentra tions (mean ± SEM) 
following intragastric administration of probenecid at a 75 mg/kg 
dosage rate.
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Fig. 4-2. Mean plasma concentrations (± SEM) of 
p ro b en e c id  in four  ho rses  a f te r  i n t r a g a s t r i c  
administration at a dose rate of 75 mg/kg.
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T im e
(h)
A m picillin  
(n=4) 
Mean ± SEM
Ampicillin and Probenecid 
(n=4)
Mean ± SEM
0 .0 3 3 3 58.07 ± 2.86 83.84 ± 4.01 *
0 .0 8 3 3 44.27 ± 1.62 67.95 ± 1.85 **
0 .2 5 32.98 ± 1.12 53.99 ± 3.60 **
0 .5 0 21.91 ± 2.89 39.35 ± 2.71 **
0 .7 5 15.03 ± 2.03 31.92 ± 2.20 **
1 10.43 ± 1.96 27.19 ± 1.96 **
1.5 5.98 ± 1.13 20.08 ± 1 .0 2  *
2 3.46 ± 0.64 14.46 ± 1.23 **
4 0.59 ± 0.12 4.65 ± 0.43 **
8 0.00 ± 0.00 0.61 ± 0.08 **
1 2 0.00 ± 0.00 0.05 ± 0.00 **
2 4 0.00 ± 0.00 0.00 ± 0.00
Table 4-3. Mean ± SEM plasma concentrations of ampicillin in 
horses after the administration of an IV bolus dose (10 mg/kg) of 
ampicillin sodium with or without the previous administration of 
an oral dose of probenecid at 75 mg/kg.
* Significantly different (P < 0 .0 5 ).
** Highly significantly different (P< 0.01 ).
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Fig. 4-3. Mean (± SEM) plasma concentrations of 
ampicillin in four horses after IV administration of a 
single bolus dose (10 mg/kg) with or without 
probenec id .
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V aria b le Ampicillin (n=4) Ampicillin and 
Probenecid (n=4)
a ( / h ) 11.70 ± 6.74 11.87 ± 5 .16
p ( / h ) 0.99 ± 0.02 0.58 ± 0 .02
t l /2  a (h) 0 .0 5 9 0 .0 5 8
t l /2  p (h) 0 .701 1.198 *
CpO ( |ig /m l ) 70.70 ± 9.01 102.14 ± 10.46
AUC (jig .h /m l) 36.55 ± 3.42 92.33 ± 5.10 *
Vc (m l/k g ) 148.31 ± 18.11 101.10 ± 10.45
V  d area (m l/k g ) 285.67 ± 30.87 191.27 ± 18.79
V dss (m l/k g ) 235.67 ± 13.72 177.45 ± 14.04
Clb (m l/h .k g ) 280.87 ± 26.19 109.40 ± 6.71 *
k21 C/h) 5.66 ± 3.15 6.02 ± 2.49
k e l ( / h) 1.94 ± 0.16 1.10 ± 0.07
k i2 C/h) 5.09 ± 3.53 5.33 ± 2.62
Table 4-4. A m picillin  pharm acokinetic  values obtained after 
com partm ental analysis in horses following adm inistration of 
ampicillin sodium and ampicillin with probenecid.
* Significantly different (P < 0 .0 5 ).
9 2
In addition, the values obtained for the volume of the central 
com partm en t,  Vc, the apparen t volum e of d is tr ib u tio n  at 
pseudodistribution equilibrium, Vdarea, and the apparent volume 
o f  d is tr ibu tion  at steady state , Vdss, were sm aller  when 
p ro b en e c id  was ad m in is te re d  c o n co m itan tly  a lth oug h  not 
significantly  different.
W hen the results were analysed by noncompartmental analysis 
(T able  4-5, Appendix B Tables B-7 and B-8) s ign ifican t 
d if fe ren c e s  (P <0.05 ) were found in all parameters. When 
am picillin  was adm in istered  after an in tragastric  dosage of 
probenecid, the AUC0bs of ampicillin increased from 36.89 ± 3.60 
jig.h/ml to 96.50 ± 5.70}ig.h/ml. The AUMC0bs was also increased 
from 30.17 ± 4.79 | ig .h 2/ml to 153.39 ± 9.52 ) ig .h2/ml. A marked 
reduction in the Vdss0bs was observed when ampicillin was 
adm in istered  after probenecid  (166.70 ± 11.21 ml/kg versus 
207.17 ± 20.89 ml/kg). The presence of probenecid in the body 
almost doubled the MRT of ampicillin, (from 48.32 ± 2.77 minutes 
to 95.37 ± 1.64 minutes) and reduced the total body clearance 
observed CLb0bs from 278.58 ± 25.83 ml/h.kg to 104.86 ± 6.95 
m l/h .k g .
4.4 D iscuss ion
Studies carried out in horses to evaluate the effects of probenecid 
on para-am inohippuric  acid (PAHA) clearance  revealed  that 
plasma concentrations greater than 55 Jig/ml were neccessary to 
reduce the renal elimination rate of PAHA (Gronwall & Brown, 
1988). The clearance of PAHA was reduced by 50% when oral 
doses of probenecid were administered at a dose rate of 75 
mg/kg. Since the excretion of 6-lactam antibiotics from the body 
is very similar to that of PAHA (partly by glomerular filtration 
but mainly by active transport in the proximal renal tubule) it 
was considered reasonable to extrapolate the results obtained by 
Gronwall and Brown (1988) with PAHA, and a dosage of 75 
mg/kg was chosen to be administered during the present study.
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V a ria b le Am picillin
(n=4)
Ampicillin and 
Probenecid (n=4)
AUCobs ( j ig .h /m l)  
AUMCobs ( j ig .h 2/m l)  
MRT (m in) 
Vdssobs (m l/k g )  
Clbobs (m l/h .k g )
36.89 ± 3.60 
30.17 ± 4.79 
48.32 ± 2.77 
207.17 ± 20.89 
278.58 ± 25.83
96.50 ± 5.70 * 
153.39 ± 9.52 * 
95.37 ± 1.64 * 
166.70 ± 11.21 * 
104.86 ± 6.95 *
Table 4-5. Ampicillin pharmacokinetic values obtained after non­
com partm ental analysis in horses following adm inistration of 
ampicillin sodium and ampicillin with probenecid.
* Significantly different (P < 0 .0 5 ).
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The oral route of administration of probenecid was chosen as it 
has been shown that probenecid has an oral bioavailability in the 
horse greater than 90% (Donecker et al ., 1986; Gronwall & Brown, 
1988; Juzwiak et al., 1989), reaching a Cmax at approximately one 
hour after its administration (Donecker et al., 1986). Other routes 
of administration such as IV have been used in sheep (Guerrini et  
a l ., 1985) but have been claimed to cause irritation in the horse 
(D onecker et al., 1986). On this basis, a 75 mg/kg oral dose of 
probenecid was administered in the present study and ampicillin 
sodium was administered at the predicted time of maximum 
plasma concentration of probenecid (one hour post-probenecid). 
The probenecid  plasm a concentration profile  showed a peak 
plasma concentration, Cmax, two hours after its administration, 
representing slower absorption than in the previous reports. This, 
however, did not appear to be a problem  because plasm a 
probenecid concentrations greater than 55 |ig /m l were present 
from 15 minutes after administration and persisted in plasma for 
a period of at least 9 hours (Table 4-2). The results obtained after 
n o n c o m p a r tm e n ta l  a n a ly s is  o f the  p ro b e n e c id  p la sm a  
concentra tions showed that when the drug was adm inistered 
orally it persisted for a long time in the body as reflected by an 
MRT of almost 10 hours (Table 4-1). It should, however, be 
emphasized that a proper evaluation of the probenecid behaviour 
in the equine body after oral administration cannot be described 
from this study since these results were obtained when ampicillin 
was present in the animals, and this drug acts as a competitor of 
probencid's renal excretion.
Ampicillin plasma concentrations were significantly higher in 
animals treated with probenecid. These results are in agreement 
with those found after administration of probenecid followed by 
ampicillin sodium in pigs (Galtier & Alvinerie, 1979), calves (Ziv 
& Horsey, 1979) and man (Levy, 1965). The pharmacokinetic 
parameters obtained after compartm ental analysis, showed that 
the volume of the central compartment, Vc, and the volumes of 
distribution, V darea and Vdss although not significantly reduced 
were smaller when the animals received ampicillin concomitantly 
with probenecid (Table 4-4). The volume of distribution of 
ampicillin obtained after noncom partm ental analysis, V dss0bs>
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showed a statistically significant reduction when probenecid was 
co-administered (Table 4-5). These alterations of the distribution 
p a ra m e te rs  of b e ta - lac tam  an tib io tics  have a lready  been 
described in man (Gibaldi & Schwartz, 1968) and animals (Galtier 
& Alvinerie, 1979; Juzwiak et al ., 1989, Villa et a l ., 1991). In 
addition, the administration of probenecid in combination with 
phenylbutazone to mares, reduced significantly the Vdss value of 
the non-steroidal antiinflammatory drug (Zertuche et al., 1992). 
It appears that probenecid might limit the access of penicillins 
and other drugs to some parts of the body, either by competing 
with active  transport m echanism s or by com petitive  tissue 
b ind in g . T h is  w ould  reduce  the c o n ce n tra t io n s  o f the 
antim icrobial in some body organs and thereby increase the 
plasm a concentrations (Gibaldi & Schwartz, 1968). This was 
shown in rats where probenecid administered concurrently with 
rad io labe lled  benzylpen icillin  lim ited the penetration  of the 
antibiotic into liver and kidney parenchym a (Bergholz et al., 
1980). In the present study, the alteration of ampicillin plasma 
disposition when administered in conjunction with probenecid, 
was mostly due to a decrease in its elimination rate from the 
body. This was reflected in a longer elimination half-life ( t l /2  6) 
and a reduced total body clearance (Clb) when compared to 
animals receiving ampicillin alone (Table 4-4). The prolongation 
of the elimination half-life and the reduction of the total body 
clearance produced an increase in the area under the plasma 
concen tra tion  versus tim e curve when the anim als were 
administered probenecid. The noncompartmental model analysis 
showed similarly a significant reduction in the observed body 
clearance, Clb0bs> an<3 an increase in the MRT as a consequence of 
substantial increases in the AUC0bs an<3 the AUM C0bs when 
probenecid was administered (Table 4-5).
Since the penicillins are almost entirely excreted into the urine 
(Rang & Dale, 1987b), it appears that the decreased body 
clearance of ampicillin is due to a reduction of the excretory 
capacity of the kidney in the presence of probenecid. This has 
been previously demonstrated and is the result of competition for 
the active transport of organic anions in the proximal tubule of 
the nephron (Beyer et al., 1951; Levy, 1965). When the horses
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were given ampicillin and probenecid, plasma concentrations of 
am picillin  sodium were almost 1 jig /m l 8 h after antibiotic 
administration and were still detected after 12 h. Bacteria with 
minimum inhibitory concentration (MIC) of less than 1 jig/ml are 
considered susceptible to ampicillin (Baggot & Prescott, 1987). 
These include many common pathogens of the horse such as 
S t r e p to c o c c u s  z o o e p i d e m i c u s , S trep tococcu s  e q u i , non beta- 
lactamase producing Staphylococci , Actinobacil lus  equuli  , C o r y  
n e b a c te r iu m  p s e u d o tu b e r c u lo s i s , F u so b a c te r iu m  n e cro p h o ru m  
and a large percentage of Pasteure l la  species (Knight and Hietala, 
1978; Keefe et al ., 1980; Adamson et al ., 1985; Hirsh & Jang, 
1987). Since bacterial growth does not resume until a few hours 
after plasma concentrations fall below the MIC (post-antibiotic 
effect) (Koritz, 1984), dosage every 12 h would be sufficient 
when the antibiotic is administered together with probenecid. 
This represen ts  a two-fold increase in the dosing in terval 
recom mended for ampicillin in the horse (Prescott & Baggot, 
1988b; Horspool et al ., 1992). However, it should be pointed out 
that probenecid might limit the penetration of penicillins into 
certain body "compartments" as the reduction in volumes of 
d istribution suggests. This phenomenon could lead to lower 
ampicillin concentrations in some tissues. It is impossible to 
determine to what extent this would occur in different tissues 
without measuring specific ampicillin concentrations in the target 
tissue following concurrent administration with probenecid.
4.5 Conclus ion
The co ncurren t adm in is tra tion  of an in tragas tr ic  dose of 
p robenecid  and an in travenous dose of am pic illin  sodium  
prolonged the persistence of the antibiotic in horses. Probenecid 
was well tolerated and was an appropriate agent to prolong the 
ampicillin dosing interval as reflected in the reduction in the total 
body clearance of the antibiotic when the combination was given. 
The n oncom partm en ta l analysis  o f the am p ic il l in  p lasm a  
concentrations in both phases of the study, revealed a statistical 
decrease in the Vdss0bs for ampicillin administered in conjunction
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with probenecid. These results suggest that probenecid might 
limit the penetration of ampicillin to some areas of the body.
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5.1  I n t r o d u c t i o n
Ampicillin sodium is administered m ainly for the treatment of 
bacterial infections, however it is also commonly administered as 
a prophylactic for the prevention of post-operative infections. 
D uring  su rg ica l p rocedures , it is im p ortan t  to adm in ister  
antibiotics at the correct dose and the right time in order to have 
sufficient concentration at the site and at the time of bacterial 
contam ination since it has been shown that these are crucial 
factors for the prevention of post-surgical infections (Hirschmann 
& Inui, 1980; Gorbach, 1983; van den Bogaard & Weidema, 1985; 
Brown, 1986; Kirk, 1986). In practice, many different regimens 
are used depending on the type of surgery to be performed and 
the likelihood of bacterial contam ination during the surgical 
procedure and these involve different types of antibiotic, time of 
adm inistration and dosage (Guglielmo et al .y 1983; Bartlett & 
Burton, 1983). Some authors have suggested that the optimal 
regimen for administration of antibiotic for the prevention of 
such infections is im m ediately  prior to the operation when 
administered intravenously or at least half an hour before if 
given intramuscularly and one hour before when administered 
orally (Clark, 1980). Several investigators have also concluded 
that in most circum stances, that an tib io tics should only be 
adm in istered  during the surgical p rocedu re  (Van Scoy & 
Wilkowske, 1983; Hirschmann & Inui, 1980).
Among the routes of administration of antibiotics during surgical 
procedures, continuous intravenous infusion have been evaluated 
(A lexander & A lexander, 1976). Infusion  adm inistra tion  is 
extensively used in human medicine for prophylactic antibiotic 
therapy and for drugs with narrow therapeutic indices. It allows 
control over the amount of drug delivered to the (body) systemic 
com partm ent at each m om ent and perm its  m ain tainance  of 
desired concentrations over prolonged periods of time.
In the present study, an experim ental model for prolonged 
administration of ampicillin sodium to horses was developed. The 
objectives of the study were to achieve steady-state  plasma 
concentrations when infusing the drug and to determine the dose 
rate required to obtain plasma concentrations between 5 and 10
1 0 0
jig/ml. In addition, the method was evaluated as an alternative 
way of adm inistering  prophylactic  an tib io tics during equine 
surgical procedures.
5.2 M ateria ls  and methods
The experiment involved IV infusion of ampicillin at a constant
rate with a peristaltic pump over a 4-hour period after an initial
intravenous bolus dose of 2 mg/kg.
5.2 .1  A nim als
Three geldings 7, 21 and 22 years old (animals 1, 3. and 4) and 
weighing 600, 540, and 580 kg respectively were used in this 
experiment. The animals were healthy and had water and hay 
available ad libitum  during the experiments. Each animal was 
restrained in stocks, with an intravenous catheter placed in each 
jugular vein.
5.2 .2  In travenous bolus and infus ion  adm in is tra t ion
An IV bolus dose (2 m g/kg) of am picillin  sodium  was 
administered prior to infusion in order to achieve steady-state 
plasma concentrations rapidly. The constant infusion pump was 
activated and infusion was carried out as described previously.
5.2.3 Calculation of  the intravenous infusion dose rate
The amount of ampicillin required for the infusion was calculated
according to the equation 5-1:
Cpss = Ro / Vdss.(3 (Eq. 5-1)
with: Cpss = plateau (steady-state) concentration of drug in the
plasma during constant rate (zero-order) infusion.
Ro = rate of intravenous infusion (constant zero-order)
Vdss = steady-state volume of distribution.
(3 = overall elimination rate constant of drug from the body.
1 0 1
The pharm acokinetic  parameters used to calculate the rate of 
infusion during the present study were determined previously 
following single dose IV administration of ampicillin to horses 
(H orspool et a l ., 1992). A Vdss of 210.8 ±16 ml/kg and p of 
0 .0154 min-1 were used. The Cpss required during the infusion 
period was estimated to be 5 - 10 p g /m l .  It was therefore  
calculated that an infusion rate of Ro = 20.0 jig/min/kg would be 
adequate  to achieve the desired concentra tion  and this was 
adm in is te red  to three anim als in the f irs t  phase  o f  the
e x p e r im e n t .
In addition, in a second phase of the experiment, one animal 
(animal 3) received two further intravenous infusions at different 
dose rates (13.78; and 23.48 pg/m in/kg ) to assess if variations 
in the dose adm inistered would correlate  directly with the 
plasma concentrations obtained. The amount of ampicillin sodium 
required for each animal was calculated according to the weight 
of the animal. In each case, the IV infusion was continued for 4 
hours .
5.2.4 S a m p lin g  reg im e  a n d  d ru g  a n a ly s is
During the infusion period samples were collected from the 
contralateral jugular vein at 2, 5, 10, 15, 30 and 45 minutes and
at 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75 and 4 h.
Immediately after collection of the 4 h sample, the infusion pump 
was disconnected and further samples were taken at 2, 5, 10, 15, 
30 minutes and 1, 2, 4, 8, 12, and 24 hours thereafter. Sample 
storage and analysis was carried out as described previously (See 
General materials and methods).
5.3 R e su l ts
5.3.1 F i r s t  P h ase
At the first blood sampling time (2 min after in travenous 
injection of the bolus dose) the mean ± SEM concentration of 
ampicillin in plasma was 16.75 ± 0.59 p g /m l  and declined
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progressively during the first hour until it reached a steady state 
level at approximately 1.25 h (Table 5-1; Appendix C Table C -l; 
Fig 5-1).
When the peristaltic pump was disconnected after the four-hour 
infusion period the concentration of the antibiotic declined in an 
exponential manner and the last sample in which ampicillin could 
be detected was four hours after the end of the infusion period 
(Fig. 5-1). The plasma concentration values obtained during this 
period allowed calculation of the actual values of the elimination 
rate constant, P and elimination half-life ( t l /2  p) shown in Table 
5-2. The area under the plasma concentration versus time curve 
for observed values, AUC0bs = 4.34 ± 0.45 pg.h/m l and the area 
under the first moment curve for observed values, AUM C0bs = 
3.83 ± 0.66 p g .h 2/ml enabled calculation of an MRT value of 0.87 
± 0.07 h for ampicillin after disconnection of the pump (Table 5- 
2; Appendix C Table C-2).
During the infusion, the dose (infusion) rate (Ro) varied from
19.07 to 19.34 pg/m in/kg in the three animals with a mean of 
19.19 ± 0.08 pg/min/kg (Table 5-3; Appendix C Table C-3). The 
mean plasma concentration during the steady-state period (1.25 
h - 4 h) was Cpss ( a c t u a l )  = 5.95 ± 0.10 pg /m l with a maximum 
steady-state ampicillin plasma concentration Cpmax of 6.73 ± 
0.50 p g /m l  and a m inim um  steady-sta te  am picillin  p lasm a 
concentration Cpmin of 5.42 ± 0.33 p g /m l.
When substituting the actual values obtained, Ro, Cpss and P in 
equation (5-1), a Vdss ( a c t u a l )  of 204.3 ± 13.9 ml/kg was
obtained. Also a total body clearance C l b ( a c t u a l )  of 194.7 ± 10.6 
ml/h.kg was obtained after dividing the infusion rate Ro by the 
ampicillin  plasm a concentra tion  at s teady-sta te  Cpss ( a c t u a l )  
(Table 5-3; Appendix C Table C-3).
In addition, the total area under the curve ( A U C 0 b s - t o t a l )  f° r the 
infusion and post-infusion period, was calculated and a mean ± 
SEM value of 31.78 ± 2.19 pg. h/ml was obtained (Table 5-3).
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Infusion period
T im e Mean ± SEM
0 0 (n=3)
0 .0 3 3 16.75 ± 0.59
0 .0 8 3 14.47 ± 0.74
0 .1 6 6 12.12 ± 1.23
0 .25 10.30 ± 0.91
0 .5 0 8.77 ± 0.89
0.75 7.46 ± 0.61
1.00 7.01 ± 0.63
1.25 6.62 ± 0.60
1.50 6.17 ± 0.50
1.75 6.51 ± 0.37
2 .00 5.96 ± 0.29
2.25 5.96 ± 0.32
2 .50 6.00 ± 0.23
2.75 5.77 ± 0.38
3.00 5.69 ± 0.22
3.25 5.98 ± 0.31
3 .50 5.49 ± 0.31
3.75 5.66 ± 0.26
4 .00 5.56 ± 0.38
Post-infusion period
T im e Mean ± SEM
(h) (n=3)
0 .03 3 5.50 ± 0.20
0 .083 5.09 ± 0.08
0 .1 6 6 4.23± 0.22
0 .25 3.69 ± 0.21
0 .5 0 2.62 ± 0.27
1.00 1.31 ± 0.19
2 .0 0 0.44 ± 0.08
4 .0 0 0.08 ± 0.02
8 .00 0.00 ± 0.00
12 .00 0.00 ± 0.00
2 4 .0 0 0.00 ± 0.00
Table 5-1. Mean ± SEM plasma ampicillin values following an IV 
bolus of ampicillin sodium at 2 mg/kg dose rate and continuous 
IV adm inistration of am picillin  sodium at a 19.19 ± 0.08 
p g /m in /k g  in fusion  ra te . P lasm a am p ic il l in  concen tra tion s  
following disconnection of the peristaltic pump were collected 
over a 24 hour period.
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Fig. 5-1. Mean ± SEM plasma concentration of ampicillin 
during and after IV infusion at a dose rate of 19.19 ± 0.08 
pg/min/kg to three horses.
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V a ria b le Mean ± SEM 
(n=3)
P ( / h) 0.961 ± 0.076
t l / 2 p  (h) * 0 .7 2
AUCobs (p g .h /m l) 4.34 ± 0.45
AUMCobs ( | ig .h 2/m l) 3.83 ± 0.66
MRT (h) 0.87 ± 0.07
Table 5-2 Pharmacokinetic values obtained after analysis of the 
plasma ampicillin concentrations recorded in animals 1, 3, and 4 
following disconnection of the peristaltic pump.
* Harmonic mean
V aria b le Mean ± SEM 
(n=3)
Cpmax ( | ig /m l) 6.73 ± 0.50
Cpmin ( p g /m l) 5.42 ± 0.33
Cpss(actual) ( j ig /m l) 5.95 ± 0.10
Ro ( j ig /m in /k g ) 19.19 ± 0 .08
Vdss (actual) (m l/k g ) 204.3 ± 13.9
Clb (actual) (m l/h .k g ) 194.7 ± 10.6
AUCobs-total (jag .h /m l) 31.78 ± 2.19
Table 5-3. Pharmacokinetic values obtained after analysis of the 
plasma ampicillin concentrations recorded in animals 1, 3, and 4 
during ampicillin IV constant rate infusion.
AUCobs-total corresponds to the AUC during the infusion and post­
infusion periods.
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5.3.2 Second Phase
A direct relationship between the increase in the infusion dose 
rate and the p lasm a steady-state values obtained (correla tion 
coefficient = 0.994) was obtained (Fig. 5-2). The three different 
dose rates 13.78, 19.34 and 24.48 produced steady-state plasma 
concentrations of 4.98 ± 0 .1 1 ,  6.37 ± 0 .0 8  and 8.25 ± 0.10 p g /m l ,  
respectively  (Tables 5-4 and 5-5; Fig. 5-3). In addition, the 
in c re a se  in dose  ra te s  co rre la ted  very  w ell w ith  the 
corresponding AUC obtained (correlation coefficient = 0.994) with 
values of 27.83, 33.89 and 42.10 pg . h/ml, respectively (Table 5- 
4).
5.4 D iscuss ion
Several experim enta l and clin ical studies have shown that 
antib iotics should be adm inistered preoperatively  rather than 
during the postoperative period to reduce the incidence of wound 
infections (Alexander et al.y 1960; Bernard & Cole, 1964; Burke, 
1961; Polk & Lopez-Mayor, 1969). However, it is unclear which is 
the most suitable route of administration of antibiotics for the
prevention of infection in the contam inated  wound. In an 
experim ental study carried  out to evaluate  the re la tionsh ip  
betw een the route  of adm inistra tion  and the wound flu id
concentrations, Alexander & Alexander (1976) showed that when
ampicillin was given as an intravenous bolus the concentrations
in wound fluid were achieved much faster and were higher in the 
early period when compared to the intramuscular administration 
or the intravenous continuous infusion but the antibiotic was also 
eliminated more rapidly from the body when administered by 
the intravenous route. However, no intravenous loading dose was 
administered prior to the intravenous infusion and therefore a 
relatively long period of infusion was necessary to achieve 
effective plasma and wound fluid concentrations.
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Fig. 5-2. Correlation (0.994) between the infusion 
rate and the steady-state plasma concentration 
achieved.
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V a ria b le Animal number
3 3 3
Ro ( p g /m in /k g ) 13.78 19.34 2 4 .4 8
P ( / h) 0 .9 4 0 1.006 0 .8 7 5
Cpm ax ( p g /m l) 5 .76 6.91 8 .9 0
Cpmin (p g /m l) 4 .53 6 .00 7 .4 5
C p ss (actual) (p g /m l) 4.98 ±0.11 6.37 ±0.08 8.25 ± 0 .10
Vdss (actual) (m l/k g ) 176 .67 181 .09 2 0 4 .0 0
C lb (actual) (m l/h .k g ) 166 .0 2 182 .17 1 7 8 .03
AUCobs-total (p g .h /m l) 27 .83 33 .8 9 4 2 .1 0
Table 5-4. Pharmacokinetic values obtained after analysis of the 
plasma ampicillin concentrations recorded in animal 3 during 
ampicillin IV constant rate infusion at three different infusion 
ra te s .
AUCobs-total corresponds to the AUC during the infusion and post­
infusion periods.
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Infusion period
Infusion rate ( j ig /m in /k g )
Time (h) 13 .78 19 .34 23 .4 8
0 .0 3 3 17.85 17 .76 19.45
0 .0 8 3 15 .26 15.26 16.49
0 .1 6 6 12.91 13 .02 14.11
0 .25 10.67 11 .60 12.45
0 .5 0 8 .26 8.62 9.81
0 .75 7 .2 0 7 .70 9.09
1.00 6.11 7.23 8.38
1.25 5 .76 6.91 8.56
1.50 5.33 6 .62 8.22
1.75 5 .27 6.71 8.01
2 .0 0 5 .18 6 .42 7.97
2 .25 5.21 6 .49 7.45
2 .5 0 4 .78 6 .26 8.25
2 .75 4.63 6.15 8.31
3 .0 0 4.81 6 .00 8.28
3 .25 4.53 6.48 8.90
3 .5 0 4 .99 6.07 8.33
3 .75 4 .68 6.15 8.24
4 .0 0 4.63 6 .19 8.73
Time (h) Post-infusion period
0 .03 3 4 .3 4 5.73 7 .39
0 .08 3 3 .79 5 .19 5.95
0 .1 6 6 3 .36 4 .59 5.58
0 .25 3 .07 3.97 4 .87
0 .5 0 2 .02 2 .89 3 .39
1.00 1.08 1.54 2 .19
2 .0 0 0.31 0 .50 0 .69
4 .0 0 0 .06 0 .08 0.15
8 .00 0 .0 0 0 .00 0 .00
12 .00 0 .0 0 0 .00 0 .00
Table 5-5 Ampicillin plasma concentrations in animal number 3 
following an IV bolus of ampicillin at a 2 mg/kg dose rate and 
constant rate infusions at three different rates.
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Fig. 5-3. Plasma ampicillin concentrations during 
and after IV infusions at three different rates to 
animal number 3.
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These results led them to conclude that when rapid and sustained 
wound fluid concentrations are required an intravenous bolus 
should be followed either by an intramuscular injection or an
intravenous continuous infusion.
W hen drugs which obey first-order kinetics are administered by 
continuous intravenous infusion, a period corresponding to 5 
times the elimination half-life of the drug is necessary to reach 
96.9% of the steady-state plasma concentration. This is the reason 
why an intravenous loading dose is used when rapid steady- 
state concentrations are required. No matter what quantity of
drug is administered continuously, it will take this time to reach 
this fraction of plateau concentration if no bolus is administered 
at the beg inn ing  of the in fusion . The am ount o f drug 
a d m in is te r e d  d u r in g  the  in fu s io n  w ill  d e te rm in e  the 
concentration at steady-state but not the rate at which steady- 
state is achieved (Baggot, 1977c). Since the elimination half-life of 
ampicillin in horses is 0.75 hours (Horspool et al.9 1992) it would 
have taken 3.75 hours to alm ost attain the p lateau  level. 
Adm inistration of an initial loading dose may remove the lag 
period . Tw o types of load ing  dose can be adm in istered  
im m ediate ly  before the start of an intravenous infusion. An
initial loading dose, D l ,  aimed at achieving an immediate plasma
concentration equal to the calculated Cpss. This is calculated by 
multiplying Cpss by the volume of the central compartment, Vc, 
into which drug initially distributes. However, using this regime 
the plasma concentration equal to the Cpss at the time zero will 
decline below steady state levels as drug distributes through 
other body tissues, reach a minimum and increase gradually until 
Cpss is achieved. On the other hand, a loading dose D 2, calculated 
by multiplying the Cpss by the Vdss will produce an initial peak 
above the Cpss level but the plasma concentration will not fall 
below the Cpss at any time. With this latter method the lipid 
solubility of the drug to be infused is important. For instance, 
highly lipid-soluble drugs have large volumes of distribution, 
Vdss, and therefore the loading dose will produce a high ratio of 
initial to steady-state plasma concentration (Cpo : Cpss). This is an 
important factor when dealing with lipid-soluble toxic drugs since 
the initial plasma concentrations could produce undesirable side
1 12
effects. To overcome this problem a model for achieving steady- 
state p lasm a concentrations of lipid-soluble drugs with narrow 
therapeutic window rapidly and safely was developed (Rigg & 
Wong, 1981). This model, is based on the administration of an 
initial loading dose where the initial concentration, Cpo, is equal 
to Cpss, followed by a constant rate infusion and an infusion rate 
d e c re a s in g  e x p o n e n t ia l ly  w ith  tim e. H o w ev er ,  in m ost  
circumstances and if the drug to be infused is relatively non­
toxic, a loading dose corresponding to an intermediate value 
between D1 and D2 is generally administered (Gibaldi & Perrier, 
1975). Considering the m axim um  desirable  Cpss during the 
infusion (in this study) (lOjig/ml), the two possible loading doses 
D l=1 .676  mg/kg and a D2= 2.108 mg/kg were calculated (Vc 
= 167.6 ml/kg and Vdss = 210.8 ml/kg) and it was decided to 
adm inister  an in term ediate  loading dose corresponding to 2 
m g /k g .
In the first phase of the experim ent, the intravenous bolus 
produced a peak plasma concentration of 16.75 ± 0.59 pg /m l (2 
min sample) and the plasma concentration declined progressively 
until a steady-state concentration was achieved at approximately 
1.25 hours (Fig. 5-1). From that moment the concentrations were 
maintained at a steady-state level of Cpss ( a c t u a l )  = 5.95 ± 0.10
pg/m l (range: 6.73 ± 0.50 pg/m l to 5.42 ± 0.33 pg/m l) until the
infusion pump was disconnected at 4 hours. Once the infusion 
pump was disconnected, the concentration of antibiotic declined 
in an exponential manner and the last sample in which ampicillin 
could be detected was four hours after the end of the infusion 
period. The analysis of the curve  after d isconnecting  the
peristaltic pump allowed the calculation of the actual elimination 
rate constant of the drug , (3 (actual) and of the actual elimination 
half-life of the drug, 11/2 (3 (actual) together with the MRT. These 
results which are shown in Table  5-2, appeared to be in 
agreem ent with values obtained in other experim ents where 
ampicillin was administered as an IV bolus dose (Chapters 3, 4 
and 6).
W hen the  e s t im a te d  C pss w as c a lc u la te d  fro m  the
pharmacokinetic values of ampicillin sodium in the horse and the 
dose rate administered, a Cpss (estimate) = 19.19 / 210.8 x
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0.0154 = 5.91 pg /m l was obtained. The similarity between the 
Cpss (estimate) = 5.91 and the Cpss (actual) = 5.95 shows that 
from a single intravenous plasma disposition study a dose rate 
for continuous infusion can be predicted accurately for this drug. 
In addition the AUC values obtained in the three horses showed 
very slight differences. Similarly, the values obtained during the 
infusion for the Clb (actual) and Vdss (actual) also appeared to be 
within the range encountered in previous studies.
In the second phase of the experiment, a linear relationship was 
observed between the dose rate adm inistered, and both the 
plasma concentrations at steady-state and the A U C  obtained. This 
was reflected in high correlation coefficients (0.994) between the 
dose adm inistered and the corresponding Cpss(actual) and the 
AUCobs-total-
In both phases of the experiment, the p lasm a concentrations 
obtained during the infusion were high enough to kill susceptible 
bacteria and some m oderately susceptible bacteria (Adamson et  
a l ,, 1985; Prescott & Baggot, 1988c). Ampicillin sodium is a highly 
w ater-soluble antibiotic and is thought to cross phospholipid 
membranes very poorly and therefore does not penetrate readily 
into cells. However, the fact that it is only 6.8 to 8.0 per cent 
plasma protein-bound in the horse (Diirr, 1976), means that its 
concentra tion  in the ex trace llu lar  fluid (ECF), where most 
infections occur, is almost equal to the concentration in plasma 
since the free drug d iffuses  through cap illa ry  pores and 
equilibrates in the ECF (Keen, 1989). This is reflected in a small 
steady state volume of distribution (204.3 ± 13.9 ml/kg), very 
similar to the value of ECF volume of most tissues (200 ml/kg). 
Therefore, it is likely that the concentrations obtained in plasma 
would be very similar to those in most tissue fluids.
The present study indicates that administration by continuous 
infusion is accurate and usable; however, an IV bolus of 10 
mg/kg would have yielded concentrations above or equal to the 
Cpss of the first phase for a period of almost two hours (Horspool 
et al ., 1992). Thus a single IV bolus administered at a high 
enough dose level (mg/kg) or an IV bolus followed by an IM 
injection, would produce similar plasma concentra tions to the
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ones obtained here. As ampicillin toxicity is very low, high peak 
concentrations are unlikely to produce side effects.
5.5 Conclusion
For practical purposes and when non-toxic antimicrobials such as 
am picillin  are adm inistered, sim pler routes of adm inistration 
such as the in travenous, or in travenous and in tram uscu lar 
administration may produce similar results and would be more 
appropria te  under field  cond itions  for p rophy lax is  during 
surgery. However, for drugs with a narrow therapeutic window 
which produce toxic side effects when high peak concentrations 
are achieved, in travenous infusion may be appropria te . In 
addition, the combination of an IV bolus dose followed by a 
constant IV infusion has been advocated as the most suitable 
method of administration of prophylactic antimicrobials in those 
patien ts  su ffering  from  shock, w here the im paired  tissue 
pe rfu s io n  w ould  l im it  the ab so rp t io n  of a n tim ic ro b ia ls  
administered IM (Alexander & Alexander, 1976)
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C h a p te r  6
S tu d ie s  on b a c a m p ic i l l in  h y d ro c h lo r id e  in po n ies  an d
h o r s e s
1 1 6
6.1 I n t r o d u c t i o n
Various studies carried out in the equine have shown the 
unsuitability of the oral route for the administration of penicillins 
in this species. Follow ing oral adm in istra tion  of d iffe ren t 
penicillins to adult horses, the poor absorption of these antibiotics 
was observed and in many cases the presence of gastrointestinal 
disturbances was also recorded (Wilson et al., 1988; Baggot et al., 
1990; Ensink et al., 1992; Horspool, 1992).
In hum an an tib io tic  therapy, the developm ent of d iffe ren t 
pen icillin  prodrugs for oral adm inistration led to a m arked 
im provem ent o f their b ioavailab ility . N um erous experim ental 
studies carried out in humans have shown that the greater oral 
b io av a ilab ili ty  of these prodrugs when com pared to their 
corresponding active compounds, is responsible for the presence 
of higher peak plasma and tissue concentrations together with a 
faster absorption rate. In addition, the enhanced absorption has 
also been shown to be responsible for a reduced incidence of 
disturbances of the intestinal flora ecosystem  (Sjovall et al. , 
1986).
One of these prodrugs, pivampicillin, was recently investigated in 
the horse and appeared to be absorbed after oral administration, 
to a much larger extent than other penicillins (Ensink et al.,
1992).
In the fo llow ing  stud ies , bacam pic il lin  hydroch lo r ide , an 
ampicillin prodrug, was investigated as a possible alternative for 
the administration of penicillins orally to horses and ponies.
6.2 Materials and methods
6.2.1 Animals
Three Thoroughbred geldings (numbers 1, 2 and 5) weighing 615, 
607 and 612 kg respectively and four ponies (numbers 8, 9, 10, 
and 11) with weights of 294, 168, 232 and 237 kg were used in 
the study.
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6.2.2 In travenous  admin i s trat ion  o f  ampici l l in  sodium
Ampicillin sodium was administered intravenously at a dose rate 
of 10 mg/kg. Blood samples were subsequently taken from the 
contralateral jugular  vein at 2, 5, 10, 15, 30 and 45 minutes and 
at one, 1.5, 2, 4, 8, 12 and 24 hours, stored and analysed as 
described previously (General Materials and Methods).
6.2.3 Ad min i s t ra t io n  of  bacamp ic i l l in  hydrochlor ide
Bacampicillin hydrochloride (Ambaxin, Upjohn Limited, Crawley, 
England) was suspended in water (500 ml for horses and 250 ml 
for ponies) and administered intragastrically via stomach tube at 
a dose rate of 13.52 mg/kg (equivalent of 10 mg/kg of ampicillin 
sodium). Heparinised blood samples were then collected at 15,
30 and 45 minutes and one hour, 1.5, 2, 4, 6, 8, 12 and 24 hours 
after bacampicillin administration. After centrifugation at 1700 x 
g for 15 minutes, plasma was collected and stored at -20 2 C until 
analysis which was carried out on the following day.
6.2.4 Admin i s t ra t ion  of  bacampic i l l in  hydroch lor ide  and  
d i c h l o r v o s
Dichlorvos, 0 - (2 , 2- dichloro - vinyl) 0, 0- dimethyl phosphate, 
(Atgard® vet., Fermenta Animal Health Europe S. A., Belgium), 
was mixed in a small volume (200 - 400 g) of coarse mix 
containing a blend of molasses and soya oil and fed to the horses 
and ponies at a dose rate of 40 mg/kg bodyweight. Samples for 
determination of p lasma pseudocholinesterase  and erythrocyte 
acetylcholinesterase were collected in syringes containing EDTA 
(EDTA KE/2.7 ml Monovette, Sarstedt Limited, Leicester, England) 
four days prior to dichlorvos administration and at one, 2, 3, 4, 7,
10, 20, 30, 45, 60, and 90 days after its administration. Following 
sample collection the haematocrit values were measured by using 
a m icrohaem atocr i t  cen tr i fuge  (Hawkesley  M icrohaem atocr i t  
Centrifuge, Hawkesley & Sons, Lancing, U. K) and the values 
rec o rd ed  fo r  r e t r o s p e c t iv e  d e te r m in a t io n  of e ry th o c y te  
acetylcholinesterase. A 0.1 ml volume of blood was removed from
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each sample and the remainder centrifuged at 1700 x g for 15 
minutes, whole blood and plasma were subsequently stored at - 
20 Q C until analysis.
B acam p ic i l l in  was adm in is te red  one day after  d ich lorvos  
administration at a dose rate of 13.52 mg/kg intragastrically and 
blood samples were collected as described previously (See 6.2.3 
Administration of bacampicillin hydrochloride).
6.2.5 Ad min i s t ra t io n  o f  bac am pic i l l in  hyd roch lor ide  and
p r o b e n e c i d
Bacampicill in hydrochloride was administered intragastrically at 
a dose rate of 13.52 mg/kg immediately after the administration 
of probenecid by the same route at a dose rate of 75 mg/kg. 
Blood samples were collec ted  and stored subsequent ly  as 
described previously (See 6.2.3 Administration of bacampicillin 
hydroch lo r ide) .
6.2.6 P la sma  ampic i l l in  co ncen tra t ion s
P lasm a  am pic i l l in  c o n ce n t ra t io n s  a f te r  ad m in is t r a t io n  of
b aca m p ic i l l in  h y d ro ch lo r id e  and am pic i l l in  sod ium  were 
determined by the agar diffusion microbiological assay using 
Bacillus subtilis as described previously.
6.2.7 De ter min at ion  o f  p lasma  p s eu do ch o l in es t e ra se  and
e r y t h r o c y t e  a c e t y l c h o l i n e s t e r a s e
A commercial ly  avai lable colorimetric  method (Cholinesterase  
(PTC), SIGMA Chemical Co. Ltd, Dorset, England) was used to 
determine plasma and erythrocyte esterase concentrations. The 
estimation of enzymatic activity was based on the Ellman reaction 
(Dietz  et a l ., 1973) and was carr ied  out by m easur ing
spectrophotometrically (SP8-500 UV/Visible  Spectrophotometer)  
the hydrolysis of propionylthiocholine into thiocholine at 405 nm. 
The measurements were carried out in plasma and in blood 
haemolysate, the latter being carried out by adding 1.9 ml of 
sterile distilled water to 0.1 ml of whole blood collected before
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centrifugation of the sample. The plasma pseudocholinesterase 
concentrations together with the haemolysate  concentrations and 
the  h a e m a to c r i t  va lues  p e rm i t t e d  d e te rm in a t io n  of the  
erythocyte  acetylcholinesterase concentrations.
6.2 .8  P la sma  probenec id  c on cen tra t i on s
Plasm a probenecid  concentra t ions  were de termined by high 
performance liquid chromatography (HPLC) at a wavelength of 
254 nm as described previously (See General Materials  and 
M e tho d s)
6.2 .9  P h ar m ac o k in e t i c  analy s is
Plasma ampicillin concentrations after IV administration, were 
a n a ly se d  by c o m p a r tm e n ta l  m o d e l  a n a ly s i s  and non-
com par tm enta l  analysis.  When ampici l l in  was measured in 
p l a s m a  a f t e r  i n t r a g a s t r i c  b a c a m p i c i l l i n  a d m i n i s t r a t i o n  
(experiments 6.2.3, 6.2.4 and 6.2.5), the results were analysed by 
noncompartmenta l  analysis.  Probenecid  plasma concentra tions 
were analysed by noncompartmental  analysis.
6.2.10 Stat i s t i cal  ana lys i s
A W ilcoxon  s igned-rank  test was used to compare  the 
p h a r m a c o k in e t i c  v a r i a b le s  o b ta in e d  a f t e r  b a c a m p ic i l l i n
hydrochloride administration during the various experiments.
6.2.11 In vitro evaluat ion of  bacampic i l l in  metabol i sm
Equim olar  s tandards of bacampici l l in  hydroch lor ide  (Sigma
Chemical Co Ltd., Dorset, UK) and ampicillin (equivalent of 1, 5, 10 
and 20 pg/ml ampicillin) were prepared in phosphate buffer (pH 
= 7.00), whole equine blood, plasma, equine caecal fluid and 
equine caecal fluid filtered (bacteria free) with a 0.2 p m  f i l t e r  
(Acrodisc, Gelman Sciences, Michigan, USA). The standards were 
analysed by microbiological assay as described previously (see 
General materials and methods).
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6.3 Results
6.3.1 In travenous  admin is t ra t ion  of  ampici l l in  sodium
The administration of ampicillin sodium as an IV bolus produced 
p la s m a  c o n c e n t r a t io n s  tha t  were  b es t  d e sc r ib ed  by a 
b ie x p o n e n t i a l  d i sp o s i t io n  curve .  A m p ic i l l in  was rap id ly  
e liminated from the body after administrat ion,  with the last 
concentra tion detected 8 hours after administrat ion in three 
animals (animals 1, 2, and 11) (Table 6-1; Appendix D Table D-l  ; 
Fig 6-1).
The rapid elimination was reflected in the elimination half-life 
( t l /2  p) of 0.664 hours and the total body clearance of 372.30 ± 
36.79 ml/h.kg (Table 6-2; Appendix D Table D-2). In addition, 
when the data was analysed by noncompartmental analysis, the 
rapid elimination of ampicillin was reflected by a mean residence 
time, MRT of 46.67 ± 7.19 minutes and a Clb0bs of 365.40 ± 34.70 
ml/h.kg (Table 6-3; Appendix D Table D-3).
The values obtained for the volumes of distribution at steady- 
state, Vdss = 293.51 ± 18.04 ml/kg and Vdss0bs = 262.80 ± 17.40
ml/kg (Tables 6-2 and 6-3; Appendix D Tables D-2 and D-3) 
reflected a limited distribution of the antibiotic into body tissues, 
and suggested that ampici llin was probably confined to the 
extracellular fluid.
6.3.2 Admin i s t ra t ion  of  bacampic i l l in  hydroch lor ide
When bacampicillin was administered intragastrically, absorption 
of the antibiotic was rapid as reflected in mean ± SEM plasma 
ampicillin concentration of 3.80 ± 0.41 pg/ml, 15 minutes after 
administration (Table 6-4; Appendix D Table D-4; Fig. 6-2). This 
rapid absorption was also perceived in a mean ± SEM peak 
plasma concentration Cmax of 6.08 ± 0.54 pg /ml achieved at 
tmax = 42.86 ± 8.92 minutes after administration (Table 6-5). 
Once the peak plasma concentration was reached,  ampicillin 
concentrations declined and were detected in all animals 4 hours 
after administration but only in two animals (animals 1 and 2) 8 
hours after administration (Appendix D Table D-4).
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Tim e
(h)
Mean ± SEM 
(n=7)
0 .033 57.85 ± 2.67
0 .083 42.83 ± 2.24
0 .1 6 6 31.23 ± 1.29
0 .25 25.83 ± 1.32
0.5 16.12 ± 1.21
0.75 9.80 ± 0.98
1 6.70 ± 0.72
1.5 3.86 ± 0.68
2 2.32 ± 0.49
4 0.48 ± 0.21
8 0.06 ± 0.03
1 2 0.00 ± 0.00
2 4 0.00 ± 0.00
Table 6-1. Mean ± SEM plasma ampicillin concentrations after an 
IV bolus of ampicillin sodium at a 10 mg/kg dosage rate.
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Figure 6-1. Ampicillin plasma concentrations (mean ± 
SEM) following administration of an IV bolus at a 10 
mg/kg dose rate to horses and ponies (n=7).
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V ar ia b le Mean ± SEM 
(n=7)
a ( / h) 10.93 ± 3.22
P ( / h ) 1.04 ± 0.144
t l /2  a (h) 0 .0 6 8
t l /2  p (h) 0 .6 6 4
CpO ( l ig /m l) 74.65 ± 9.06
AUC ( | ig .h /m l ) 28.35 ± 2.57
Vc ( m l /k g ) 142.93 ± 12.68
V darea (m l /k g ) 377.84 ± 32.05
V d ss ( m l /k g ) 293.51 ± 18 .04
Clb (m l/h .k g ) 372.30 ± 36.79
k21 ( / h) 3.68 ± 0.87
k e l ( / h) 2.80 ± 0.43
k j  2 ( / h ) 4.76 ± 2.12
Table 6-2. Pharmacokinetic  values obtained by compartmental 
analysis of ampicillin plasma concentration after an IV bolus of 
ampicillin sodium at a 10 mg/kg dosage rate.
V a r iab le Mean ± SEM  
(n=7)
AUCobs ( j ig .h /m l) 28.78 ± 2.56
AUMCobs (p g .h 2/m l) 24.13 ± 5.83
MRT (min) 46.67 ± 7.19
V dssobs ( m l /k g ) 262.80 ± 17.40
Clbobs (m l /h .k g ) 365.40 ± 34.70
Tab le  6-3. P h a rm a c o k in e t ic  va lues ob ta in ed  a f te r  non- 
compartmental  analysis of ampicillin plasma concentration after 
an IV bolus of ampicillin sodium at a 10 mg/kg dosage rate.
1 2 4
T im e
(h)
Bacampicil l in
(n=7)
Bacampicil l in
a n d
Pro b e n ec id
(n=6)
Bacampicil l in
a n d
Dichlorvos
(n=7)
0 .25 3.80 ± 0.41 0.39 ± 0.11 3.79 ± 1.12
0 .3 0 5.79 ± 0.48 1.25 ± 0.14 5.75 ± 0.87
0 .75 5.96 ± 0.60 2.16 ± 0.27 6.01 ± 0.52
1 4.93 ± 0.53 2.42 ± 0.26 6.31 ± 0.61
1.5 3.15 ± 0.69 2.38 ± 0.37 4.41 ± 0.51
2 2.33 ± 0.67 2.10 ± 0.30 3.01 ± 0.35
4 0.81 ± 0.27 0.99 ± 0.30 0.66 ± 0.27
6 0.30 ± 0.12 0.58 ± 0.25 0.10 ± 0.07
8 0.03 ± 0.00 0.36 ± 0.18 0.00 ± 0.00
1 2 0.00 ± 0.00 0.34 ± 0 . 1 9 0.00 ± 0.00
2 4 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Table 6-4. Mean ± SEM Plasma ampicillin concentrations after 
intragastr ic  administrat ion of bacampicil lin , bacampicil lin and 
probenecid, and bacampicillin and dichlorvos. Bacampicillin was 
administered at a 13.52 mg/kg dose rate in the three phases of 
the study.
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Fig. 6-2. Ampicillin plasma concentrations (mean ± SEM) 
following oral administration of bacampicillin (n=7) and 
bacampicillin and dichlorvos (n=7) to horses and ponies.
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V ariab le Bacampicil l in
(n=7)
Bacampicil l in
a n d
Dichlorvos
(n=7)
Bacampicil l in
a n d
P ro b e n ec id
(n=6)
Cmax (jig/ml) 
tmax (min) 
P ( / h )  
AUCobs (jig.h/ml) 
A U M C 0bs(lig.h2/ml) 
MRT (min)
F (%)
MAT (min)
6.08 ± 0.54* 
42.86 ± 8.92 
0.757 ± 0.104 
12.29 ± 2.26 
21.67 ± 5.88* 
95.82 ± 9.67* 
41 .01  
49.15 ± 5.05
6.95 ± 0.47* 
45.00 ± 7.32 
0.949 ± 0.109* 
13.82 ± 1.29 
22.26 ± 4.42* 
95.10 ± 10.30* 
4 8 .0 2
2.61 ± 0.32 
65.00 ± 8.37 
0.38 ± 0.10 
11.31 ± 2.93 
58.60 ± 28.00 
255.5 ± 60.1 
3 7 .7 2
Table 6-5. Mean ± SEM pharmacokinetic values for ampicillin 
after intragastric administration of bacampicillin,  bacampicil lin 
and dichlorvos and bacampicillin and probenecid. Bacampicillin 
was administered at a 13.52 mg/kg dose rate in the three phases 
of the study.
* Statis t ically  d ifferent  (P < 0 . 0 5 ) from bacampici l l in  with 
probenec id .
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When pharmacokinetic analysis was carried out, an MRT of 95.82 
± 9.67 minutes was found. In addition, an oral bioavailability of 
41.01% was obtained when the A U C 0bs after oral administration 
was divided by the A U C 0 bs after IV administration of ampicillin. 
The mean absorption time MAT, for bacampicillin using the active
ampicillin derivative was calculated to be 49.15 ± 5.05 minutes
(Table 6-5; Appendix D Table D-5).
6.3 .3  Admin i s t ra t i on  of  bacampic i l l in  hyd roch lor ide  and  
d i c h l o r v o s
The oral adm inis t ra t ion  of d ichlorvos  produced a marked 
reduc t ion  o f  p lasm a  p seu do ch o l ines te rase  and e ry th rocy te  
acetylcholinesterase  concentration in all animals. P lasma and 
erythrocyte  cholinesterase concentrations were measured three 
days prior to dichlorvos administration and immediately before 
administration. The pre values allowed calculation of a mean ± 
SEM value for normal plasma and erythrocyte cholinesterase. 
Assuming that pre values corresponded to a 100 % activity of 
p l a s m a  and e r y t h r o c y te  c h o l i n e s t e r a s e s ,  b a c a m p i c i l l i n  
hydrochloride was administered at 13.52 mg/kg (Day 1 after
dichlorvos administration), when there was a reduction of 96.26 
% in p lasma cholines terase  act ivity and 98.75 % in the
e r y t h r o c y te  c h o l i n e s t e r a s e  a c t iv i t y  (T a b le  6 -6 ) .  T he
c ho l in es te rase  concen tra t ions  subsequen t ly  inc reased  in a 
logarithmic manner (Figs. 6-3 and 6-4) with 90.72 % of the
p lasm a pseudocho l ines te rase  activity and 99.06 % of  the
erythocyte  acetylcholinesterase  activity present  90 days after 
dichlorvos administration (Table 6-6; Appendix D Tables D-6 and 
D-7). The inhibition of cholinesterase activity did not affect the 
behaviour of bacampicillin after its administration.  This was 
ref lected in similar p lasma ampicil lin  concentra t ions  when
bacampici l lin was administered alone or following dichlorvos
administration (Table 6-4; Fig. 6-2; Appendix D Table D-8). In 
addition, none of the pharmacokinet ic  values calculated for
bacampici llin after dichlorvos administrat ion, were statistically 
different from those obtained after bacampicillin administration 
alone (Table 6-5; Appendix D Tables D-5 and D-9).
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P la s m a Activiy E ry th ro c y te Activ iy
Day esterase levels (%) esterase levels (%)
(U/L) (U /L )
P re 4307.0 ± 264.0 10 0 .0 0 8114.0 ± 614.0 1 0 0 .0 0
1 161.2 ± 11.9 3 .74 101.7 ± 20.9 1.25
2 256.7 ± 24.8 5 .96 212.6 ± 39.3 2 .62
3 454.0 ± 52.2 10.54 590.6 ± 99.6 7 .28
4 613.2 ± 75.6 14.24 1099.8 ± 190.4 13.55
7 1249.7 ± 165.7 29.01 2219.2 ± 339.3 2 7 .35
10 1835.3 ± 267.6 42.61 3647.5 ± 551.9 4 4 .9 6
2 0 2529.1 ± 425.3 5 8 .7 2 4767.8 ± 743.4 5 8 .7 6
30 2705.1 ± 290.2 62.81 5254.4 ± 698.5 6 4 .7 6
45 3169.8 ± 403.4 7 3 .6 0 5959.5 ± 889.5 7 3 .45
6 0 3427.6 ± 379.1 79 .5 8 6897.5 ± 691.3 85.01
90 3907.3 ± 377.7 9 0 .7 2 8038.0 ± 887.7 9 9 .0 6
Table 6-6. Plasma and erythrocyte cholinesterase activity before 
and after administration of dichlorvos orally at a 40 mg/kg dose 
ra te .
Pre value represents the Mean ± SEM of values obtained 4 days 
prior to dichlorvos administration.
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Fig. 6-3. Plasma cholinesterase levels (mean ± 
SEM) following oral administration of dichlorvos 
to ponies and horses at a 40 mg/kg dosage rate. 
Value on day 0 calculated as mean ± SEM of 
values obtained during four pre days.
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Fig. 6-4. Erythrocyte  cholinesterase  levels 
(mean ± SEM) following oral administration of 
dichlorvos to ponies and horses at a 40 mg/kg 
dosage rate.
Value on day 0 calculated as mean ± SEM of 
values obtained during four pre days.
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6.3.4 Administration of bacampicillin hydrochloride and 
p r o b e n e c i d
The p resence  of  p robenec id  im pa ired  the absorp t ion  of 
b a c a m p ic i l l i n  as r e f le c ted  in low er  p la sm a  a m p ic i l l in  
concentrations (Table 6-4; Fig. 6-5). There was a significantly 
(P < 0 . 0 5 ) lower peak plasma concentration of ampicillin when 
bacampic i l l in  was administered with probenecid  than when 
bacampicillin was administered alone (Cmax. = 2.61 ± 0.32 j ig /ml  
vs Cmax = 6.08 ± 0.54 j ig/ml)  (Table 6-5). The Cmax for 
a m p ic i l l in  a f te r  con cu r ren t  b aca m p ic i l l in  and d ich lo rvos  
administration was statistically higher than the value obtained 
w hen  b acam pic i l l in  was adm in is te red  co nco m itan t ly  with 
probenecid (Cmax = 6.95 ± 0.47 jag/ml vs Cmax. = 2.61 ± 0.32 
j ig/ml) . However, the presence of probenecid prolonged the 
e limination rate of ampicil lin present  in plasma. This was 
reflected in a mean ± SEM ampicillin concentration of 0.34 ± 0.19 
jig/ml, 12 hours following administration of bacampicillin and 
p rob en ec id  (Tab le  6-4; A ppend ix  D Table  D-10) .  The 
pharmacokinetic  analysis also revealed a prolongation of the 
antibiotic presence in the body as reflected in a significantly 
(P < 0 .0 5 ) longer MRT when probenecid was present (MRT = 255.5 
± 60.1 vs 95.82 ± 9.67 minutes). The longer MRT was the result of 
a significant (P < 0 .0 5 ) increase of the AUMC0bs of ampicillin in the 
presence of probenecid (Table 6-5; Appendix D Table D - l l ) .  Also, 
the MRT and AUMCobs values for bacampicillin in the presence of 
probenecid,  were statistically higher (P < 0 . 0 5 ) than the values 
achieved when dichlorvos and bacampicillin were administered 
together (Table 6-5). Probenecid was rapidly absorbed from the 
gastrointes t inal  tract after  administrat ion. Plasma probenecid 
concentrations of 54.45 ± 7.59 pg/ml were measured 15 minutes 
after administrat ion and after 24 hours, probenecid levels of 
28.51 ± 9.76 p.g/ml could still be detected (Table 6-7; Appendix 
D Table D-12; Fig. 6-6). Peak plasma probenecid concentrations 
(Cmax) of 153.7 ± 20.3 jig/ml were reached at 165.0 ± 63.8 
minutes (Table 6-8). In addition, non-compartmental analysis of 
plasma probenecid concentrations,  yielded an MRT value of 
981.60 ± 309.00 minutes (Table 6-8; Appendix D Table D-13).
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Fig. 6-5. Ampicillin plasma concentrations (mean ± SEM) 
following oral administration of bacampicillin (n=7), and 
bacampicillin and probenecid (n= 6 ) to horses and ponies.
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T im e
(h)
Mean ± SEM 
(n=6)
0 .25 54.45 ± 7.59
0 .30 100.47 ± 17.87
0 .75 119.04 ± 24.60
1 128.40 ± 25.80
1.5 140.85 ± 20.55
2 140.54 ± 17.30
4 99.66 ± 8.27
6 92.08 ± 10.60
8 79.16 ± 13.36
1 2 62.36 ± 14.81
2 4 28.51 ± 9.76
Table 6-7. Mean ± SEM plasma probenecid concentrations after 
i n t r a g a s t r i c  administration of bacampicil lin hydrochloride at a 
13.52 mg/kg dose rate and probenecid at a 75 mg/kg dose rate.
V a r ia b le Mean ± SEM 
(n=7)
Cmax ( j ig /m l ) 153.70 ± 20.30
tm a x (min) 165.00 ± 63.80
p ( / h ) 0.0799 ± 0.0188
AUCobs O g . h / m l ) 3147.00 ± 111 5 .0 0
AUMCobs (Hg.h2/m l) 79582.00 ± 55397.00
MRT (min) 981.60 ± 309.00
Table  6-8.  P h a rm ac o k in e t ic  va lues  of  p ro b e n e c id  after  
in tragas tr ic  adm in is t ra t ion  at a 75 mg/kg dose rate  in 
combination with the intragastric administration of bacampicillin 
hydrochloride at a 13.52 mg/kg dose rate.
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Fig. 6 - 6 . Mean ± SE M  p l a s m a  p r o b e n e c i d  
concentrat ions following intragastr ic  administ rat ion 
of probenecid  at a 75 mg/kg dose rate  and 
bacampicillin hydrochloride at a 13.52 mg/kg dose 
rate to horses and ponies (n= 6 ).
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Following the intragastric administration of bacampicillin with 
probenecid animals had a reduced appetite and passed dark solid 
faeces for 12 hours after the administration. In addition, animals 
number 1, 10 and 11, showed abdominal discomfort and periods 
of sternal recumbency. The animals appeared normal by 48 hours 
after administration. Routine bacteriological examination of faecal 
samples from all animals 24 hours after bacampicil lin and 
probenecid administration was characterised by heavy growth of 
lactose fermenting E. coli .
One of the animals was excluded from the calculations (used in 
tables 6-4 and 6-5) since the stomach tube got blocked during 
the adm in is t ra t ion  of  bacam pic i l l in  and p robenecid .  The 
experiment  was not repeated in this animal since potential  
gastrointestinal  disturbances had been identified in the initial 
s tudy .
6.3.5 In  vitro e v a l u a t i o n  o f  b a c a m p ic i l l i n  m e ta b o l i s m
The diameter  of the bacterial  growth inhibit ion zones for 
bacampicillin and ampicillin standards made up in various body 
fluids, were compared to the zones of inhibition for equivalent 
ampicillin concentrations made up in phosphate buffer (pH = 
7.00) and the recovery was then calculated. Ampicillin recoveries 
from ampicillin standards made up in different  body fluids 
ranged from a minimum of 94.27 % in filtered caecal fluid to a 
maximum of 102.07 % in blood.
Ampicillin recoveries from bacampicillin standards indicated that 
75.44 % bacampicillin was transformed into active ampicillin 
when the standards were made up in phosphate buffer. The 
transformation of the ester in equine caecal fluid was of 82.85 % 
when the caecal fluid was filtered and of 81.78 % when no 
filtration was carried out. In addition, bacampicillin standards 
made up in whole blood and plasma were transformed into active 
ampicillin to a 89.89 % and 93.23 %, respectively (Table 6-9).
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Concentration (Jig/ml)
1.0 5.0 10.0 20 .0 M e an
Ampicillin in 97.71 98 .0 8 9 8 .8 4 98 .37 98 .25
P la s m a (n=4) (n=4) (n=4) (n=4) (n=16)
Bacampicillin in 90 .87 93 .26 9 4 .4 6 94 .35 93 .23
P la s m a (n=4) (n=4) (n=4) (n=4) (n=16)
Ampicillin in 103 .76 101 .18 102 .35 100 .99 102 .0 7
Blood (n=4) (n=4) (n=4) (n=4) (n=16)
Bacampicillin in 82 .76 90 .45 92 .57 93 .79 8 9 .8 9
Blood (n=4) (n=4) (n=4) (n=4) (n=16)
Ampicillin in 90.61 96 .33 96 .85 97 .4 2 9 5 .3 0
C.fluid (n=4) (n=4) (n=4) (n=4) (n=16)
Bacampicillin in 7 0 .3 2 83 .02 8 6 .2 4 87.55 81 .7 8
C.fluid (n=4) (n=4) (n=4) (n=4) (n=16)
Ampicillin in 88 .8 2 9 4 .7 0 9 5 .5 0 98 .06 9 4 .2 7
C. fluid filtered (n=4) (n=4) (n=4) (n=4) (n=16)
Bacampicillin in 72.41 84.53 8 5 .6 0 88.88 82 .85
C. fluid filtered (n=4) (n=4) (n=4) (n=4) (n=16)
Ampicillin in 1 00 .00 100 .00 1 00 .00 100 .00 1 0 0 .0 0
B uffe r (n=4) (n=4) (n=4) (n=4) (n=16)
Bacampicillin in 63 .5 2 7 6 .4 2 79.41 82 .42 7 5 .4 4
B uffe r (n=4) (n=4) (n=4) (n=4) (n=16)
Table 6-9. In vitro  recoveries  (in %) of ampici l l in  and 
bacampicil lin  standards (1, 5, 10 and 20 p g / m l  a m p ic i l l in  
equimolars) in different fluids.
The recoveries were calculated after comparing the zones of 
b ac te r ia l  g rowth  inh ib i t io n  p roduced  by am pic i l l in  and 
bacampicillin standards in different fluids to zones of inhibition 
of ampicillin standards made up in phosphate buffer.
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6.4 D iscu ss ion
The administration of different penicillins to adult horses by the 
oral route has been shown to be of no value for the treatment of 
infections. Studies carried out to evaluate the extent of absorption 
of various penicill ins in the horse, demonstrated that when 
penicillin G was administered to adult horses, only 2.87 % of the 
administered dose was absorbed from the gastrointestinal tract 
(Baggot  et al ., 1990). Penici llin V, an antibiotic administered 
orally in humans, appeared to be even less well absorbed than 
penici l l in  G when given to adult horses, with an absolute 
bioavailability of 1.65 % (Baggot et al ., 1990). In addition, the 
administration of these two antibiotics, produced severe colic and 
diarrhoea in most of the animals. When amoxycillin, a broad 
spectrum semisynthetic  penicil l in ,  was administered to adult 
horses at a 20 mg/kg dose rate, the oral bioavailability was 10.4 
%, (Wilson et a l ., 1988), or 5.3 % (Ensink et a l ., 1992).
Consequently no suitable penicillin for oral antibiotherapy in the 
adult horse has been identified. However, a recent study carried 
out in adult  horses, demons tra ted  that  p ivam pic i l l in ,  the
p iva loxy l-oxym ethy l-es te r  of ampicil lin,  was absorbed after 
intragastric administration to a much larger extent than those 
penicil l ins  previously investigated.  When pi v am pic i 11 i n was 
administered at 19.19 mg/kg (equivalent of 15 mg/kg ampicillin) 
to starved horses and fed horses, an oral bioavailability of 30.9 % 
and of 35.9 % respectively were observed (Ensink et al ., 1992). 
Bacampicillin, the a-ethoxycarbonyloxyethyl ester of ampicillin, 
has a significantly greater oral bioavailability than ampicillin 
itself when administered orally to humans (Neu, 1981). In the 
present study and to evaluate the extent of absorption of
bacampicillin from the equine gastrointestinal tract in the various 
experiments, an IV bolus of ampicillin sodium at a 10 mg/kg dose 
rate was administered to all animals. The results obtained for the 
el imination half-life, ( t l / 2  (3 = 0.66 hours) were similar to
previous reports where ampicillin sodium administered at a 10 
mg/kg dose rate yielded a t l /2  (3 of 0.75 hours in horses and 
t l/2  (3 of 0.68 hours in ponies (Horspool et al ., 1992). In addition,
a t l /2  (3 of 0.70 hours was found for ampicil lin  when
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administered to horses in a previous study (See Chapter 4). Other 
pharmacokinet ic  parameters  calculated also seemed to be in 
agreem ent  with previous  exper iments ,  including total body 
c learance  and volumes of d is t r ibution,  and confi rmed that 
am pic i l l in  is rap id ly  excre ted  f rom  the body  after  IV 
adm inis t ra t ion  in the equine  and that  its physicochem ica l  
characteristics restrict its distribution to the extracellular fluid.
In the present experiments,  when bacampici l lin hydrochloride 
was administered to fed horses at a 13.52 mg/kg dose rate 
(equimolar  dose  of 10 mg/kg ampici l l in  sodium), an oral 
bioavailability of 41.01 % was achieved. This compares with 3.5 % 
when ampici l l in  was administered in tragas tr ical ly  to ponies 
(Horspool, 1992). Thus administration of ampicillin as an ester 
prodrug, (ie bacampicillin), produces a substantial and significant 
increase in the the extent of absorption. A study carried out in 
hum ans  by Simon and others  (1978)  repor ted  an oral 
bioavailability of 35 % when ampicillin was administered orally, 
which was increased  to 95 % when bacam pic i l l in  was
administered by the same route. Increases in the bioavailability 
of ampicillin when administered in its esterified form were also 
reported by Magni and others (1978) with a bioavalability 2 to 3 
times higher for bacampicil lin compared to ampicillin and by 
Rozencweig and others (1976) who found an increase in the
bioavailability of 30 to 40 %.
The esterification of the ampicillin molecule has also been shown 
to be responsible for faster absorption in man when administered 
orally. Bacampicillin was shown to be absorbed five times faster
(Rozencweig  et al ., 1976) and to produce a much sharper and
higher peak plasma concentration than parent ampicillin after 
oral administration (Swahn, 1976; Sjovall et al., 1978; Ehrnebo et 
al., 1979; Scheife and Neu, 1982). Another study demonstrated 
tmax intervals of 0.75 and 1 hour for bacampicillin when doses of 
400 mg and 800 mg were administered to humans and of 1.5 and 
2 hours when ampicillin was administered at 500 mg and 1000 
mg (Magni el al,. 1978). Similarly, Swahn (1976) recorded higher 
peak plasma concentrations achieved faster when bacampicillin 
was administered orally than when the active compound (i e 
ampicillin) was administered by the same route (tmax = 53 min
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vs tmax = 100 min). Also Simon and others, (1978) observed that
bacampici l l in  reached peak plasma concentrations faster  than
ampicillin (tmax = 60 min vs tmax = 150 min) following oral
administration of both compounds. The results of this study in 
the horse seem to be similar to those obtained in humans, since 
peak plasma ampicillin concentrations were achieved at 42.86 ±
8.92 minutes after intragastric administration of bacampicillin.
The esterification of ampicillin is responsible for the higher and 
faster  absorption of bacampicil lin from different parts  of the 
gastrointestinal tract. When radiolabelled, [35S] bacampicillin, was 
a d m in is te re d  in t r a g as t r i c a l ly  to hum ans ,  m e a su re m e n t  of 
bacampicillin in gastrointestinal aspirates demonstrated that 20 
% of the dose was absorbed from the stomach, 65 % had been 
absorbed by gut proximal to and including the duodenum and 71 
% in the gut proximal to and including jejunum (Swahn, 1976). 
Soon after absorption, bacampicillin was shown to be metabolised 
into ampicillin, acetaldehyde, carbon dioxide and ethanol by small 
intestine and blood esterases (Fig. 6-7). Studies carried out in 
rats  showed that  when p ivampici l l in  was adminis tered ,  it 
penetrated into the epithelial cells in the ester form and was 
subsequently hydrolysed by non-specific esterases present in the 
apical cytoplasm of the cells (Shindo et a l ., 1978).  When
bacam pic i l l in  was admin is tered  in tragas tr ica l ly  in humans,  
m e ta b o l i sm  occu rred  very  rap id ly  s ince  no un c h an g e d  
bacampicil lin could be detected in p lasma 10 minutes after 
administration (Neu, 1981; Sjovall et al ., 1985).
In the present study, plasma ampicillin concentrations of 3.80 ± 
0.41 p g /m l  were measured 15 minutes after bacampici l l in  
administration to horses and ponies indicating rapid absorption of 
the ester. A mean ± SEM peak plasma concentration Cmax = 6.08 
± 0.54 jig/ml was subsequently reached at 42.86 ± 8.92 minutes 
and ampicillin concentrations could still be detected in plasma 
eight hours after bacampicillin administration. When the results 
of this study were compared to those obtained after intragastric 
administration of pivampicillin to horses at a 19.19 mg/kg dose 
rate (equivalent of 15 mg/kg of ampicillin) (Ensink et al ., 1992), 
it appeared that bacampicillin absorption was greater and faster 
than that of pivampicillin.
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Fig. 6-7. Transformation of bacampicillin into ampicillin, 
acetaldehyde, carbon dioxide and ethanol.
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Mean maximum peak plasma concentrations of ampicillin of 3.80 
and 5.12 were achieved when the pivampicillin was administered 
to starved and fed horses respectively (Ensink et al ., 1992). These 
values were lower than those obtained following bacampicil lin
administration to fed horses and ponies during this study (Cmax =
6.08 ± 0.54 j ig/ml)  especial ly when it is considered that the 
equimolar dose of ampicillin was lower (15 mg/kg equimolar 
dose of ampicillin vs 10 mg/kg equimolar dose of ampicillin). It is 
unlikely that the ponies in this study were the reason for the 
higher peak plasma concentration achieved, since the individual
higher peak plasma values following bacampicillin administration
were obtained in the three horses (animals 1, 2 and 5) (Appendix 
D Table D-4). In addition, bacampicillin was absorbed faster than 
pivampici l l in  as reflected in a tmax of 42.86 minutes  for 
bacampicillin and of 1 hour for pivampicillin.
The measurement of ampicillin concentrations after IV ampicillin 
adm inis t ra t ion  and in tragas tr ic  bacampici l l in  admin is t ra t ion ,  
permitted calculation of the mean residence time (MRT) and the 
mean absorption time (MAT). An MRT of 46.67 ± 7.19 minutes 
was obtained for ampicillin when administered IV and an MRT of 
95.82 ± 9.67 minutes was calculated for ampicillin in plasma after 
bacampicillin administration. The MAT of 49.15 ± 5.05 minutes 
for bacampicillin (as ampicillin), suggests flip-flop kinetics where 
the MAT is greater than the MRT following IV administration.
The oral administration of dichlorvos has been shown to produce 
a reduction in plasma and red blood cell esterases levels in dogs 
(Ward & Glicksberg, 1971) and pigs (Bossen et al ., 1973). In 
addition, plasma esterases were also reduced in horses fed with 
dichlorvos  (Snow, 1974). Since it  has been shown that  
bacampicillin is metabolised into ampicillin by esterases (Swahn, 
1976), the effects of a reduction of the esterase levels on the
metabolism and fate of bacampicillin were evaluated.
The results showed that the oral administration of dichlorvos at 
40 mg/kg reduced dramatically plasma esterase levels 24 hours 
after the administration. A depression of plasma esterase activity 
of 96.26 % was found 24 hours after administration and by day 
90 after administration, 90.72 % of the original plasma esterase 
activity had returned. A mean depression of plasma esterase
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levels of 79.28 % was recorded in horses by Snow (1974), 24 
hours after oral dichlorvos administration. These lower levels can 
explained by the lower dichlorvos intake in the study carried out 
by Snow (1974) (Mean ingested dose of 30.57 mg/kg vs Mean 
ingested dose of 40 mg/kg in the present study).
Erythrocyte esterase levels were also markedely depressed in all
animals 24 hours after dichlorvos administrat ion during the 
present experiment (Table 6-6; Appendix D Table D-7). Only 1.25 
% of  the p re-va lue  erythrocyte  es terase  activity could be 
measured 24 hours after dichlorvos administrat ion, but the 
activity returned progressively to normal and by day 90 after 
administration an activity of 99.06 % was recorded. These results 
are in disagreement with the study carried out by Snow (1974), 
where a much smaller depression of erythrocyte esterase activity 
(89.5 % activity 24 hours after dichorvos) was detected in two 
animals in which it was measured. Snow (1974) administered a 
lower dose of organophosphate; however, the differences are 
greater than those which could be ascribed the lower dose.
The marked depression in both plasma and erythrocyte esterase 
activities achieved during the present experiment, did not affect 
the ph a rm a co k in e t ic  behav iou r  of b acam pic i l l in .  It was 
anticipated that a reduction in plasma and erythrocyte esterase 
activity could slow down the hydrolysis of bacampicillin into 
ampicillin and possibly prolong the ampicillin persistence in the 
body. However,  it was impossible to tell from these results
whether the drug present  in p lasma and measured in the
microbiological assay was in the bacampicillin or the ampicillin 
form at the time of sample collection. Despite the fact that 
bacampicil lin lacks antimicrobial  act ivity per  se , the in vitro 
study reve a le d  that  when b acam p ic i l l in  s tandards  were 
incubated overnight by microbiological assay in phosphate buffer 
(pH = 7.00), a 75.44 % of bacampicillin was tranformed into 
ampicillin (Table 6-9). This could be the result of the overnight 
incubat ion  tem pera tu re  (312C), the presence  of  esterases  
produced by the test bacteria, B . subtilis , in the agar plates, or the 
phosphate buffer pH (pH = 7.00).
However, the almost identical shape of the ampicillin plasma 
concentra tion versus t ime curves during  both experiments
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(bacampicillin alone and bacampicillin after dichlorvos), suggest 
that bacampicil lin was hydrolysed into ampicillin despite  the 
minimal plasma and erythrocyte esterase activity at the time of 
bacampicillin administration. It may be that despite the major 
reduction in plasma and red blood cell esterase concentrations, at 
the time of bacampicil lin administration, there still was some 
activity (3.74 % for plasma and 1.25 % for erythrocytes) sufficient 
to convert  bacampici l l in  into ampici llin. Also various other 
experimental studies have demonstrated the presence of esterase 
activity within the gastrointestinal tract, the liver and the kidney 
(Swahn, 1976; Fukuda et al ., 1978; Shindo et al ., 1978). Esterase 
levels in those tissues could not be measured during this 
experiment and it is not known whether they were reduced when 
dichlorvos was administered and if so to what extent.
The plasma ampicillin concentration versus time curve obtained 
for ampicillin after bacampicillin and dichlorvos administration, 
was characterised by a peak plasma ampicillin concentration of 
6.95 ± 0.47 Jig/ml achieved 45 minutes after administration of 
bacampicillin. The oral bioavailabilty for bacampicillin during this 
experiment was 48.02 %, slightly greater than the value obtained 
when bacampicillin was administered alone, but not statistically 
d i f fe ren t .  The  M RT o b ta in ed  when b a c a m p ic i l l i n  was 
administered after dichlorvos (MRT - 95.10 ± 10.30 min) was 
almost identical to the value obtained when bacampicillin was 
administered alone (MRT - 95.82 ± 9.67 min), suggesting that the 
reduction in plasma and erythrocyte esterases did not affect the 
disposition of bacampicillin.
When probenecid was administered at 75 mg/kg to the animals, 
it was extensively absorbed from the gastrointestinal tract and a 
Cmax of 153.70 ± 20.30 jig/ml was reached 165 minutes after 
administration. The peak p lasma concentration measured was 
similar to that obtained in a previous study (Chapter 4) where a 
Cmax of 188.6 ± 19.27 | ig /m l  was measured when probenecid 
was administered intragastrically at the same dosage. The time at 
which Cmax was reached  appeared to be longer in this 
experiment (tmax 165.00 ± 63.80) minutes than in the previous 
experiment (tmax = 120.00 ± 21.21) minutes. This longer tmax
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value in the present study appeared to be the result of one 
animal (animal number 2) having a tmax of 8 hours.
The measurement of ampicillin in plasma after bacampicillin and 
p r o b e n e c id  a d m in is t r a t io n  show ed tha t  the p resen ce  of  
probenecid at the time of administration, appeared to limit the 
absorption of the antibiotic from the gastrointestinal  tract as 
reflected in statistically lower (P < 0 . 0 5 ) ampicillin peak plasma 
concentration. Since probenecid is a competi t ive inhibitor  of 
penicil l in  excretion in the kidney,  it may be that impaired 
absorption of bacampicillin was related to the presence of an 
active carrier mechanism for penicillin in the small intestine or 
that the presence of both compounds resulted in some interaction 
that reduced the absorption of the antimicrobial .  Sjovall and 
o thers  (1985)  observed  that  when inc reas in g  doses  of 
bacam pic i l l in  were adminis tered  to humans ,  there was a 
saturable increase in peak plasma concentration, plasma AUC and 
u r in a ry  e x c re t io n  of  am p ic i l l in .  T h ey  p o s tu la t e d  that  
bacampici l l in  and other aminopenicil l ins  are absorbed by a 
saturable specialized transport mechanism as well as by passive 
diffusion. Studies carried out in everted gut sac and enterocyte 
brush-border membrane vesicles, for the evaluation of intestinal 
absorption of beta-lactam antibiotics confirmed the existence of 
an active transport mechanism for these antibiotics in the small 
intestine. Nakashima and others (1984) recorded mixed type 
kinetics (saturable and non-saturable processes)  for beta-lactam 
antibiotics in the rat jejunum and observed that the carrier was 
common for various dipeptides and the antibiotics. This carrier 
system, which transfers dipeptides and beta-lactam antibiotics 
was shown to be dependent on a proton influx from the intestinal 
lumen into the epithelial cells (Okano et al ., 1986). The proton 
influx is generated from a Na+/ H + exchange pump which ensures 
the constant presence of protons and consequently  an acidic 
microclimate in the vicinity of the brush-border membrane of 
enterocytes (Lucas, 1983; Shiau et al., 1985). This mechanism has 
been shown to be present in rats and humans (Kleinman et al., 
1988) and might be responsible for the good oral bioavailabilities 
of beta - lac tams in these species.  W hether  the poor  oral 
bioavailabilities of beta-lactam antibiotics in the horse are caused
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by the lack of a suitable acidic microclimate in the proximity of 
brush-border membranes in this species is unknown.
The presence of symptoms of gastointestinal  disturbance with 
r e d u c ed  appet i te  and mild colic  af ter  adm in is t ra t ion  of 
bacampicil lin and probenecid, may have been the result of a 
reduced absorption of bacampicillin in the small intestine and 
consequently higher concentrations of the antiobic present in the 
large intestine. The oral administration of probenecid is unlikely 
to be the cause of the observed gastrointestinal disturbance as 
this drug is well tolerated by the oral route in the horse 
(Donecker et al ., 1986). When bacampicillin was administered in 
combinat ion with probenecid to human beings, adverse effects 
including nausea and diarrhoea were observed (Wagner  et al ., 
1981). However, ampicillin concentrations were not measured 
following administration of bacampicillin and probenecid, and the 
study did not evaluate the presence of adverse effects for 
bacampicillin administered alone.
In this study, the disturbance of the bacterial ecosystem as 
reflected in profuse cultures of E. coli must have occurred after 
transformation of bacampicillin into ampicillin since bacampicillin 
lacks antibacterial activity per se. This result is in disagreement 
with some studies which claim that the lack of antibacterial 
activity of bacampicillin is responsible for a lower incidence of 
intestinal microflora disturbances (Sjovall et al ., 1986). The lower 
incidence of microflora disturbances recorded after bacampicillin 
administrat ion is likely to be caused by the improved oral
bioavailability of this compound and thus smaller concentrations 
reaching the large intestine. The hydrolysis of bacampicillin into 
ampic i l l in  has p rev ious ly  been shown to occur  in the 
gastrointestinal  tract of humans with almost all bacampicillin 
remaining unchanged in gastric aspirates , but 50 to 100 % 
degradation in duodenal and upper jejunal  aspirates (Swahn,
1976). In addition, incubation of 35 S-pivampici l l in  and 35S -  
bacampicillin in buffer at different pH's showed that both esters 
remained in the original form in the range of pH 1.0 - 5.0.
However marked degradation into ampicillin occurred when the 
pH was increased, and less than 50% of pivampicill in and
bacampicillin remained intact when a pH of 7.0 was reached
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(Swahn, 1976). These results are in agreement with the study 
carried out by Sommers and others (1984) who found that a 
reduction in the gastric acidity induced by the administration of 
ran itid ine , an H 2-receptor antagonist, and sodium bicarbonate 
m arkedly  decreased  the oral b ioavailab ility  of bacam picillin  
when administered to humans. Also the in vitro evaluation of 
bacam picillin  m etabolism  in duodenal aspirates dem onstra ted  
that the lower the pH of the aspirate, the smaller the degradation 
of bacampicillin, but in addition when the specimens were boiled, 
the extent of degradation was drastically reduced (Swahn, 1976). 
T hese  resu lts  appear to ind ica te  tha t the deg rada tion  of 
bacampicillin into ampicillin may be the result of a combination 
of various factors including a higher pH in the lower parts of the 
intestine and the presence of esterases. The in vitro study (Table 
6-9) demonstrated that bacampicillin was metabolised in equine 
caecal fluid up to 81.78 % and bacteria-free caecal fluid up to 
82.85 %, presumably as a result of the more alkaline pH in the 
large intestine and the presence of esterases. It is likely that 
bacteria  p resen t in the equine large in testine  are able to 
sy n thes ise  es te rases  tha t could  have co n tr ib u ted  to the 
degradation of bacampicillin into ampicillin in this study. The 
production of esterases by bacteria has been shown to occur in 
the bovine rumen, particularly among strains capable of digesting 
starch and cellulose (Fay et al.y 1990). It is therefore likely that 
bacterial strains with similar characteristics to those encountered 
in the rumen are present in the equine caecum and could have 
contributed to the bacampicillin hydrolysis.
During the present experim ent, the fraction of bacam picillin  
absorbed from the gastrointestinal tract after bacampicillin and 
dichlorvos administration, appeared to remain in the body for a 
prolonged period. This was reflected in an MRT of 255.5 minutes, 
which is over 2.5 times longer than the value obtained when 
bacam picillin  was adm in istered  on its own (M RT - 95.82
minutes). The prolongation of the ampicillin persistence was also 
reflected in a mean ± SEM plasma concentration of 0.34 ± 0.19 
jig /m l, 12 hours after adm in istra tion . In addition, reduced  
absorption of bacampicillin should have resulted in a smaller 
AUCobs unless the antibiotic persisted for a longer period, this
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appeared to be the case since the AUCobs value after 
bacampicillin and probenecid of 12.29 |ig.h/ml was very similar 
to the value obtained when the antibiotic was administered alone 
(AUCobs = 11.31|ig.h/ml)
These results are in agreem ent with a previous study (See 
Chapter 4) and confirm that ampicillin renal excretion can be 
e f f e c t iv e ly  d e la y e d  w hen  p ro b e n e c id  is a d m in is te re d  
c o n cu rren t ly .
6.5 C o n c lu s io n
The administration of bacampicillin hydrochloride to ponies and 
horses produced the highest bioavailability ever recorded for a 
penicillin in the adult horse following intragastric administration. 
The high peak  am pic illin  p lasm a co ncen tra tions  and the 
persistence of the antibiotic 6 to 8 hours after administration 
suggest that bacampicillin hydrochloride could be administered at 
8 to 12 hour intervals by the oral route and would achieve high 
enough concentrations for the treatment of infections caused by 
susceptible microorganisms. The co-administration of probenecid 
with bacampicillin limited the absorption of the antibiotic from 
the gastrointestinal tract and led to gastrointestinal disturbances 
in the animals making this combination unsuitable for therapy. In 
addition, the reduc tion  of p lasm a and e ry throcy te  esterase  
activity following dichlorvos administration, did not affect the 
disposition and fate of bacampicillin.
The results obtained following bacampicillin administration are of 
potential interest, since there is a lack of suitable preparations for 
the oral administration of antibiotics to horses and ponies. The 
advantages of oral administration compared to the intramuscular 
or the intravenous injection of antibiotics are that the owner may 
adm inister the drug and the possibility  o f reactions at the 
injection site is removed. These practical advantages together 
with the achievem ent of good concentrations observed, make 
bacampicillin a potential candidate for the future development of 
an oral penicillin preparation for use in equ idae .
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C h a p te r  7
S e n s i t iv i t ie s  o f  e q u in e  b a c te r ia l  iso la tes
a n t i b i o t i c s
d i f f e r e n t
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7 .1  I n t r o d u c t io n
F o r  s u c c e s s fu l  a n t ib io t ic  th e ra p y ,  a c o m b in a t io n  of 
pharm acok inetic  in form ation  concerning the antib iotic  to be 
administered and the sensitivity of the bacteria responsible for 
the  in fe c t io n  to tha t p a r t ic u la r  a n t ib io t ic  is req u ired . 
P ha rm aco k ine tic  studies p rovide in vivo  in form ation  about 
plasma and tissue concentrations of the drug administered over 
a period of time. On the other hand, bacterial sensitivity tests 
determine if  the infectious agent is susceptible or not to the 
antibiotic administered (qualitative tests) and if so, what is the in  
v i t ro  antibiotic concentration necessary to kill or inactivate it 
(quantitative tests).
The fact that qualitative sensitivity tests, of which disc-diffusion 
test is the most common, are easy to perform and inexpensive, 
m akes this m ethod  m ore w idely  used  than q u an ti ta t iv e  
sensitiv ity  tests used to determ ine the m inim um  inhibitory  
concen tra tion  (M IC). Q ualita tive  tests do not provide  the 
information necessary to establish a therapeutic regime as the 
concentrations required to inactivate  or destroy the bacteria 
cannot be predicted from the results. However the data provided 
by the MIC tests combined with pharm acokinetic information 
enables an appropria te  therapeutic  regim e to be established 
(dose, route of administration and dosage interval).
Although the MIC of a particular bacterial species is seldom 
required by the clinician it is nevertheless very useful to carry 
out MIC tests on as many pathogenic bacteria as possible and 
c lassify  them in to  groups such as suscep tib le , m oderately  
susceptible and resistant to different antibiotics. This information 
provides criteria neccessary to establish appropriate  treatment 
and in addition, indicates changes of sensitivity patterns during 
the emergence of resistan t strains. Since sensitivity  patterns 
change, it is advisable  to select appropria te  an tib io tics in 
accordance with up-to-date bacterial sensitivity patterns.
In the horse, many studies have been carried out to evaluate the 
sensitivity patterns of equine pathogenic bacteria (Adamson e t  
a l . y 1985; Ensink et a l ., 1993; Hirsh et al., 1985; Hirsh & Jang, 
1987; Knight & Hietala, 1978; Prescott, 1981; Snyder et al.y 1987).
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In the present study, a number of bacteria were isolated from 
equine clin ical specimens over a three-year period. Following 
culture and identification of the bacteria, disc-diffusion and MIC 
tests to a range of an tib io tics were carried to define the 
se n s i t iv i ty  p a tte rn s  o f  six com m only  encoun tered  equ ine
p a th o g en s .
7.2 M ater ia ls  and m ethods
7.2.1  Bacter ia l  i so lat ion  and ident i f icat ion .
N inety-five  bacterial isolates were obtained follow ing routine 
bacterio logical exam ination of equine clinical specim ens from 
different anatomical sites and pathological conditions. The initial
examination consisted of an examination of a gram-stained smear 
followed by culture of the sample on sheep blood agar aerobically 
(7 % sheep blood in Blood Agar base number 2 CM271, Oxoid, 
Unipath Ltd, Basingstoke, England) MacConkey agar aerobically 
(MacConkey CM7, Oxoid), horse blood agar anaerobically (7 % 
horse blood in Blood Agar base number 2 CM271, Oxoid) and 
occasionally "chocolate" agar microaerophilically at 37Q C for 24 to 
48 hours. The iso lation  of equine bacterial pathogens for 
retrospective  in vitro sensitivity determination focussed on six 
d ifferen t bacterial species com m only encountered  in equine 
pathology, these were Actinobacillus equuli (n=12), E s c h e r i c h ia  
coli  (n= 23), P s e u d o m o n a s  species (n=13), S a l m o n e l l a  
t y p h im u r iu m  (n  = l l ) ,  S ta p h y lo c o c c u s  au reus  (n=16) and
Streptococcus zooepidemicus  (n=20). The identification of bacteria 
was carried  out using a b iochem ical charac te r isa tio n  and
identification system, (API system, API Laboratory Products LTD, 
Grafton Way, Basingstoke, Hants, UK). The identification of S.  
zo o e p id e m ic u s  was also confirmed using sugar fermentation tests 
(trehalose, sorbitol, mannitol, salicin, lactose, raffinose, inulin and 
esculin) and evaluation of haemolysis type in sheep blood agar 
plates. During the identification of S a lm o n e l la  species, the sample 
was incubated in iodine containing tetrathionate broth (0.2 ml 
iodine per 10 ml of te trathionate) (Tetrath ionate  broth base 
CM29, Oxoid, Unipath Ltd, Basingstoke, England) overnight and
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then cultured in SS agar (S a lm o n e l la - S h ig e l la ) (SS Agar CM533, 
Oxoid). In addition, a urease production test was carried out 
together with overnight incubation in TSI (Triple Sugar Iron agar) 
slopes (TSI agar CM 277, Oxoid).
7.2 .2  B ac ter ia l  sens it iv i ty  tests .
7 .2 .2 .1  D isc -d i f fu s io n  sens i t iv i ty  tests .
Following bacterial isolation and identification, the Kirby-Bauer or 
d isc-d iffusion  sensitiv ity  test was carried out. The bacterial 
isolate was subcultured onto D.S.T. agar (Diagnostic Sensitivity 
Agar CM 261, Oxoid, Unipath Ltd, Basingstoke, England) and 9 
discs (Oxoid, Antimicrobial Susceptibility Test Discs, Unipath Ltd, 
Basingstoke, England) corresponding to different antibiotics were 
placed onto the inoculated plate. The discs contained specific 
concentrations of the antibiotics: ampicillin (10 jig), penicillin G 
(10 jig), gentamicin (10 jig), erythromycin (10 pig), streptom ycin 
(10 J ig ) ,  t r i m e t h o p r i m - s u l p h a m e t h o x a z o l e  (25  J i g ) ,  
oxy tetracycline  (30jig), lincomycin (2jig) and chloram phenicol 
(30 jug).
Following a 24 hour incubation at 37 2 C, the zones of bacterial 
growth inhibition surrounding the different antibiotic discs were 
measured. A 3 mm or greater zone of bacterial growth inhibition 
from the edge of the disc indicated that the bacteria tested were 
susceptible to that particular antim icrobial. No attem pts were 
made to give a quantitative estimation of the sensitivity, and the 
evaluation of the growth inhibition size classified bacteria  as 
susceptible (S) or resistant (R).
7.2 .2 .2  M in im u m  inh ib itory  concen tra t ions  (MIC)
The MICs were carried out by the broth dilution method in 
com m ercially  availab le  suscep tib il ity  testing p la tes  (Agnum  
urinary plates and ME gram-negative urinary plates, Sensititre 
Plates for Susceptibility Testing, Sensititre LTD, East Grinstead, 
England). A number of original isolates (n = 21) could not be 
tested for amoxycillin/clavulanic acid, ciprofloxacin, carbenicillin,
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ceftriaxone  and ceftizox im e, since the original susceptib ility  
te s t in g  p la tes  (A gnum  u rinary  p la te s )  w ere  no long er  
commercially available. The plates were a micro-version of the 
broth d ilu tion  m ethod and contained d ifferen t an tim icrobial 
agents at appropria te  d ilu tions d istribu ted  in 92 wells. In 
addition 3 positive control wells not containing any antibiotic 
were used to check that the test organism grew satisfactorily in 
the absence of any antimicrobial.
Follow ing iden tification  and subculture o f bacteria, a small 
number of colonies were collected and diluted in demineralised 
water until a 0.5 MacFarland turbidity standard, equivalent to 
10 8 cfu/ml (colonies forming units / ml) was reached. A 10 |i l  
volum e from the d ilu tion  was then transferred  and mixed 
thoroughly into 10 ml of supplemented M ueller Hinton broth 
with TES (n - tr is [H y d roxy m ethy l]m ethy l-2 -am ino e thanesu lfon ic  
acid; 2 -([2 -H ydroxy-l,  1 -bis (hydroxym ethyl) - ethyl] amino) 
ethanesulfonic acid) (Sensititre Ltd Product, The Manor, Crawley, 
W est Sussex, England) buffer. Each well of the plate was 
subsequently inoculated with 50 jil of the seeded broth and then 
incubated for 24 hours at 37 Q C. Following the incubation period, 
the MIC value for each antibiotic was determined as the lowest 
antibiotic concentration capable of inhibiting bacterial growth. 
The antibiotics tested and the appropriate concentration range 
are shown in table 7-1.
7.3 R e su l ts
Equine bacterial isolates were largely recovered from respiratory, 
gastrointestinal and musculoskeletal sites (Table 7-2; Appendix E 
Table E - l ) .  G ram -positive  m icroorganism s, S. aureus  and S . 
zo o e p id e m ic u s  were isolated mainly from samples of respiratory 
origin with 50 % of both isolates recovered from this source. They 
also could be found in quite high num bers in samples of 
musculoskeletal infection and in wounds. S. typhimurium  and A . 
e q u u l i  isolates were found largely in samples of gastrointestinal 
origin as reflected in 81.82 % and 66.67 % of the isolates 
recovered from this source respectively.
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A ntib io tic Concentration range ( j ig /m l)
A m picillin 1 - 2 - 4 - 8 - 1 6 - 3 2 - 6 4 - 1 2 8
A m oxycillin/Clavulanic acid 8 / 4 - 1 6 / 8 - 3 2 / 1 6 - 6 4 / 3 2
C arbenicillin 1 6 - 3 2 - 6 4 - 1 2 8
Mezlocillin 1 6 -3 2 - 6 4 - 1 2 8
Cefoxitin 1 - 2 - 4 - 8 - 1 6 - 3 2 - 6 4 - 1 2 8
Ceftizoxime 1 6 - 3 2 - 6 4 - 1 2 8
C eftriaxone 8 - 1 6 - 3 2 - 6 4
C ephalo th in 1 - 2 - 4 - 8 - 1 6 - 3 2 - 6 4 - 1 2 8
A m ikac in 1 - 2 - 4 - 8 - 1 6 - 3 2 - 6 4
G entam ic in 0 .5 - 1 - 2 - 4 - 8 - 1 6 - 3 2
T o b ram y c in 0 .5 - 1 - 2 - 4 - 8 - 1 6 - 3 2
T etracy c line 2 - 4 - 8 - 1 6
T r im e th o p r im /S u lfa m e th o x a z o le 2 / 3 8 - 4 / 7 6 - 8 / 1 5 2 - 1 6 / 3 0 4
Norfloxacin 1 - 2 - 4 - 8 - 1 6 - 3 2 - 6 4 - 1 2 8
Ciprofloxacin 0 .0 6 -0 .1 2 -0 .2 5 -0 .5 -1 -2 -4 -8
Table 7-1 Concentration ranges of the antibiotics tested with the 
broth dilution method.
Isolates ori gin
Iso la te s M S/W R G.I G.U O (n=)
A. equuli 2 5 .0 0 8.33 66 .67 0 .00 0 .00 1 2
E. coli 34 .7 8 8 .70 2 6 .0 9 30 .43 0 .0 0 23
Pseudomonas  spp. 15.38 53 .8 5 3 0 .7 7 0 .00 0 .0 0 13
S. typhimurium 0 .00 0 .00 8 1 .8 2 0 .00 18.18 1 1
S. aureus 2 5 .0 0 5 0 .0 0 6 .25 0 .00 18.75 1 6
S. zooepidemicus 3 0 .0 0 5 0 .0 0 0 .0 0 10.00 10 .00 2 0
Table 7-2. Origin of bacterial isolates expressed as percentage of 
the total for each isolate.
M S /W : M u s c u lo s k e le ta l /W o u n d s .  R: R e s p i r a to ry .  G .I:
Gastrointestinal. G.U: Genitourinary. O: Others.
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Finally P s e u d o m o n a s  spp. were isolated from various sources 
although the majority of isolates (53.85%) were found in samples 
of respiratory origin (Table 7-2; Appendix E Table E -l) .
Q ua lita t iv e  sen s it iv i ty  pa tte rns  g iven by the K irby -B auer  
sensitiv ity  d iscs were obtained for all bacteria  (Table 7-3; 
Appendix E Table E-2). The MIC50 and MIC90 values for equine 
bacterial isolates to the antibiotics tested were calculated. The 
M IC 50  is the antibiotic concentration at which 50 % of the isolates 
were inhibited and the M IC 90  the antibiotic concentration at 
which 90 % of the isolates were inhibited (Tables 7-4, 7-5, 7-6; 7- 
7). In ad d it ion , MIC values ob ta ined  were expressed  as 
cum ulative  percen tages of sensitive bacteria  to the various 
antibiotics (Appendix E Tables E-3 and E-4).
7.4 D iscuss ion
Antibiotic pharm acokinetic  studies provide information on the 
plasma and tissue concentration profiles of the drugs studied. 
However, a study of the sensitivity patterns of the commonly 
encountered pathogens is neccessary to evaluate w hether the 
achievable p lasm a and tissue concentrations are sufficient to 
successfully kill the bacteria. Qualitative sensitivity tests for 
antimicrobials such as the Kirby-Bauer disc sensitivity test are 
commonly carried  out in practice and indicate w hether the 
organism responsible for the infection is sensitive or resistant to 
the various antibiotics tested. However, these tests do not provide 
a realistic approach and can sometimes be misleading, since no 
information on the amount of the antibiotic necessary to kill the 
bacteria  is given. On the other hand, minimum inh ib ito ry  
concen tra tions  (M IC) p rov ide  in vitro  quantitative data  (in 
pg /m l)  on the susceptib ility  of the various pathogens. This 
information can be related to the plasma and tissue concentration 
data obtained during pharmacokinetic studies.
For practical purposes, MIC data can be expressed in terms of 
percentages (MIC50 and MIC9 0 ) giving quantitative information on 
the susceptibility and also indicating the presence of resistance of 
a particular bacterial species to a specific antibiotic.
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A ntib io tic
Iso la te s AMP
(10 )
GEN
(10)
OXT
(30)
ER
(1 0 )
PEN
(10 )
LIN
(2)
STR
(10)
CHL
(3 0 )
T /S
(2 5 )
A. equuli 83.3 5 0 100 83.3 91 .7 100 41.7 10 0 91 .7
E. coli 5 2 .2 1 0 0 56.5 0 0 0 43.5 87 .0 60 .9
Pseudomonas  sp 0 1 0 0 15.4 0 0 0 53 .8 30 .8 7 .7
S. typhimurium 18.2 1 0 0 0 0 0 0 9.1 18.2 3 6 .4
S. aureus 68 .7 93 .7 87.5 100 62 .5 100 1 00 1 0 0 1 0 0
S zooepidemicus 10 0 1 5 100 95 1 0 0 100 100 1 0 0 95
Table 7-3 Percentage of bacterial isolates sensitive to different 
antibiotics tested with the disc-diffusion method.
AMP: Ampicillin; GEN: Gentamicin; OXT: Oxytetracycline; ER: 
E ry th rom ycin ; PEN: Pen ic illin  G; LIN: L incom ycin ; STR:
S trep to m y c in ;  CHL: C h lo ram p h en ico l;  T IS: T r im e th o p r im
/S u lp h am e th o x azo le .
Numbers in brackets correspond to the antibiotic concentrations 
in jig.
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P e n i c i l l i n s AM P AMOX/ C.A CARB MEZ
MIC MIC MIC MIC MIC MIC MIC MIC
50 90 50 90 50 90 50 90
A. equuli <1 <1 < 8 / 4 < 8 / 4 <16 <16 <16 <16
E. coli 4 >128 < 8 / 4 16 /8 <16 >128 <16 >128
Pseudomonas  sp >128 >128 >64/32 >64/32 32 64 32 128
S. typhimurium >128 >128 3 2 / 1 6 3 2 / 1 6 >128 >128 >128 >128
S. aureus <1 4 < 8 / 4 < 8 / 4 <16 <16 <16 <16
S. zooepidemicus <1 <1 < 8 / 4 < 8 / 4 <16 <16 <16 <16
Table 7-4. MIC50 and MIC90 values for equine bacterial isolates to 
different penicillins.
AMP: Ampicillin; AMOX/ C.A: Amoxycillin/ Clavulanic acid;
CARB: Carbenicillin; MEZ: Mezlocillin.
C e p h a l o s p o r i n s CEFOX CEFTIZ CEF1R CEPHA
MIC MIC MIC MIC MIC MIC MIC MIC
50 90 50 90 50 90 50 90
A. equuli <1 <1 <16 <16 <8 <8 <1 <1
E . coli 4 8 <16 <16 <8 <8 8 64
Pseudomonas  spp >128 >128 32 128 16 64 >128 >128
S. typhimurium 8 8 <16 <16 <8 <8 16 16
S. aureus 2 4 <16 <16 <8 <8 <1 <1
S . zooepidemicus <1 <1 <16 <16 <8 <8 <1 <1
Table 7-5 MIC50 and MIC90  values for equine bacterial isolates to 
different cephalosporins.
CEFOX: Cefoxitin; CEFTIZ: Ceftizoxime; CEFTR: Ceftriaxone; CEPHA: 
C ephalo th in
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A m i n o g l y c o s i d e s AM I GENT TOBR
MIC MIC MIC MIC MIC MIC
50 90 50 90 50 90
A. equuli 4 8 1 2 1 1
E. coli 2 2 <0.5 1 1 1
Pseudomonas  sp p 4 4 2 8 <0.5 2
S. typhimurium <1 2 <0.5 <0.5 1 1
S. aureus 2 4 <0.5 <0.5 <0.5 <0.5
S . zooepidemicus <1 4 <0.5 1 <0.5 1
Table 7-6 MIC50 and MIC90  values for equine bacterial isolates to 
different am inoglycosides.
AMI: Amikacin; GENT: Gentamicin; TOBR: Tobramycin.
M i s c e l l a n e o u s TETR TM P/S NORF CIPR
MIC MIC MIC MIC MIC MIC MIC MIC
50 90 50 90 50 90 50 90
A. equuli <2 <2 <2 /3 8 < 2 / 3 8 <1 <1 <0.06 <0.06
E. coli <2 >16 < 2 /3 8 >16/304 <1 <1 <0.06 <0.06
Pseudomonas  sp >16 >16 8 /152 >16/304 <1 8 0.25 2
S. typhimurium 16 >16 >16/304 >16/304 <1 <1 <0.06 <0.06
S . aureus <2 >16 < 2 /3 8 < 2 / 3 8 <1 <1 0.12 0.25
S. zooepidemicus <2 <2 < 2 /3 8 < 2 / 3 8 4 8 1 1
Table 7-7 MIC50 and MIC90 values for equine bacterial isolates to 
tetracycline, trim ethoprim /sulphonam ide and fluoroquinolones.
TETR: Tetracycline; TMP/S: Trimethoprim/ Sulphonamide; NORF: 
Norfloxacin; CIPR: Ciprofloxacin.
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In the present study, MIC data for the penicillins appeared to 
indicate that this group of antibiotics was a suitable choice for the 
treatment of gram-positive infections caused by S. aureus  and S.  
z o o e p id e m ic u s  (Table 7-4). This result appeared to contradict the 
results obtained by the disc-diffusion test where over 30 % of the 
S. aureus tested were resistant to ampicillin (Table 7-3). In 
addition, A. equuli , a gram negative equine pathogen appeared to 
be susceptible to all penicillins tested during the study. The 
presence of resistance  to penicillins was particularly  obvious 
among the E. coli tested. This was reflected in low concentrations 
for the MIC50  and very high concentrations for the MIC90 e x c e p t  
fo r the a m o x y c il l in /  c lav u lan ic  acid  com bina tio n . T hese  
differences in susceptibility  of E. coli isolates to a particular 
antibiotic are in agreement with the results reported by Ensink 
and others (1993). They found that susceptibility of E. coli , 
S a lm o n e l la , K lebs ie l la  spp and coagulase positive S ta p h y lo c o c c u s  
spp to d iffe ren t  an tim icrob ia ls  varied  ex tensively  betw een 
isolates. On this basis they recommended that MIC determination 
should be carried  out particu larly  on those isolates where 
variation in the susceptibility pattern is most likely to occur.
In this study, P s e u d o m o n a s  spp. was resistant both to ampicillin 
and a m o x y c i l l in /c la v u la n ic  acid c o m b in a t io n s  and h igh  
concentrations of carbenicillin and mezlocillin, two penicillins 
used for the treatm ent of P s e u d o m o n a s  in f e c t io n s ,  w ere  
necessary to kill the bacteria. S. typhimurium  appeared resistant 
to all penicillins tested except to the amoxycillin/clavulanic acid 
combination where an M IC 90 of 32/16 pg /m l was recorded. The 
lower antibiotic concentrations required to kill S a l m o n e l l a , when 
the amoxycillin was combined with clavulanic acid, a beta- 
lactamase inhibitor, suggest that this bacteria was resistant to the 
other penicillins by producing beta-lactamase enzyme.
The cephalosporins appeared to be very effective antibiotics for 
the treatment of infections caused by S. aureus , S. zooepidemicus  
and A. equuli. In addition, E. coli and S. typhimurium  isolates 
were sensitive to cefoxitin, a second generation cephalosporin, 
and to th ird  g en era tion  c e p h a lo sp o r in s  ce f t iz o x im e  and 
ceftr iaxone. C eph a lo th in , a f irs t genera tion  c ep h a lo sp o r in , 
appeared to have some activity against S. typh im ur ium  with
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MIC50 and MIC90 values of 16 jig/ml but resistance among E. coli 
isolates appeared to be common as reflected in an MIC90 value of 
64 |ig /m l. Finally, P s e u d o m o n a s  spp. were resistant to the first 
and second generation  cephalosporins  and only ceftr iaxone 
appeared to have activity against this bacteria although high 
concen tra tions  (MIC50 = 16 Jig/ml andMIC9o = 64 jig/m l) were 
required for effect (Table 7-5).
T he a m in o g ly c o s id e s  te s te d ,  a m ik ac in ,  g e n ta m ic in  and 
tobram ycin, appeared to be effective against m ost bacteria 
tested including gram positive bacteria, S. typhimurium  and E . 
coli .  P s e u d o m o n a s  spp was sensitive to this group of antibiotics 
and a gentamicin concentration of 8 Jig/ml was sufficient to kill 
90 % of the isolates. The am inoglycosides, and particu larly  
gentamicin and tobram ycin, were effective against A . equuli  
(Table 7-6).
The results obtained for tetracycline showed the presence of 
res is tance  to this an tib io tic  particu larly  among E. coli , S . 
t y p h i m u r i u m , and P s e u d o m o n a s  spp. On the other hand, A . 
e q u u l i .  and S . zooepidemicus  appeared  to be pa rticu la rly  
sensitive  to this an tib io tic  (Table 7-7). The tr im ethoprim / 
sulfam ethoxazole  com bination was effective against the gram 
positive pathogens and A. equuli. but of limited value for the 
treatment of salmonella and pseudomonas infections. 65.2 % of 
the E. coli isolates tested were inactivated by concentrations of 
less than or equal to 2/38 p. g /m l of the t r im e th o p r im  
/sulphonamide combination, the remaining E . coli isolates were 
resistant (Table 7-7; Appendix E Table E-3).
The two quinolone antibacterials, norfloxacin and ciprofloxacin, 
were tested for their activity against equine pathogens. The 
results showed that these two antibiotics were highly effective 
against A. equuli, E. coli and S. typhimurium  at low concentrations 
(<1 pg/m l for norfloxacin and <0.06 pg /m l for ciprofloxacin). A 
large percentage of P s e u d o m o n a s  spp isolates also appeared 
sensitive to the quinolones at low concentrations (Table 7-7). 
Norfloxacin appeared to be effective against S. aureus  but less so 
against S. zooepidemicus  as reflected in an MIC50 of 4 pg /m l and 
M IC 90 of 8 pg/m l for the latter pathogen. Lower concentrations of 
ciprofloxacin were neccessary to kill the gram-positive bacteria.
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A more prac tical way to classify bacteria  according to their 
susceptibility  can be applied when pharmacokinetic information 
about the antibiotic is available. The bacteria can be classified 
into four categories according to its susceptibility in relation to 
the pharmacokinetic profile of the antibiotic. This four-category 
guideline system suggested by Ericsson and Sherris (1971) and 
the National Committee for Clinical Laboratory Standards (NCCLS) 
(1983), classifies bacterial pathogens into four:
1) Susceptible, when the infecting organism is usually inhibited 
by concentrations of a particular antibiotic that are attained in 
tissues by the usual dosage.
2) M odera te ly  susceptib le , the in fec ting  organism  is only 
inh ib ited  by blood or tissue concen tra tions achieved with 
maximum dosage.
3) Resistant, the organism is resistant to normal achievable or 
tolerated concentrations of the drug.
4) Conditionally susceptible, the organism causes infection in sites 
where tissue or body fluid concentrations of drug greatly exceed 
those present in most areas of the body.
Although the guidelines for the interpretation of MIC data for all 
a n t ib io t ic s  in v e te r in a ry  m e d ic in e  are  no t  a v a i la b le ,  
pharmacokinetic studies carried out with some antimicrobials in 
the horse have allowed the creation of guidelines for ampicillin, 
gentamicin, amikacin and tetracycline among the antimicrobials 
included in the present study (Table 7-8) (Prescott & Baggot, 
1988c).
A ntib io tic  Suscep tib le  M o d e ra te ly  R es is tan t  C onditionally
Suscep tib le S u scep tib le
AMP <1 2 - 1 6 >16 3 2 - 1 2 8
GENT <2 4 - 8 >8 1 6 -6 4
AM I <4 8 -1 6 >16 3 2 - 1 2 8
TETRA <1 2 - 4 >4 8 - 1 2 8
Table 7-8. Suggested guidelines for the interpretation of MIC 
(jig/ml) data in equidae  (Prescott & Baggot, 1988c).
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A ccord ing  to these  guidelines, 100% of A. equuli  and S . 
z o o e p i d e m i c u s  isolates and 68.7 % of S. aureus  isolates were 
sensitive to ampicillin (<1 jig/ml) with the rest of the S. aureus  
isolates falling into the m oderately susceptible category (2-16 
p,g/ml). Also, 52.2% of E. coli and 18.2 % of S. typh im ur ium  
isolates were moderately susceptible. The rest of the isolates 
including all P s e u d o m o n a s  sp were resistant to ampicillin 
(Appendix E Table E-3).
One hundred per cent of all bacterial species isolates and 53.8 % 
P s e u d o m o n a s  spp. were classified as sensitive (<2 jig /m l) to 
gentamicin and up to 38.5 % of P s e u d o m o n a s  spp fell into the 
m oderate ly  susceptib le  category (4-8 jig /m l). S im ilar results  
were found for amikacin, with 100 % of E. coli, S. typhimurium, S . 
a u r e u s  and S.  z o o e p i d e m i c u s  susceptible (<4 pg /m l)  to this 
aminoglycoside. In addition, 16.7 % of A. equuli fell into the 
m od era te ly  su scep tib le  ca tegory  (8-16 pg /m l)  and 7.6 % 
P s e u d o m o n a s  spp were resistant. Finally, 56.5 % of the A. equuli, 
9.1% of the S. typhimurium  isolates, 87.5 % of the S. aureus  and 
95 % S. z o o e p i d e m i c u s  were classified as belonging to the 
susceptible and moderately susceptible category (up to 4 j ig /m l) .  
The other isolates were resistant to amikacin (Appendix E Table 
E-3).
These results, obtained by interpretation of the MIC data, were 
compared to those obtained with the disc-diffusion method. The 
ampicillin  sensitiv ity  patterns were alm ost identical by both 
methods. However, A. equuli and S. zooepidemicus  appeared to be 
more resistant to gentamicin when tested by the K irby-Bauer 
disc-diffusion method, since 50 % of the A. equuli isolates were 
sensitive to gentamicin when tested by the disc-diffusion test and 
100 % were sensitive when tested by the broth dilution method. 
Similarly, only 15 % of the S. zooepidemicus  iso la te s  were 
sensitive to gentamicin by the Kirby-Bauer method compared to a 
100 % according to these MIC results. Finally the tetracycline 
sensitivity results appeared to be quite similar by both methods, 
except for the P s e u d o m o n a s  isolates where 15.4 % sensitive to 
tetracycline when tested with the discs and 0 % when tested by 
the broth dilution method. In addition, the MIC results for S . 
t y p h i m u r i u m  showed that 9.1 % of the isolates fell into the
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tetracycline susceptible and moderately susceptible category but 
none of the isolates appeared susceptible to this antibiotic when 
tested by the disc method.
Although the in vitro determination of sensitivity patterns does 
not take into account a number of factors that occur in vivo, such 
as the bactericidal activity of the host immune system or the 
enhanced killing of antibiotic-damaged bacteria by macrophages, 
MIC determination is an important guide for the establishment of 
an appropriate antimicrobial therapy (Prescott & Baggot, 1985). 
The UK Veterinary Products Committee recommends that peak 
plasm a concentrations of at least twice the MIC should be 
achieved and that plasma concentrations greater than or equal to 
the MIC should be maintained for at least half the interdosing 
in te rv a l .
7.5 Conclus ion
The lack of comprehensive clinical trials in veterinary medicine, 
has made the use of MIC data together with antim icrobial 
pharmacokinetic information (plasma and tissue disposition), the 
basis for the establishment of antibacterial therapy.
The MIC quantitative susceptibility method gives a more precise 
description of the bacterial susceptibility than the disc-diffusion 
method, and it can also be related directly to the pharmacokinetic 
param eters of the an tib io tic . How ever, it is im portan t to 
emphasize that MIC data should be interpreted cautiously since 
the results are in agreement with the free non-protein bound 
fraction of the antibiotic and not with the total drug concentration 
(Derendorf, 1989). In addition, factors occuring in vivo relating to 
the immune system are not taken into account when testing 
bacterial susceptibility in vitro.
Despite these limitations, MIC values for bacteria responsible for 
the infection should be determined since they indicate which is 
the most suitable antibiotic to be administered and reflect the 
emergence and incidence of bacterial resistance to the various 
an tim icrob ia ls .
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C h a p te r  8 
G e n e r a l  d i s c u s s io n
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W hen am picillin  sodium was administered IV to horses and 
ponies , it was e lim inated  rapidly  from the body, thus an 
elimination half-life and MRT of less than one hour, and high total 
body clearance value were obtained. The rapid elimination of 
ampicillin in the horse represents a therapeutic drawback, since 
frequent doses of the antimicrobial have to be administered in 
o rd e r  to m a in ta in  su f f ic ie n t ly  h igh  p lasm a  and tissue  
co n cen tra t io n s .
A m ajor objective of the present study was to modify the 
absorption and elimination patterns of ampicillin in the horse in 
order to achieve a prolonged persistence of the antibiotic in the 
body after administration and consequently reduce the frequency 
of administration.
The attempt to modify the excretion pattern of ampicillin in the 
horse by altering the urinary pH had no effect. This may have 
been a ttr ibu tab le  to the chem ical s truc ture  of am picillin , 
containing two ionisable groups (an amino and a carboxyl group) 
within its molecule. The presence of at least one of the groups in 
the ionised form would limit the ability of the molecule to cross 
phospholipid, barriers such as those present in the renal tubule 
and therefore impair the transfer of ampicillin from the urine 
into plasma. However, alterations of urinary pH have been shown 
to have marked effects on the plasma disposition of some drugs 
excreted partly in the urine and this has been demonstrated for 
the sulphonamides in the dog (Baggot, 1968). In the horse, Gelsi 
(1979) observed  that tr im ethoprim  and su lphadoxine  were 
excreted in the urine by glomerular filtration, active tubular 
secretion and back-diffusion. The mechanisms responsible for the 
excretion of both compounds, were determined by measuring the 
creatinine clearance (an indicator of the glom erular filtration 
rate), the plasma concentration of unbound drug, the urinary flow 
rate and the urinary pH. Both the urinary pH and and the plasma 
concentration of unbound drug had an effect on the excretion rate 
of trimethoprim and sulphadoxine. In addition, the urinary flow 
ra te  appeared to have an influence  on the excretion  of 
trim ethoprim . It would therefore be interesting to investigate 
whether, the plasma concentration of the drug and the urinary
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flow rate would have an effect on the excretion rate of ampicillin 
in the horse.
The present studies also revealed that although no changes in 
p lasm a d isposition  were found follow ing altera tions of the 
urinary pH, these changes had an effect on the degradation of the 
antibiotic in the urine, since ampicillin was markedly degraded in 
alkaline urine. It would therefore be interesting, to investigate 
the extent o f degradation of ampicillin and other penicillins in  
v i v o  at d ifferen t urinary pH values and determ ine whether 
special considerations should be taken during the treatment of 
urinary tract infections with these antibiotics.
The concurren t adm in istra tion  of am picillin  and probenecid  
proved to be an effective way of prolonging the persistence of the 
antibiotic in the equine body. This was reflected in a prolonged 
elim ination half-life and MRT of ampicillin together with a 
reduction  in the total body clearance when am picillin  was 
administered after an intragastric dose of probenecid. In addition, 
the presence of probenecid appeared to reduce the distribution of 
am picillin  in the body as reflected  in sm aller volumes of 
d is tr ibu tion  values for the an tib io tic  in the p resence  of 
probenecid. This finding seems to be in agreement with results 
observed in other species (Gibaldi & Schwartz, 1968; Galtier & 
Alvinerie, 1979; Juzw iak et al .y 1989; Villa et a l ., 1991) and 
appears to be the result of probenecid limiting the access of 
pen ic illins  in some tissues such as the liver and kidney 
parenchym a (Bergholz et al.y 1980). It would be interesting to 
compare ampicillin concentrations in these organs following the 
administration of ampicillin and ampicillin in conjunction with 
probenecid. The results would confirm the effects of probenecid 
on the d is tr ibu tion  of am picillin  and indicate  w hether an 
adjustment of the dose would be required to treat infections 
localised in the organs, where the distribution of the antibiotic 
might have been impaired.
Prolonged persistence of ampicillin within the equine body was 
achieved by administration as an IV infusion over a 4-hour 
period. The system enabled accurate control of the amount of 
antibiotic administered to each individual during the procedure. 
However, the impracticality of the method makes it useful only in
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those situations w here the antib iotic  to be adm inistered is 
potentially toxic at high concentrations. It may also be a suitable 
method for the adm inistration of antib iotics prophylactically  
during surgical procedures particularly in those situations where 
a compromised vascular supply (ie shocked patient) would limit 
the absorption of drugs administered by other routes (Alexander 
& Alexander, 1976).
Oral administration was investigated as a method of delaying 
absorption, and consequently  elim ination, of ampicillin in the 
body. In the neonatal foal, the greater perm eability  of the 
gastrointestinal tract enables the administration of drugs that are 
poorly absorbed in the adult (Baggot & Short, 1984). This was 
observed  by B agg o t and o thers  (1988a) fo llow ing  oral 
administration of amoxycillin (30 mg/kg) to 5-to 10-day old foals 
in that oral bioavailability was 42.7 %. However, in the adult 
horse, a maximum oral bioavailability of 10.4 % for a penicillin 
was recorded following oral administration of amoxycillin (Wilson 
et al .y 1988). Recently  Ensink and others (1992) obtained a 
bioavailability of 35.9 % following intragastric administration of 
pivampicillin, an ampicillin prodrug, to adult animals. In this 
study, the intragastric administration of bacampicillin, another 
ampicillin prodrug designed for oral administration, yielded the 
highest oral bioavailability of active ampicillin (41.0 %) obtained 
for any penicillin administered per os to the adult horse. It would 
therefore appear that the administration of ampicillin prodrugs 
could play a role in the future of oral antibacterial therapy in the 
horse where there is a substantia l lack of suitable  oral 
p re p a ra t io n s .
However, it is important to point out that despite the results 
achieved following pivampicillin and bacampicillin administration 
to horses, the bioavailabilities values remain relatively low when 
compared to those obtained in humans for the same antibiotics. 
For instance , when p ivam pic ill in  and bacam pic illin  were 
administered to humans, 83 % and 71 % of the dose were 
absorbed respectively (Swahn, 1976). Another study showed that 
up to 98 % of the bacampicillin dose administered to humans was 
absorbed from the gastrointestinal tract (Rozencweig et al., 1976). 
Similarly, the oral administration of ampicillin and amoxycillin to
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humans is charac terised  by greater bioavailabilities than are 
achieved in the horse. A maximum oral bioavailability of 10.4 % 
and of 3.5 % following oral administration of amoxycillin and 
ampicillin to horses have been recorded (Wilson et al., 1988; 
Horspool, 1992). Comparatively, a larger fraction of the antibiotic 
is absorbed from the gastrointestinal tract when administered to 
humans. For instance 44 % of ampicillin was absorbed from the 
gastrointestinal tract in humans (Swahn, 1975) and more than 70 
% of amoxycillin when administered by the same route (Arancibia 
et al.y 1980). Thus despite being in their ionised form, ampicillin 
and a m o x y c i l l in  are  a b so rb ed  s u b s ta n t ia l ly  from  the 
gastrointestinal tract, and this may be attributed to the presence 
of an active transport carrier system capable of transferring the 
am inopenicillins from the intestinal lumen into the systemic 
c irculation (W estphal et al., 1991). This was demonstrated for 
amoxycillin and bacam picillin  in man where both antibiotics 
appeared to have dose-dependent oral bioavailabilities (Sjovall et  
al.y 1985). Also, several in vitro studies have demonstrated the 
presence of a carrier-mediated process involved in the absorption 
of am ino-p-lac tam  antibiotics in addition to passive transfer 
m echanism s (N akash im a et al.y 1984). The carrier system has 
been shown to be driven by a H+ gradient, resulting from a 
Na+/H+ exchange system, and is responsible for the absorption of 
dipeptides from the in testinal lumen (Okano et al.y 1986). 
Similarly, the dipeptide carrier system has been shown to be 
present in renal brush border m em branes of the rat and is 
though t to be re sp o n s ib le  for tu b u la r  rea b so rp t io n  of 
aminocephalosporins (Inui et al., 1983; Inui et a l y 1984).
In the equine, the aminopenicillins and the ampicillin esters are 
absorbed to a much less extent than in man. This could be 
attributed to the antibiotics binding to food particles, however it 
seems unlikely in this case since a higher oral bioavailability was 
obtained for pivampicillin when the antibiotic was administered 
to fed horses than when it was administered to starved horses 
(Ensink et al ., 1992). W hether the equine lacks the H + gradient 
and the carrier system responsible for the partial transfer of 
aminopenicillins in humans is not known. However, it would be 
interesting to investigate the presence of these carriers in the
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equine small in testine in order to clarify the m echanisms of 
penicillin  absorption and give an explanation for their low 
bioavailability following oral administration in the equine.
In order to slow down the transformation of bacampicillin into 
ampicillin  following administration, an attempt was made to 
reduce the enzymatic activity responsible for the conversion of 
the inactive  com pound into am picillin . Despite  a m assive 
reduction  in both p lasm a and e ry throcy te  esterase  activ ity  
following the administration of dichlorvos, the m etabolism  of 
bacampicillin was not altered, suggesting that the prodrug is not 
only converted by plasma and erythrocyte esterases but also 
possibly by other factors including the more alkaline pH of the 
plasma and esterases present in the intestinal wall and other 
tissues.
These studies also suggested that although bacampicillin may 
play a role in the future treatment of equine infectious diseases, 
further studies should be conducted to investigate the possibility 
of gastrointestinal side effects following its adm inistration to 
horses and ponies since mild gastrointestinal disfunction was 
observed. The co-administration of probenecid and bacampicillin 
resulted in the presence of mild gastrointestinal disturbances. 
These were related to a decrease in the absorption of the 
antibiotic from the intestinal lumen and consequently a larger 
p roportion  passing  into the large in testine . Swahn (1976) 
demonstrated a correlation between the alkalinity of the media 
and the extent of degradation of bacampicillin, and it may be that 
the pH of the large intestinal contents (pH= 6.8-7.2) contributed 
to transform the inactive bacampicillin into the active ampicillin 
leading to a disturbance of the microbial ecosystem and the 
presence of side effects. It would be interesting to investigate 
whether bacampicillin was also transformed into ampicillin by 
the esterases produced by bacteria present in the equine large 
intestine. Fay and others (1990) reported the production of 
esterases by bacteria in the bovine rumen and it is therefore 
quite likely that this occurs in the equine caecum and colon 
where the bacterial fermentation processes take place.
The susceptibility of equine pathogens to ampicillin was tested in 
vitro  using MIC tests. Ampicillin appeared very effective for the
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treatment of diseases caused by S. zooepidemicus  and A. equuli. 
However, a large proportion of E. coli  (47.8 %) and of S . 
t y p h im u r iu m  (81.8 %) isolated were resistant (MIC > 16jig/ml) to 
the antibiotic. Hirsh and Jang (1987) found that 26 % of E. coli and 
55 % of S. typhimurium  were resistant to ampicillin in 1987. The 
larger proportion of resistant strains found during the present 
survey indicate an increase in the proportion of these two gram- 
n ega tive  pa thog ens  re s is ta n t  to a m p ic il l in .  N e v e r th e le ss ,  
interpretation of MIC data should be done cautiously since major 
variations in bacterial sensitivity patterns can occur in different 
geographical areas. The presence of resistant stains among certain 
bacteria indicates that susceptibility testing should be carried out 
routinely particularly on those isolates where the susceptibility 
cannot be predicted (Ensink et al ., 1993). It is important to bear 
in mind that in vitro susceptibility data do not take into account 
many of the circumstances that occur in the animal and should 
therefore be interpreted on that basis. Unfortunately information 
on antim icrobial dosages provided by clinical trials is very 
limited in the veterinary field and consequently most antibiotic 
dosages are based on a combination of pharmacokinetic data and 
sensitivity patterns.
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A p p e n d i c e s
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A p p e n d i x  A
Studies on the effects of  urinary pH on plasma  
ph arm acok in et ics  o f  ampicil l in  in the horse
Animal number
Time (h) 1* 3* 4* 5
0 .0 3 3 5 2 .1 9 6 1 .7 9 59 .4 9 5 5 .43
0 .08 3 43 .41 5 4 .2 7 5 0 .2 2 4 1 .6 2
0 .25 34.71 38 .01 3 7 .8 4 30 .57
0.5 27 .1 8 2 5 .9 4 29 .58 15.65
0 .75 16.03 18 .26 21 .38 10.08
1 7.01 14.11 14.39 7 .89
1.5 5 .33 6.95 8.35 3.81
2 3.21 3 .39 4 .16 2.33
4 0.41 0 .39 1.27 0.47
8 0.03 0 .0 0 0.13 0 .00
12 0 .0 0 0 .0 0 0 .00 0 .00
2 4 0 .0 0 0 .0 0 0 .00 0 .00
T ab le  A - l .  P la sm a  a m p ic i l l in  c o n c e n tra t io n s  a f te r  IV 
administration of ampicillin sodium at a 10 mg/kg dosage rate to 
horses with normal urine.
* Results from a previous study (Horspool et al ., 1992).
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Animal num ber
Time (h) 1 2 3 6
0 .03 3 5 1 .4 6 61 .4 6 57 .11 71 .2 9
0 .083 4 3 .7 8 5 5 .58 5 1 .2 8 50 .3 0
0 .25 32 .1 8 47 .48 3 4 .3 4 31 .37
0.5 20 .91 26.61 19 .92 25.51
0 .75 14.75 14.37 14 .06 13.43
1 12.97 10.85 12 .0 4 10.57
1.5 8.01 7 .5 0 5 .7 2 10.28
2 5 .17 3 .55 3 .6 9 3.71
4 1.68 0 .6 4 0 .75 0.61
8 0 .08 0 .0 0 0 .0 0 0 .0 0
1 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 4 0 .00 0 .0 0 0 .0 0 0 .00
T ab le  A -2. P la sm a  am p ic i l l in  c o n c e n tra t io n s  a f te r  IV 
administration of ampicillin sodium at a 10 mg/kg dosage rate to 
horses with alkaline urine.
Animal number
Time (h) 1 2 3 6
0 .033 6 4 .2 4 6 1 .26 72 .21 68 .10
0 .08 3 5 9 .0 4 5 1 .69 71 .0 3 62 .92
0 .25 3 5 .7 0 37 .3 9 4 1 .3 7 3 9 .30
0.5 23 .17 2 2 .19 2 7 .2 8 25 .73
0 .75 17 .62 14.91 16 .62 15.97
1 11.79 10 .74 1 2 .34 9 .66
1.5 6.67 5 .0 0 6 .42 4 .98
2 4.11 3 .19 4 .0 4 2 .74
4 0 .86 0 .6 0 0 .65 0 .34
8 0 .07 0 .1 0 0 .0 6 0 .0 0
1 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 4 0 .00 0 .0 0 0 .0 0 0 .0 0
T ab le  A -3. P la sm a  a m p ic i l l in  c o n c e n tra t io n s  a f te r  IV 
administration of ampicillin sodium at a 10 mg/kg dosage rate to 
horses with acidic urine.
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Animal number
V a r ia b le 1* 3* 4* 5
a  ( /h ) 1.98 6 .66 1.84 4 .4 0
P ( / h ) 0 .8 0 1.28 0 .57 0 .93
t l /2  a  (h ) 0 .35 0 .1 0 4 0 .3 7 7 0 .1 5 7
t l /2  p (h ) 0 .87 0 .5 6 8 1.213 0 .741
CpO (p g /m l) 53 .1 7 6 7 .9 2 59 .6 7 5 9 .8 8
AUC (pg .h /m l) 3 8 .0 9 41 .2 7 4 7 .9 4 2 8 .7 6
Vc (ml/kg) 188.1 147 .2 167.6 167 .0
Vdarea ( m l /k g ) 32 9 .8 198.7 365 .3 3 7 1 .8
Vdss (ml/kg) 2 2 9 .9 186 .0 231 .3 2 7 5 .0
Clb (ml/h.kg) 2 6 2 .6 242 .3 20 8 .6 3 4 7 .7
k2l ( /h ) 1 .129 4 .9 3 7 0 .8 3 4 1 .979
kel C / h ) 1.396 1.646 1.245 2 .0 8 2
k i2  C / h ) 0 .251 1.299 0 .3 2 0 1 .279
T ab le  A-4. P ha rm acok ine tic  variab les  a fte r  com partm en ta l 
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a 10 mg/kg dose rate to horses with normal 
u rine .
* Results from a previous study (Horspool et al ., 1992).
Animal number
V a r ia b le 1* 3* 4* 5
AUCobs (|!g .h/m l) 3 6 .43 4 2 .27 4 8 .6 2 29. 37
A U M C 0bsOtg.h2/ml) 2 9 .0 7 3 1 .3 0 5 1 .9 4 21. 96
MRT (min) 4 7 .8 9 44 .43 6 4 .1 0 44. 87
C L b0bs(m l/h .kg) 2 7 4 .4 9 2 3 6 .5 9 2 0 5 .6 7 340 .53
Vdssobs (ml/kg) 2 1 9 .0 7 175 .20 2 1 9 .7 3 254 .69
Table A-5. Pharm acokinetic  variables after non-com partm ental 
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a lOmg/kg dose rate to horses with normal 
u rine .
* Results from a previous study (Horspool et al ., 1992)
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Animal number
V aria b le 1 2 3 6
a  ( /h ) 4 .25 2 .77 4.41 15 .15
P ( / h ) 0.71 0 .9 6 0 .88 1 .04
t l /2  a  (h ) 0 .163 0 .2 5 0 0 .1 5 7 0 .0 4 6
t l /2  p (h ) 0 .9 7 4 0 .7 2 2 0 .7 83 0 .6 6 9
CpO (jig /m l) 55 .7 2 6 8 .0 4 65.21 9 6 .2 6
AUC (pg.h/m l) 42 .0 2 4 4 .0 2 3 6 .8 0 3 9 .2 6
Vc (ml/kg) 179.5 147 .0 153.3 103 .9
Vdarea (m l/k g ) 334 .6 2 3 6 .6 3 0 7 .0 2 4 7 .3
Vdss (ml/kg) 286 .2 186 .6 2 4 5 .2 2 2 3 .9
Clb (ml/h.kg) 23 8 .0 2 2 7 .2 27 1 .7 2 5 6 .3
k 2l ( /h ) 2 .2 8 2 1.721 2 .2 0 2 6 .3 6 5
k el ( /h ) 1 .326 1 .546 1.772 2 .4 6 7
ki2 ( /h ) 1.357 0 .4 6 4 1.319 7 .3 5 5
T able  A-6. Pharm acok ine tic  variab les  a fte r  co m partm en ta l  
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a 10 mg/kg dose rate to horses with alkaline 
u rine .
Animal number
V ariab le 1 2 3 6
AUCobs (jJ-g.h/ml) 44 .08 4 3 .4 2 38 .2 6 4 1 .2 3
A U M C 0bs(pg-h2/m l ) 53 .8 2 3 3 .5 7 32 .8 6 3 4 .2 1
M R T  (min) 73 .26 4 6 .3 9 5 0 .9 4 4 9 .7 7
C L b 0b s (m l /h .k g ) 2 2 6 .8 4 23 0 .3 3 2 6 1 .3 6 2 4 2 .5 2
Vdssobs (ml/kg) 27 6 .9 7 178 .0 4 2 2 4 .5 0 2 0 1 .1 8
Table A-7. Pharm acokinetic variables after non-com partm ental 
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a lOmg/kg dose rate to horses with alkaline 
u rine .
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Animal number
V ariab le 1 2 3 6
a  ( /h ) 3.73 2.73 4 .4 4 4 .8 4
P ( / h ) 0 .7 4 0 .6 4 0 .8 0 1.20
t l /2  a  (h ) 0 .1 8 6 0 .2 5 4 0 .1 5 6 0 .14 3
t l /2  p (h ) 0 .9 3 4 1 .080 0 .8 7 0 0 .5 7 6
CpO ( |ig /m l) 7 0 .2 0 64 .36 83 .95 7 7 .1 4
AUC (ng.h/m l) 42 .9 3 39 .35 4 5 .5 9 3 8 .5 9
Vc (ml/kg) 142.5 155 .4 119.1 129.6
Vdarea (m l/k g ) 3 1 3 .8 396 .1 2 7 5 .4 21 5 .6
Vdss (ml/kg) 23 8 .7 2 5 2 .0 2 1 0 .6 180.1
Clb (ml/h.kg) 2 3 2 .9 254.1 219 .3 259 .1
k 2l ( /h ) 1 .694 1.072 1 .920 2 .9 1 2
k ei C/h) 1 .635 1.636 1 .840 1.999
ki2 C/h) 1 .145 0 .6 6 6 1 .470 1.133
T able  A-8. P ha rm acok ine tic  variab les  after  com partm enta l 
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a 10 mg/kg dose rate to horses with acidic 
u rine .
Animal number
Variable 1 2 3 6
AUCobs (j^g.h/ml) 43 .3 5 3 8 .97 4 5 .9 2 3 9 .3 4
AU M C obs(|ig-h2/ml) 4 0 .7 4 34 .17 3 8 .1 4 2 5 .8 7
MRT (min) 5 6 .4 0 5 2 .6 0 4 9 .8 3 3 9 .4 6
CLb0bs(ml/h.kg) 2 3 0 .6 8 256.61 2 1 7 .7 7 2 5 4 .1 9
Vdssobs (rnl/kg) 2 1 6 .8 4 225 .05 180 .75 167 .26
Table A-9. Pharm acokinetic  variables after non-com partm ental 
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a lOmg/kg dose rate to horses with acidic 
u rine.
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A p p e n d i x  B
Studies on the effects of  probenecid on ampicil l in  
ph arm a co k in et ic s  in the horse
Animal num ber
V a ria b le 1 2 5 7
Cmax (jig/m l) 1 5 0 .0 0 163 .40 2 3 2 .7 0 2 0 8 .3 0
tmax (min) 9 0 .0 0 90 .00 1 2 0 .0 0 18 0 .0 0
AUCobs Oig.h/ml) 1579 .71 2 5 0 9 .2 4 2 7 1 9 .3 2 13 05 .1 3
A U M C 0bsOig.h2/ml) 1 2 6 2 8 .3 5 3 1 3 8 8 .5 0 3 3 5 1 6 .5 4 7 8 2 3 .0 4
MRT (h) 7 .9 9 12.51 12 .32 5 .9 9
Table B - l .  Pharm acokinetic  variables after non-com partm ental 
analysis of probenecid plasma concentrations following an IV 
bolus of am picillin  sodium  at a lOm g/kg dose rate  and 
intragastric  administration of probenecid at a 75 mg/kg dose 
ra te .
Animal num ber
T im e
(h)
1 2 5 7
0 .25 54 .4 8 66 .4 4 7 7 .3 6 5 4 .0 6
0.5 97.81 97.31 1 32 .07 111 .93
1 122 .63 98 .23 1 8 0 .2 9 185.8
1.5 1 33 .80 128.03 2 3 2 .7 0 2 0 8 .3 0
2 115 .0 2 163 .40 1 9 6 .2 0 195 .55
3 150 .0 0 154.68 1 89 .87 153 .17
5 119 .05 160.17 16 8 .77 9 4 .4 2
9 69 .03 124 .67 9 5 .3 6 3 7 .1 4
13 46 .33 62 .03 6 8 .3 4 2 5 .1 8
2 5 6.38 28 .47 3 2 .2 8 3 .64
Table B-2. Plasma probenecid concentrations (jig /m l) follow ing 
an intragastric administration of probenecid at 75 mg/kg dosage 
ra te .
2 0 4
Animal number
Time (h) 1 2 5 7
0 .033 5 2 .1 9 55 .43 6 5 .5 4 5 9 .1 4
0 .083 43 .41 4 1 .6 2 4 8 .9 9 4 3 .0 6
0.25 34.71 30 .5 7 3 1 .6 0 3 5 .0 6
0.5 2 7 .1 8 15.65 18 .34 2 6 .4 7
0.75 16.03 10.08 14.16 19 .8 4
1 7.01 7 .89 11 .14 1 5 .69
1.5 5.33 3.81 5.65 9 .15
2 3.21 2.33 3 .00 5 .29
4 0.41 0.47 0 .53 0 .95
8 0 .00 0 .00 0 .00 0 .0 0
1 2 0 .00 0 .00 0 .0 0 0 .0 0
2 4 0 .0 0 0 .00 0 .0 0 0 .0 0
Table B-3. Plasma ampicillin concentrations (jig/ml) following an 
IV administration of ampicillin sodium at a 10 mg/kg dosage 
ra te .
Animal number
Time (h) 1 2 5 7
0.033 9 0 .8 6 7 2 .2 9 85 .5 0 8 6 .7 0
0 .083 7 1 .1 7 6 4 .60 71 .15 6 4 .9 0
0.25 53 .2 8 45 .5 5 6 3 .1 6 5 3 .9 6
0.5 4 4 .4 7 31 .98 4 2 .0 7 3 8 .8 8
0.75 33 .6 5 2 5 .6 2 32 .6 0 3 5 .8 2
1 2 7 .5 2 2 1 .5 9 2 9 .3 4 3 0 .3 3
1.5 2 0 .4 2 17.10 21 .27 2 1 .5 3
2 14.78 11.52 14.02 17.53
4 5 .24 3.59 4.31 5 .45
8 0 .80 0 .60 0 .65 0 .38
1 2 0 .06 0 .06 0 .04 0 .0 2
2 4 0 .0 0 0 .00 0 .0 0 0 .0 0
Table B-4 Plasma ampicillin concentrations (jig/ml) following an 
IV administration of ampicillin sodium at a 10 mg/kg dosage rate 
and an intragastric administration of probenecid at a 75 mg/kg 
dosage rate.
2 0 5
Animal number
V ar iab le 1 2 5 7
a  ( /h ) 2 .0 8 5 4 .4 00 8 .8 1 0 3 1 .5 0
P C/h) 0 .9 7 4 0 .935 1.065 0 .9 7 7
t l /2  a  (h ) 0 .3 3 2 0 .157 0 .0 7 9 0 .0 2 2
t l /2  (3 (h ) 0 .711 0.741 0 .651 0 .7 1 0
CpO (fig/ml) 5 3 .16 59.87 76 .2 8 93 .5
AUC (jig.h/ml) 36 .98 28 .76 3 5 .1 2 45 .3 5
Vc (ml/kg) 188 .10 167.03 1 3 1 .1 0 1 0 7 .0 0
V d area ( m l /k g ) 2 7 7 .6 0 3 7 2 .0 0 2 6 7 .7 0 2 2 5 .8 0
Vdss (ml/kg) 2 1 5 .9 0 2 7 5 .1 0 2 3 3 .7 0 2 1 8 .0 0
Clb (ml/h.kg) 2 7 0 .5 0 3 4 7 .7 0 2 8 4 .8 0 2 2 0 .5 0
k 2i ( / h) 1 .413 1.977 4 .3 2 0 1 4 3 9 2 5
k ei C/h) 1 .438 2 .082 2 .1 7 0 2.061
k i 2 C/h) 0 .2 0 9 1.279 3 .3 8 0 15.49
Table  B-5. Pha rm acok ine t ic  variables  af te r  com par tm en ta l  
analysis of ampicillin plasma concentrations following an IV bolus 
of ampicillin sodium at a 10 mg/kg dose rate.
2 0 6
Animal number
V ar iab le 1 2 5 7
a  ( /h) 12 .6 5 0 4 .4 6 0 4 .1 6 0 2 6 .2 1 0
P(/h) 0 .5 5 4 0 .5 26 0 .585 0 .6 4 9
t l /2  a  (h ) 0 .0 5 5 0 .155 0 .1 6 6 0 .0 2 6
t l /2  p (h ) 1.251 1.318 1.185 1.067
CpO (j ig/ml) 11 2 .24 79 .38 90.95 125 .9 8
AUC (jig.h/ml) 100 .07 77 .2 9 95 .84 96 .11
Vc (ml/kg) 8 9 .1 0 126 .00 109 .90 7 9 .4 0
Vdarea ( m l / k g ) 180 .4 0 2 4 6 .0 0 178 .40 1 6 0 .3 0
Vdss (ml/kg) 172 .30 2 1 8 .4 0 162 .80 1 5 6 .3 0
Clb (ml/h.kg) 9 9 .9 0 129 .30 104 .30 1 0 4 .1 0
k 2l ( / h) 6 .2 4 8 2 .285 2 .566 12 .981
k el ( / h) 1.121 1.027 0 .949 1 .312
ki2  C/h) 5 .8 3 3 1.676 1.233 1 2 .575
T able  B-6. Pharm acok ine t ic  variab les  after  co m p ar tm en ta l
analysis of ampicillin plasma concentrations following an IV bolus 
of ampicillin sodium at a 10 mg/kg dose rate and intragastric
administration of probenecid at a 75 mg/kg dose rate.
Animal number
V ar iab le 1 2 5 7
AUCobs (jag.h/ml) 35 .93 29 .36 35.55 4 6 .7 0
A U M C 0bsOig.h2/ml) 27 .08 21 .95 27 .64 44 .0 3
MRT (min) 4 5 .2 2 44 .85 46 .65 5 6 .57
C L b 0bs(ml/h.kg) 2 7 8 .3 2 3 4 0 .6 0 2 8 1 .2 9 2 1 4 .1 2
Vdssobs (ml/kg) 2 0 9 .7 6 25 4 .4 3 2 1 8 .5 6 20 1 .9 1
Table B-7. Pharmacokinetic  variables after non-compartmental  
analysis of ampicillin plasma concentrations following an IV bolus 
of ampicillin sodium at a lOmg/kg dose rate.
2 0 7
Animal number
Var iab le 1 2 5 7
AUCobs (ng.h/ml) 102 .17 7 9 .6 9 99 .48 104 .65
A U M C obs(M-g-h2/ml) 169.61 1 27 .10 151 .94 1 64 .9 2
MRT (min) 99 .6 0 95 .69 91 .64 94 .5 6
C L b0bs(ml/h.kg) 97 .88 125 .49 100 .52 95 .5 6
Vdssobs (ml/kg) 162 .48 199 .53 153 .80 150 .98
Table B-8. Pharmacokinetic  variables after non-compartmental  
analysis of ampicillin plasma concentrations following an IV bolus 
of ampicillin sodium at a lOmg/kg dose rate and intragastric 
administration of probenecid at a 75 mg/kg dose rate.
2 0 8
A p p e n d ix  C
Intravenous infusions of  am pic i l l in  in horses .
Infusion period
Animal number
T im e
(h)
1 3 4
0 .033 15 .72 17.76 16.76
0 .0 8 3 13 .00 15.26 15.16
0 .1 6 6 9.68 13.02 13.66
0 .25 8 .54 11.60 10.75
0 .50 7 .30 8.62 10.39
0.75 6 .30 7 .70 8.38
1.00 5.83 7.23 7.98
1.25 5 .47 6.91 7.49
1.50 5 .17 6.62 6.73
1.75 5 .80 6.71 7.03
2 .00 5.41 6.42 6 .04
2.25 5.37 6.49 6.01
2 .50 5.55 6.26 6.19
2.75 5.01 6.15 6.16
3 .0 0 5.27 6.00 5.79
3.25 5 .40 6.48 6.05
3 .50 5 .02 6.07 5.39
3.75 5 .26 6.15 5.58
4 .00 4 .87 6.19 5.61
Infusion rate 
( j i g / m i n / k g )
19.07 19.34 19.15
Table C-l  Ampicillin plasma concentrations during IV constant 
rate infusion over a 4 hour period.
2 0 9
Post-infusion period
Animal number
T im e
(h)
1 3 4
0 .0 3 3 5.67 5.73 5 .09
0 .0 8 3 5.13 5 .19 4 .9 4
0 .1 6 6 3.82 4 .59 4 .28
0 .25 3.28 3.97 3 .8 2
0 .5 0 2.09 2 .89 2 .9 0
1.00 0.93 1.54 1.47
2 .00 0.28 0 .50 0 .5 4
4 .0 0 0.05 0.08 0.11
8 .00 0 .00 0 .00 0 .0 0
12 .00 0 .00 0 .00 0 .0 0
2 4 .0 0 0 .00 0 .00 0 .0 0
Table C-l  (cont). Ampicillin plasma concentrations following 
disconnection of the peristaltic pump after a 4 hour infusion 
per iod .
Animal number
V ar ia b le 1 3 4
P ( / h )
t l / 2 p  (h)  
AUCobs ( ( ig .h /m l)  
A UM Cobs ( j ig .h2/m l)  
M RT (h)
1 .065
0 .65
3.43
2.55
0 .74
1.006
0 .69
4.78
4.21
0.88
0 .8 1 2
0.85
4 .80
4.73
0 .99
Table C-2. Pharmacokinetic variables obtained after analysis of 
the plasma ampicillin concentrations recorded in animals 1, 3, 
and 4 following disconnection of the peristaltic pump.
2 1 0
Animal number
V ar iab le 1 3 4
Cpmax ( j ig /m l ) 5 .80 6.91 7 .49
Cpmin ( j ig /m l ) 4 .87 6 .0 0 5 .39
C p S S ( a c t u a l ) ( j ig /m l ) 5 .30±0.07 6 .37±0 .08 6 .1 7 ± 0 .18
Ro ( p g / m i n / k g ) 19.07 19 .34 19.15
Vdss ( a c t u a l ) ( m l /k g ) 20 2 .68 18 1 .09 2 2 9 .2 0
C l b ( a c t u a l ) ( m l /h .k g ) 2 15 .85 182 .17 186 .22
A U C 0 b s - to ta ] (p g .h /m l ) 27 .40 3 3 .8 9 34 .03
Table C-3 Pharmacokinetic variables obtained after analysis of 
the plasma ampicillin concentrations recorded in animals 1, 3, 
and 4 during ampicillin IV constant rate infusion.
A U C o b s - t o t a l  corresponds to the AUC during the infusion and post­
infusion periods.
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A p p e n d ix  D
S tu d ies  on b a c a m p ic i l l in  h y d r o c h lo r id e  in p o n ies  and  
h o r s e s .
Animal number
Time
(h)
1 2 5 8 9 1 0 1 1
0 .033 4 8 .9 4 5 3 .1 3 5 4 .3 2 65 .5 2 53 .1 7 63 .5 8 6 6 .3 2
0.083 39.31 4 3 .0 9 40 .9 8 3 5 .7 0 39 .35 4 8 .6 0 52 .7 9
0 .166 28 .49 3 3 .9 6 2 7 .8 0 3 0 .9 2 30 .27 30 .1 8 37.41
0.25 28 .07 2 8 .5 4 2 2 .4 2 2 8 .1 4 2 0 .5 4 23 .7 5 2 8 .9 4
0.5 19.74 19.97 15.60 14.97 10.70 14.78 17.09
0.75 13.64 11 .02 9.92 10.00 5.18 8 .39 10.47
1 8.97 8 .72 6 .30 6.61 3.43 5 .55 7 .30
1.5 6 .32 6 .1 4 3 .06 3 .07 1.37 3 .1 4 3 .90
2 3.43 4 .57 1.76 1.65 0.68 1.81 2.33
4 1.00 1.51 0 .20 0 .17 0 .04 0 .25 0 .22
8 0.05 0 .2 4 0 .00 0 .0 0 0 .00 0 .0 0 0.11
1 2 0 .00 0 .0 0 0 .00 0 .0 0 0 .00 0 .0 0 0 .00
2 4 0 .00 0 .0 0 0 .00 0 .0 0 0 .00 0 .0 0 0 .00
T ab le  D - l  P la sm a  a m p ic i l l in  c o n c e n t r a t io n s  a f te r  IV 
administration of ampicillin sodium at a 10 mg/kg dosage rate.
2 1 2
Animal number
V ar iab le 1 2 5 8 9 10 1 1
a  (/h) 8 .730 3 .5 5 0 1 0 .6 9 4 2 8 .8 0 0 6.263 7 .5 7 0 5 .800
P ( / h) 0 .798 0 .4 9 6 1 .280 1 .350 1.546 1 .120 0 .7 20
t l /2  a  (h ) 0 .0 7 9 0 .1 9 5 0 .0 6 5 0 .0 2 4 0.111 0 .0 9 2 0 .119
t l /2  p (h) 0 .8 6 9 1.397 0.541 0 .5 1 2 0 .448 0 .621 0 .963
CpO (pg /m l) 5 7 .7 4 5 6 .8 4 67 .5 6 125 .75 61 .42 7 5 .7 7 77 .4 9
AUC(jig.h/ml) 35 .33 37 .1 9 24 .98 2 5 .6 7 18.13 2 4 .7 7 32 .35
Vc (ml/kg) 1 73 .20 17 5 .90 14 8 .0 0 7 9 .5 0 162 .80 132 .0 129.1
V d area(m l/kg ) 3 5 4 .7 0 5 4 1 .9 0 3 1 2 .7 0 2 8 7 .0 0 3 5 6 .8 0 3 6 1 .6 0 4 2 9 .4 0
V d s s (m l /k g ) 3 2 0 .8 0 3 8 4 .3 0 2 7 1 .1 0 2 5 2 .4 0 2 5 1 .9 0 2 6 8 .7 0 3 0 5 .4 0
Clb (ml/h.kg) 2 8 3 .0 0 2 6 8 .9 0 4 0 0 .4 0 3 8 9 .6 0 5 5 1 .5 0 4 0 3 .6 0 3 0 9 .1 0
k 2i ( /h) 4 .26 1.152 5.061 7 .9 5 8 2 .858 2 .7 6 2 1.743
kel C/h) 1 .630 1.528 2 .705 4 .8 9 9 3 .387 3 .0 5 8 2 .395
ki2 C/h) 3.63 1.365 4 .208 17.298 1.563 2 .8 6 2 2.381
Table D-2. .Pharmacokinetic values after compartmental analysis 
of ampicillin plasma concentrations after an IV bolus of ampicillin 
sodium at a 10 mg/kg dose rate.
Animal number
V ar iab le 1 2 5 8 9 10 1 1
AUCobs
( j ig .h /m l) 34 .99 38.91 25 .0 0 27 .0 9 18.66 2 5 .8 0 30 .99
A UM Cobs
( j ig .h 2/ml) 36 .9 4 5 2 .6 4 16.04 15.82 8.17 16 .24 2 3 .0 4
M RT
(m in) 63.33 81 .17 38 .49 3 5 .0 4 26 .27 3 7 .7 6 44.61
CLbobs
(m l /h .k g ) 285 .7 7 2 5 6 .9 8 3 9 9 .9 6 36 9 .1 8 53 5 .7 7 3 8 7 .5 4 3 2 2 .6 9
Vdssobs
(m l /k g ) 30 1 .63 3 4 7 .6 4 2 5 6 .5 5 2 15 .63 2 3 4 .5 6 2 4 3 .9 2 239 .9 3
Table  D-3. Pharmacokine t ic  values after non-com par tm enta l  
analysis of ampicillin plasma concentrations after an IV bolus of 
ampicillin sodium at a 10 mg/kg dose rate.
2 1 3
Animal number
Time (h) 1 2 5 8 9 10 1 1
0 .25 5.21 3 .0 4 3 .62 5 .28 2.41 3 .2 2 3 .84
0 .30 7.55 6 .67 6.46 5 .2 4 3.59 5 .3 7 5 .64
0.75 7 .65 7 .0 2 7.37 5 .27 3.21 4 .9 4 6.29
1 6.38 6 .72 4 .62 5 .0 4 2 .46 4 .9 8 4 .28
1.5 3.55 7 .0 4 2 .90 2 .53 1.43 2 .05 2.56
2 3.15 6 .0 0 2.01 1.14 0.73 1.76 1.55
4 1.57 1.74 1.36 0 .18 0.08 0 .2 8 0.47
6 0 .56 0 .47 0.08 0 .0 0 0 .00 0 .0 0 0 .09
8 0 .12 0.11 0 .00 0 .0 0 0 .00 0 .0 0 0 .00
1 2 0 .00 0 .0 0 0 .00 0 .0 0 0 .00 0 .0 0 0 .00
2 4 0 .00 0 .0 0 0 .00 0 .0 0 0 .00 0 .0 0 0 .00
Table  D-4. Plasma ampicil lin concentrations after intragastric 
administration of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate.
Animal number
V ar iab le 1 2 5 8 9 10 1 1
Cmax (pg/ml) 7 .65 7 .04 7 .37 5.28 3 .59 5.37 6.29
tmax (min) 4 5 9 0 4 5 15 3 0 3 0 45
AUCobs (pg.h/ml) 17 .82 22 .42 12.96 8.87 5 .0 0 9.07 9.91
AUMCobsOtg.h2/ml) 3 8 .2 2 47 .17 2 3 .4 9 10.15 5 .68 12.31 14.68
MRT (min) 1 28 .66 126 .22 108 .72 6 8 .6 4 6 8 .1 7 81 .49 88.85
F (%) 5 0 .9 2 5 7 .6 2 5 1 .8 4 3 2 .7 4 2 6 .7 9 35 .15 31 .98
MAT (min) 65 .33 45 .05 70 .2 3 3 3 .6 0 4 1 .9 0 43 .73 44 .24
Table  D-5. Pharmacokine t ic  values after non-compartmenta l  
analysis  of ampici l l in  p lasma concentra t ions  fo l low ing  an 
intragastric dose of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate.
2 1 4
Animal number
Day 1 2 5 8 9 10 1 1
Pre (-3) 2 0 6 4 .4 3 2 6 7 .4 4 6 6 3 .5 6 08 9 .3 5 4 5 0 .7 3 5 7 9 .3 5 4 3 5 .9
Pre (-2) 2 15 3 .5 2 9 7 0 .4 52 8 7 .3 5 8 5 1 .7 5 3 3 1 .9 3 7 2 7 .8 5 7 6 2 .6
Pre (-1) 22 2 7 .8 3 0 7 4 .4 55 8 4 .3 5 3 6 1 .6 5 53 9 .8 3 8 1 7 .0 5911 .1
Pre (0) 1797.1 2 7 1 7 .9 4 5 4 4 .7 5 45 0 .7 5 391 .3 2 7 7 7 .3 4 7 5 2 .6
1 118.8 163 .4 163 .4 193.1 148.5 133 .8 2 0 7 .9
2 2 0 7 .9 222 .8 3 1 1 .9 2 3 7 .6 163 .4 3 4 1 .6 3 1 1 .9
3 3 2 6 .7 3 5 6 .4 549 .5 6 38 .6 3 26 .7 3 5 6 .4 623 .8
4 4 30 .7 371 .3 772 .3 8 0 2 .0 5 05 .0 5 3 4 .7 876 .3
7 935 .7 9 6 5 .4 1559 .5 2 1 0 9 .0 1099 .0 9 2 0 .8 1158 .5
10 1158.5 1 203 .0 1930 .8 3 23 7 .7 1856.5 2 0 0 5 .0 1455 .5
2 0 1262 .4 18 86 .2 2 8 3 6 .7 4 7 5 2 .6 2 4 2 0 .9 1 826 .8 2 7 1 7 .9
3 0 1722 .8 18 2 6 .0 3 3 1 2 .0 3 7 27 .8 3 02 9 .8 2 2 8 7 .2 302 9 .8
4 5 1930.8 2 1 5 3 .5 3 28 2 .3 4 1 4 3 .7 3163 .5 2 6 1 3 .9 4 9 0 1 .2
6 0 1782 .2 3 1 8 5 .7 3 4 4 5 .7 45 8 9 .3 3 6 2 3 .9 2 7 4 7 .6 4 6 1 9 .0
9 0 2 2 7 2 .4 3 0 4 4 .7 4 1 2 1 .4 4 8 5 6 .6 4 1 7 3 .4 310 4 .1 4 9 1 6 .0
Table D-6. Plasma cholinesterase values (U/L) before and after 
administration of an oral dose of dichlorvos at a 40 mg/kg dose 
ra te .
Dichlorvos was administered immediate ly after blood sample 
collection on day 0.
2 1 5
Animal number
Day 1 2 5 8 9 10 1 1
Pre (-3) 352 5 .2 5 0 0 1 .5 96 0 8 .4 86 8 6 .5 1 2 1 2 8 .4 7 4 6 0 .6 1 00 0 1 .2
Pre (-2) 4 0 37 .9 4 6 1 9 .9 90 6 1 .4 8 1 0 9 .2 1 1927 .2 7 2 3 3 .5 11827 .8
Pre (-1) 3074 .3 4 6 2 5 .2 4404 .5 8 0 8 3 .4 12332 .1 7 9 2 0 .9 13000 .5
Pre (0) 29 20 .6 3 9 26 .3 7 50 1 .9 8111 .5 12696 .3 6 5 0 5 .2 1185 9 .6
1 70.9 126 .2 92.7 78.8 34 .2 99.1 209 .8
2 207 .9 148.5 107.0 3 8 1 .2 101.8 239.1 302 .7
3 4 6 5 .4 2 3 7 .6 648 .2 5 6 5 .6 530.1 578 .7 1108 .9
4 644 .8 390 .3 1481.1 1673 .3 9 25 .2 950 .5 1633 .2
7 1589 .2 954 .5 27 56 .9 3 6 1 9 .6 2 9 4 0 .7 1939 .6 211 9 .2
1 0 2257 .5 1493 .8 3334 .9 5 4 2 5 .9 5 0 9 4 .2 4 5 4 0 .9 3385 .1
2 0 223 5 .0 3 1 5 4 .5 4 2 5 9 .2 8020 .1 6 3 1 8 .9 4 0 0 7 .9 5378 .8
3 0 4 2 1 8 .0 2 3 4 7 .8 6701.1 4 8 8 6 .3 7 8 80 .7 4420 .1 63 2 6 .9
45 385 6 .4 3 4 81 .5 4826.1 7 3 4 4 .7 85 3 9 .9 4 4 5 9 .9 920 8 .2
6 0 4 7 7 7 .4 8338 .3 6950 .7 6 7 8 4 .2 9 1 14 .5 4 2 2 4 .6 8092 .6
9 0 645 3 .2 5 7 7 3 .7 92 71 .9 7 1 4 2 .2 11510 .3 5 2 8 2 .9 993 6 .0
Table D-7. Erythrocyte cholinesterase values (U/L) before and 
after administration of an oral dose of dichlorvos at a 40 mg/kg 
dose rate.
Dichlorvos was administered immediate ly  after blood sample 
collection on day 0.
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Animal number
Time (h) 1 2 5 8 9 10 1 1
0 .25 8.20 0 .0 0 0 .75 4 .6 0 6.49 2.61 3 .88
0 .30 9.28 2 .08 4.01 7 .02 6 .34 5 .23 6.33
0 .75 8.23 4 .49 5 .99 7.31 4.48 5 .7 2 5 .86
1 8.38 6 .4 2 6.08 8.06 3 .46 5 .9 6 5.83
1.5 5 .64 6 .09 4 .39 3.78 2 .14 5 .1 2 3 .74
2 3.86 4 .47 3 .34 2.18 1.83 2 .7 0 2 .67
4 0.57 2 .25 0.33 0.13 0.31 0 .33 0.67
6 0.07 0 .5 0 0 .00 0 .00 0.07 0 .03 0 .00
8 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .0 0 0 .00
1 2 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .0 0 0 .00
2 4 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .0 0 0 .00
Table D-8. Plasma ampici llin concentrations after intragastric 
administration of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate following an oral administration of dichlorvos at a 40 
mg/kg dose rate.
Animal number
V ar iab le 1 2 5 8 9 1 0 1 1
Cmax (pg /ml) 9.28 6 .42 6.08 8.06 6.49 5 .96 6.33
tmax (min) 3 0 6 0 6 0 6 0 15 6 0 3 0
AUCobs (jig.h/ml) 18 .50 18.62 11.95 12.59 9.76 12.28 13.02
A U M C 0bs(ltg*h2/ml) 2 2 .7 5 4 7 .6 2 18 .30 14.81 13.05 17.72 21 .58
MRT (min) 83.51 153 .44 91 .85 7 0 .5 6 8 0 .2 2 8 6 .5 9 99 .42
F (%) 5 2 .8 7 47 .8 5 4 7 .8 0 46 .4 7 5 2 .3 0 4 7 .6 0 42.01
Table D-9. Pharmacokinetic  variables after non-compartmental  
analysis  of  ampici l l in  p lasma concen tra t ions  fo l low ing  an 
intragastric dose of bacampicillin hydrochloride at a mg/kg dose 
rate and an oral dose of dichlorvos at a 40 mg/kg dosage rate
2 1 7
Animal number
Time (h) 1 2 8 9 10 1 1
0 .25 0.77 0.61 0 .15 0 .06 0 .3 3 2 0 .4 4
0 .30 1.71 1.45 1.22 0 .65 1.20 1.25
0.75 3.46 1.78 2 .30 1.79 1.88 1.80
1 3.17 1.59 3 .20 2.01 2.36 2 .2 0
1.5 3 .16 1.47 3 .70 1.57 2 .54 1.87
2 2 .52 1.32 3 .30 1.68 2 .24 1.56
4 2.41 0 .65 0 .9 2 0 .46 1.11 0.41
6 1.81 0 .60 0.23 0 .29 0 .34 0 .1 9
8 1.03 0.48 0 .0 0 0 .09 0.08 0 .13
1 2 0.71 0.27 0 .00 0 .0 0 0 .00 0 .05
2 4 0 .00 0 .00 0 .00 0 .0 0 0 .00 0 .0 0
Table D-10. Plasma ampicillin concentrations after intragastric 
administration of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate and an probenecid at a 75 mg/kg dose rate.
Animal number
V ar iab le 1 2 8 9 10 1 1
Cmax ( jig/ml) 3 .46 1.78 3.7 2.01 2 .5 4 2 .20
tmax (min) 45 4 5 9 0 6 0 9 0 6 0
AUCobs (jig.h/ml) 2 5 .4 2 10.50 10.51 6 .06 8.91 6.47
AUMCobs0tg.h2/ml) 190.61 76 .85 24 .18 16.53 2 3 .6 7 19.73
MRT (min) 4 4 9 .8 2 4 39 .2 3 138.01 163 .74 159 .43 182 .88
F (%) 72 .65 26 .98 3 8 .8 0 32 .46 3 4 .5 3 20 .88
Table D - l l .  Pharmacokinetic variables after non-compartmental 
analysis  of  ampici l l in  p lasma concentra t ions  fo l low ing  an 
intragastric dose of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate and probenecid at a 75 mg/kg dosage rate.
2 1 8
Animal number
Time (h) 1 2 8 9 10 1 1
0 .25 60 .98 4 5 .5 8 81.41 2 8 .97 65.51 4 4 .1 6
0 .30 110 .5 4 69 .35 178 .38 66 .61 1 11 .69 66 .2 3
0.75 118 .38 7 6 .9 6 234 .71 87 .9 8 122 .28 7 3 .9 4
1 139 .65 7 8 .4 7 2 4 2 .1 0 7 9 .3 6 144 .65 8 6 .2 6
1.5 14 9 .62 87 .68 2 2 4 .2 2 106 .59 167 .02 109 .95
2 132 .27 104.03 208 .4 3 111 .84 175 .97 110.71
4 12 9 .30 1 05 .02 101 .40 7 7 .5 4 108 .86 75 .8 3
6 111 .67 122 .86 67 .15 64 .6 6 111 .35 7 4 .8 2
8 101.61 131 .80 60.01 43 .11 5 8 .7 9 7 9 .6 6
1 2 63 .35 123.63 53 .1 6 2 1 .55 3 3 .8 0 7 8 .6 6
2 4 2 4 .5 2 67 .43 4 7 .3 6 13.23 8.69 9.81
Table D-12. Plasma probenecid concentrations after intragastric 
administration of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate and probenecid at a 75 mg/kg dose rate.
Animal number
V ar iab le 1 2 8 9 1 0 1 1
Cmax
(H g/m l) 149 .62 131 .8 0 2 4 2 .1 0 111 .84 175 .97 110.71
tm a x
(min) 90 .0 0 4 8 0 .0 0 60 .0 0 120 .00 120 .0 0 120 .00
AUCobs
( f ig .h /m l) 2 37 8 .21 2 9 8 2 .6 9 8 6 0 1 .6 9 1573 .87 1 4 3 1 .7 4 1914 .58
AUM Cobs
( p g .h 2/m l ) 2 6 1 6 6 .7 4 6 1 9 4 .9 3 5 5 4 6 3 .7 2 2 4 3 5 .4 1 0796 .3 16431 .9
MRT
(min) 6 60 .0 9 2 9 .4 2 4 7 9 .2 855 .0 4 5 2 .4 514 .8
Table D-13. Pharmacokinetic  variables after non-compartmental 
analysis  of p robenecid  p lasma concentra t ions  fo l lowing an 
intragastric dose of bacampicillin hydrochloride at a 13.52 mg/kg 
dose rate and probenecid at a 75 mg/kg dosage rate
2 1 9
A p p e n d ix  E
Sen t iv i t ie s  o f  eq u in e  b a c t e r i a l  i so la tes  to  d i f f e r e n t
a n t i b i o t i c s .
B a c t e r i a l  i so la te O r i g i n
A. equuli 1 W o u n d
A equuli 2 LRT
A. equuli 3 Faeces
A . equuli 4 I l e u m
A. equuli 5 Faeces
A equuli 6 Joint
A. equuli 1 Faeces
A. equuli 8 Faeces
A . equuli 9 Faeces
A. equuli 10 Femoral
A. equuli 11 Faeces
A. equuli 12 Faeces
E. coli 1 LRT
E. coli 2 W o u n d
E . coli 3 U rine
E. coli 4 W o u n d
E. coli 5 Cervix
E. coli 6 Cervix
E . coli 1 Cervix
E. coli 8 Faeces
E. coli 9 LRT
E. coli 10 Cervix
E. coli 11 Bone
E. coli 12 W o u n d
E. coli 13 U te rus
E. coli 14 Faeces
E. coli 15 Faeces
D i s e a s e / S y m p t o m s
Abdominal wound 
GOPD
Grass Sickness 
Colic
Chronic Weight Loss 
A r th r i t i s
Chronic Weight Loss 
Chronic Weight Loss 
Chronic Weight Loss 
head Necrosis
Chronic Weight Loss 
Chronic Diarrhoea 
GOPD
Postoperative infection 
Renal failure
Navicular bursa puncture
Chronic endometri tis
Chronic endometri tis
Chronic endometri tis
Diarrhoea
P n e u m o n ia
Necrotic vaginitis
Osteomyelit is
Delayed closure(canon)
In fe r t i l i ty
Colic
Chronic Diarrhoea
Table E -l.  Bacterial isolates, their origin, and related disease.
URT: Upper respiratory tract. LRT: Lower respiratory tract.
COPD: Chronic obstructive pulmonary disease.
2 2 0
Bact er ia l  i so late O r i g i n D i s e a s e / S y m p t o m s
E. coli 16 W o u n d Postopeartive infection
E. coli 17 I l e u m Colic
E. coli 18 Faeces Diarrhoea
E. coli 19 W o u n d Elbow wound infection
E. coli 20 Faeces ChronicWeight Loss
E. coli 21 Femoral head Necrosis
E. coli 22 W o u n d Postoperative wound
E. coli 23 E n d o m e tr iu m Vaginal Discharge
Ps. aeruginosa 1 URT Guttural pouch empyema
Ps. aeruginosa 2 Caecum Recurrent colic
Ps. aeruginosa  3 Faeces Chonic Weight Loss
Ps. aeruginosa  4 Faeces Chronic Weight Loss
Ps. fluorescens  1 URT In f lu e n z a
Ps. fluorescens 2 URT In f lu en z a
Ps. fluorescens  3 URT In f lu en z a
Ps. fluorescens  4 W ou n d Osteomyelit is
Ps. fluorescens  5 W o u n d Granulating wound
Ps. fluorescens  6 URT Sinusitis
Ps. fluorescens 1 URT Sinusitis
Ps. maltophilia URT In f lu en z a
Ps. putrefasciens Faeces Colitis
S. typhimurium  1 Abscess Thoracic abscess
S. typhimurium 2 Faeces Salmonellosis
S. typhimurium  3 Faeces Salmonellosis
S. typhimurium  4 Faeces Salmonellosis
S. typhimurium  5 Faeces Salmonellosis
S. typhimurium 6 Spleen Salmonellosis
S. typhimurium 1 Faeces Salmonellosis
S. typhimurium  8 Faeces Chronic Diarrhoea
S. typhimurium  9 Faeces Diarrhoea
S. typhimurium  10 Faeces Diarrhoea
S. typhimurium  11 Faeces Salmonellosis
Table E -l (cont.). Bacterial isolates, their origin, and related disease.
URT: Upper respiratory tract. LRT: Lower respiratory tract.
COPD: Chronic obstructive pulmonary disease.
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Bact er i a l  i solate O r i g i n D i s e a s e / S y m p t o m s
S. aureus 1 Abscess Thoracic abscess
s. aureus 2 W o u nd Postoperative infection
s. aureus 3 Joint Purulent  hygroma
s. aureus 4 Bone Osteomyeli t is
s. aureus 5 URT Sinusit is
s. aureus 6 Skin Scabs (Hepatopathy)
s. aureus 1 URT In f lu en z a
s. aureus 8 URT In f lu en z a
s . aureus 9 URT In f lu en z a
5. aureus 10 URT In f lu en z a
S. aureus  11 URT In f lu en z a
s. aureus  12 URT In f lu en z a
s . aureus  13 URT Nasal discharge
s. aureus  14 Abscess Fetlock wound
s. aureus  15 Skin Mud fever (fetlock)
s. aureus 16 Faeces Chronic Weight Loss
s. zooepidemicus 1 LRT COPD
s. zooepidemicus 2 W ou n d Shoulder fistula
s . zooepidemicus 3 LRT P n e u m o n ia
s . zooepidemicus 4 URT Purulent nasal discharge
5. zooepidemicus 5 Cervix Chronic endometri tis
s. zooepidemicus 6 LRT P n e u m o n ia
s. zooepidemicus 7 Skin Scabs (Hepatopathy)
s. zooepidemicus 8 W o u n d Frontal carpus wound
s . zooepidemicus 9 Cervix Chronic endometritis
5. zooepidemicus 10 URT In f lu en za
5. zooepidemicus 11 URT In f lu en z a
S. zooepidemicus 12 URT In f lu en z a
s. zooepidemicus 13 URT In f lu en z a
s. zooepidemicus 14 Conjunctiva Conjunctivitis
S .zooepidem icus 15 W o u n d Right hock wound
S . zooepidemicus 16 W o u n d Hock wound
Table E -l (cont.). Bacterial isolates, their origin, and related disease.
URT: Upper respiratory tract. LRT: Lower respiratory tract.
COPD: Chronic obstructive pulmonary disease.
2 2 2
Bact er ia l  i solate O r i g i n D i s e a s e / S y m p t o m s
S. zooepidemicus 17 URT Purulent nasal discharge
S. zooepidemicus 18 W o u n d  Inner thigh wound
S. zooepidemicus 19 W o u n d  Elbow wound
S. zooepidemicus 20 LRT Respiratory noise
Table E - l  (cont.). Bacterial isolates, their origin, and related disease. 
URT: Upper respiratory tract. LRT: Lower respiratory tract.
COPD: Chronic obstructive pulmonary disease.
2 2 3
A G 0 E P L S C T
M E X R E I T H /
P N T N N R L s
A. equuli 1 S S S S S R S s. s
A equuli 2 S S s S S R S S s
A. equuli 3 S s s S s R S S s
A. equuli 4 S s s S s R S S s
A. equuli 5 S R s S s R R S R
A. equuli 6 S R s S s R R S S
A. equuli 7 S R s s s R R S S
A. equuli 8 S R s R s R R S S
A. equuli 9 S S s S s R R S S
A. equuli 10 S R s S s R R s S
A. equuli 11 R R s S s R R s s
A. equuli 12 R S s R R R S s s
E. coli 1 S S s R R R S s s
E. coli 2 R S R R R R R R R
E. coli 3 S S R R R R S S S
E. coli 4 R S R R R R R R R
E. coli 5 S S S R R R S S S
E coli 6 R S S R R R R R R
E. coli 7 S S S R R R S S S
E. coli 8 R S S R R R R S R
E . coli 9 R S R R R R R S R
E. coli 10 S S S R R R S S S
E. coli 11 R S R R R R R S R
E. coli 12 R S R R R R R S R
E. coli 13 S S S R R R S S S
E. coli 14 R S R R R R R S S
E. coli 15 S S S R R R S S S
E. coli 16 R S R R R R R S R
E. coli 17 S S S R R R R S S
E. coli 18 S S S R R R R S S
E. coli 19 S s S R R R S S S
E. coli 20 S s S R R R R s S
E . coli 21 S s S R R R S s S
E. coli 22 R s R R R R S s R
E. coli 23 R s R R R R R s S
Table E-2. Disc-diffusion sensitivity results. 
S : SENSITIVE; R : RESISTANT
2 2 4
A G 0 E P L S c T
M E X R E I T H /
P N T N N R L s
Ps aeruginosa 1 R S s R R R R S R
Ps. aeruginosa 2 R S s R R R S S R
Ps aeruginosa 3 R s R R R R R R R
Ps. aeruginosa 4 R s R R R R R R R
Ps. fluorescens 1 R s R R R R R R R
Ps. fluorescens 2 R s R R R R R R R
Ps. fluorescens 3 R s R R R R R R R
Ps. fluorescens 4 R s R R R R S R R
Ps. fluorescens 5 R s R R R R S R R
Ps. fluorescens 6 R s R R R R S R R
Ps. fluorescens 7 R s R R R R S R R
Ps. maltophilia R s R R R R S S S
Ps. putrefaciens R s R R R R S S R
S. typhimurium 1 S s R R R R R S S
S. typhimurium 2 R s R R R R R R R
S. typhimurium 3 R s R R R R R R R
S. typhimurium 4 R s R R R R R R R
S. typhimurium 5 R s R R R R R R R
S. typhimurium 6 R s R R R R R R R
S. typhimurium 7 R s R R R R R R R
S. typhimurium 8 R s R R R R R R S
S. typhimurium 9 R s R R R R R R R
S. typhimurium 10 R s R R R R R R S
S. typhimurium  11 S s R R R R S S S
S. aureus 1 R s S S R S S S S
S. aureus 2 S s S S R S S S S
S. aureus 3 S s S S S S S S S
S. aureus 4 R s S S R S S S S
S. aureus 5 S s R S S S S S S
S. aureus 6 S s S S S S S S s
S. aureus 7 S s S S S S S S s
s. aureus 8 S s S S S S S S s
s. aureus 9 R s S S R S S S s
s. aureus 10 S R S S S S S S s
s. aureus 11 S s S S S S S S s
s. aureus 12 R s S S R S S S s
s. aureus 13 S s S S S S S S s
Table E-2. Disc-diffusion sensitivity results. 
S : SENSITIVE; R : RESISTANT
2 2 5
A G 0 E p L s C T
M E X R E I T H /
P N T N N R L s
S. aureus 14 S S S S s s s s s
s. aureus 15 S S S S s s s S s
s. aureus 16 R s R S R s s S s
s. zooepidemicus 1 S s S R S s R S R
s. zooepidemicus 2 S R S S S s R S S
s. zooepidemicus 3 S R S S S s R S S
s. zooepidemicus 4 S R S S S s R S S
s. zooepidemicus 5 S R S S S s R S S
s. zooepidemicus 6 S R S S s s R S s
s. zooepidemicus 7 S S S s s s R S s
s. zooepidemicus 8 S R S s s s R S s
s. zooepidemicus 9 S R S s s s R S s
s. zooepidemicus 10 S R S s s s R S s
s. zooepidemicus 11 S R S s s s R S s
s. zooepidemicus 12 S R S s s s R S s
s. zooepidemicus 13 S R S s s s R s s
s. zooepidemicus 14 S R S s s s R s s
s. zooepidemicus 15 S R s s s s R s s
s . zooepidemicus 16 S R s s s s R s s
s . zooepidemicus 18 S R s s s s R s s
s. zooepidemicus 19 S R s s s s R s s
s . zooepidemicus 20 S R s s s s R s s
Table E-2 (cont.). Disc-diffusion sensitivity results.
S : SENSITIVE; R : RESISTANT
AMP: Ampicillin; GEN: Gentamicin; OXT: Oxytetracycline; ER: 
Erythromycin;  PEN: Penicil lin  G; LIN: L incomycin;  STR:
S trep tom ycin ;  CHL: C h lo ram p h en ico l ;  T/S:  T r im e th o p r im
/Su lp h am e tho x azo le .
2 2 6
A m p i c i l l i n
n <1 2
Range ( j ig /ml)  
4 8 16 3 2 6 4 128
A. equuli 1 2 10 0 - - - - -
E. coli 23 0 21.7 5 2 .2  5 2 .2  5 2 .2 5 2 .2 5 2 .2 56.5
Pseudomonas spp 13 0 0 0 0 0 7 .6 9 7 .69 7 .69
S. typhimurium 1 1 0 18.2 18 .2  18.2 18.2 18.2 18.2 18.2
S. aureus 1 6 68 .7 87.5 93 .7  1 0 0  - - - -
S. zooepidemicus 2 0 1 0 0 - - - - -
A m o x y c i l l in  / Range (j ig /ml)
C l a v u l a n i c  Acid n < 8 /4 1 6 / 8 3 2 / 1 6 6 4 / 3 2
A. equuli 10 1 0 0 - - -
E. coli 17 82.3 94.1 94.1 1 0 0
Pseudomonas spp 1 1 0 9.1 18.2 18.2
S. typhimurium 10 10 3 0 1 00 -
S. aureus 1 2 1 0 0 - - -
S. zooepidemicus 1 4 1 0 0 - - -
C a r b e n i c i l l i n
n
Range (pg /m l)  
<16 3 2  6 4 128
A. equuli 1 0 1 0 0 - - -
E. coli 17 58.8 58.8 58.8 58.8
Pseudomonas spp 1 1 18.2 63.6 90.9 100
S. typhimurium 1 0 1 0 10 10 10
S. aureus 1 2 1 00 - - -
S. zooepidemicus 14 1 00 - - -
M e z l o c i l l i n
n
Range ( j ig /ml)  
<16 3 2  6 4 128
A. equuli 1 2 100 - - -
E. coli 23 6 5 .2 73.8 78.1 86.7
Pseudomonas spp 1 3 3 8 .4 6 76.9 84.6 92.3
S. typhimurium 1 1 27.3 27.3 27.3 27.3
S. aureus 16 1 0 0 - - -
S. zooepidemicus 2 0 1 00 - - -
Table E-3 . Cumulative percentages of bacterial sensitivities.
2 2 7
C e f o x i t i n
n <1 2
Range (]ig/ml) 
4 8 16 3 2 6 4 128
A. equuli 1 2 91.7 100 - - - - -
E. coli 23 4.3 43 .4 86.9  95.6 100 - - -
Pseudomonas spp 13 0 0 0 0 0 0 7.7 7.7
S. typhimurium 1 1 0 18.2 4 5 .4  90.8 100 - - -
S. aureus 1 6 25 68.7 100  - - - - -
S. zooepidemicus 2 0 1 0 0 - - - - - -
C e f t i z o x i m e
n
Range ( jig/ml) 
<16 3 2  6 4 128
A. equuli 10 100 - - -
E. coli 17 100 - - -
Pseudomonas spp 1 1 9.1 63.6 81.8 100
S. typhimurium 10 100 - - -
S. aureus 1 2 100 - - -
S. zooepidemicus 1 4 100 - - -
C e f t r i a x o n e Range (j ig/ml) 
n <8 1 6 3 2 6 4
A. equuli 
E. coli
Pseudomonas spp  
S. typhimurium  
S. aureus 
S. zooepidemicus
10 100  -
1 7 94.1 94.1 94.1 94.1 
1 1 4 5 .4  72.7  81.8  90.9  
10  100  - 
12  100  - 
14 100  -
Ce p h a l o t h i n
n <1 2
Range (j ig/ml)  
4 8 16 3 2 6 4 128
A. equuli 1 2 91.7 100 - - - - -
E. coli 23 0 0 4.3 52.1 82.5 86 .8 91.1 95 .4
Pseudomonas spp 1 3 0 0 0 0 0 0 0 0
S. typhimurium 1 1 0 9.1 36 .4  45.5 90.9 1 0 0 - -
S. aureus 1 6 1 00 - - - - - -
S. zooepidemicus 2 0 1 00 - - - - - -
Table E-3 (cont). Cumulative percentages of bacterial sensitivities.
22 8
A m i k a c i n
n <1
Range ( j ig /ml)
2 4 8 1 6 3 2  6 4
A. equuli 1 2 0 16.7 83.3 1 0 0  - -
E. coli 23 21.7 95.6  100 - -
Pseudomonas  spp 13 7.7 38.5  9 2 .4 9 2 .4  92 .4 1 0 0  -
S. typhimurium 1 1 72.7 1 0 0  - - -
S. aureus 1 6 49.9 81.1 100 - -
S. zooepidemicus 2 0 55 65  100 - -
G e n t a m i c i n Range ( j ig /ml)  
n <0.5 1 2 4 8 1 6 3 2
A . equuli 
E. coli
Pseudomonas spp  
S. typhimurium  
S. aureus 
S. zooepidemicus
1 2 41 .7  83.3  100  - 
2 3  82.6  95.7  100  -
I 3 0 0 53 .8  84 .6  92.3  1 0 0  -
I I  10 0  -
1 6 93.7  1 00  - 
2 0  7 5  95  10 0  -
T o b r a m y c i n
n <0.5 1
Range (j ig /ml)
2 4 8 16 3 2
A. equuli 1 2 8.3 91.7 100 - -
E. coli 23 30 .4 91.3 100 - -
Pseudomonas  spp 1 3 53.8 84.6 92.3 92.3  92.3 1 0 0
S. typhimurium 1 1 18.2 1 0 0 - - -
S. aureus 1 6 93.7 1 00 - - -
S. zooepidemicus 2 0 7 0 9 0 100 - -
T e t r a c y c l i n e
n
Range (pg /m l)  
<2 4 8 16
A . equuli 1 2 1 00 - - -
E. coli 23 52 .2 56.5 56.5 60.8
Pseudomonas spp 1 3 0 0 0 7.7
S. typhimurium 1 1 0 9.1 9.1 54.5
S. aureus 1 6 87.5 87.5 87.5 87.5
S. zooepidemicus 2 0 95 95 100 -
Table E-3 (cont). Cumulative percentages of bacterial sensitivities.
2 2 9
T r i m e t h o p r i m /
S u l f a m e t h o x a z o l e n < 2 /3 8
Range ( j ig /ml)
4 / 7 6  8 / 1 5 2  1 6 / 3 0 4
A . equuli 1 2 1 0 0 - - -
E. coli 2 3 6 5 .2 65 .2 65 .2 6 5 .2
Pseudomonas spp 1 3 15.4 38.5 69.3 7 7 .0
S. typhimurium 1 1 3 6 .4 36 .4 36 .4 3 6 .4
S. aureus 1 6 1 0 0 - - -
S. zooepidemicus 2 0 1 0 0 - - -
N o r f l o x a c i n Range ( j ig/ml)  
n <1 2 4 8 1 6 3 2  6 4  128
A. equuli 
E . coli
Pseudomonas spp  
S. typhimurium  
S. aureus 
S. zooepidemicus
12  1 0 0  - - - - - -  -
2 3  9 5 .6  1 0 0  - - - - -  -
I 3 61 .5  69 .2  84 .6  100  -
I I  1 0 0  - - - - - - -
16  1 0 0  - - - - - - -
2 0  0 0 5 0  95  1 0 0  -
C i p r o f l o x a c i n Range (pg /m l)
n <0.06 0 .12 0.25 0.5 1 2 4 8
A. equuli 10 1 00 - - - - - -
E. coli 1 7 1 00 - - - - - -
Pseudomonas spp 1 1 0 9.1 54.5 63.6 81.8 1 0 0  - -
S. typhimurium 1 0 1 0 0 - - - - - -
S. aureus 12 0 5 0 100 - - - -
S. zooepidemicus 1 4 0 0 0 21.4 92.8 - -
Table E-3 . Cumulative percentages of bacterial sensitivities.
2 3 0
Table E-4. Individual MIC values for all antibiotics tested.
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